Gene: EGFR

1956
ERBB|ERBB1|HER1|NISBD2|PIG61|mENA
epidermal growth factor receptor
protein-coding
7p11.2
Ensembl:ENSG00000146648 MIM:131550 Vega:OTTHUMG00000023661 UniprotKB:P00533
NG_007726.3
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
1316   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.807e-1 (AD)  2.666e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs2877260chr7:55103936 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg03046247chr7:55106050EGFRGene body7.245e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SPON10.916
ATP13A40.915
GPAM0.909
GJB60.899
SLC15A20.895
METTL7A0.894
NTRK20.888
RANBP3L0.883
GJA10.883
NOTCH20.883

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GAL-0.385
DUSP27-0.385
QRFPR-0.372
CACNA1F-0.371
TRPV2-0.361
HTR7-0.357
LIPH-0.356
SAMD3-0.353
MCHR1-0.352
LAMB3-0.35

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00002CetuximabBiotechDrug205923-56-4ApprovedTarget
DB00072TrastuzumabBiotechDrug180288-69-1Approved|InvestigationalTarget
DB00281LidocaineSmall Molecule137-58-6ApprovedTarget
DB00317GefitinibSmall Molecule184475-35-2Approved|InvestigationalTarget
DB00530ErlotinibSmall Molecule183321-74-6Approved|InvestigationalTarget
DB01259LapatinibSmall Molecule231277-92-2Approved|InvestigationalTarget
DB01269PanitumumabBiotechDrug339177-26-3Approved|InvestigationalTarget
DB03496AlvocidibSmall Molecule146426-40-6Experimental|InvestigationalTarget
DB04988IGN311BiotechDrug-InvestigationalTarget
DB05101MatuzumabBiotechDrug339186-68-4InvestigationalTarget
DB05294VandetanibSmall Molecule443913-73-3ApprovedTarget
DB05374RindopepimutSmall Molecule1108208-65-6InvestigationalTarget
DB05424CanertinibSmall Molecule267243-28-7InvestigationalTarget
DB05524PelitinibSmall Molecule257933-82-7InvestigationalTarget
DB05944VarlitinibSmall Molecule845272-21-1InvestigationalTarget
DB06021AV-412Small Molecule451493-31-5InvestigationalTarget
DB07602S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINESmall MoleculeExperimentalTarget
DB07662N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDESmall MoleculeExperimentalTarget
DB08916AfatinibSmall Molecule850140-72-6ApprovedTarget
DB09330OsimertinibSmall Molecule1421373-65-0ApprovedTarget
DB09559NecitumumabBiotechDrug906805-06-9Approved|InvestigationalTarget
DB11731Depatuxizumab mafodotinSmall Molecule1585973-65-4InvestigationalTarget
DB11737IcotinibSmall Molecule610798-31-7Approved|InvestigationalTarget
DB11828NeratinibSmall Molecule698387-09-6Approved|InvestigationalTarget
DB12202ZalutumumabBiotechDrug667901-13-5InvestigationalTarget
DB12267BrigatinibSmall Molecule1197953-54-0Approved|InvestigationalTarget
DB13164OlmutinibSmall Molecule1353550-13-6Approved|InvestigationalTarget
ID Drug Name Action PubMed
C04678311,12-epoxy-5,8,14-eicosatrienoic acid"11,12-epoxy-5,8,14-eicosatrienoic acid inhibits the reaction [Terfenadine analog results in decreased phosphorylation of EGFR protein]"19289568
C04678311,12-epoxy-5,8,14-eicosatrienoic acid"11,12-epoxy-5,8,14-eicosatrienoic acid results in increased phosphorylation of and results in increased activity of EGFR protein"20804500
C04678311,12-epoxy-5,8,14-eicosatrienoic acid"14,15-eicosa-5-enoic acid inhibits the reaction [11,12-epoxy-5,8,14-eicosatrienoic acid results in increased phosphorylation of and results in increased activity of EGFR protein]"20804500
C5525301,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane"1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane results in decreased expression of EGFR protein"26035713
C0514121,2,3,4,7,8-hexachlorodibenzofuran"1,2,3,4,7,8-hexachlorodibenzofuran results in decreased activity of EGFR protein"2718174
C5691071-(2-chlorobenzyl)-5'-phenyl-3'H-spiro(indoline-3,2'-(1,3,4)thiadiazol)-2-one"1-(2-chlorobenzyl)-5'-phenyl-3'H-spiro(indoline-3,2'-(1,3,4)thiadiazol)-2-one results in decreased expression of EGFR mRNA"23826121
C0700461,2-dioleoyloxy-3-(trimethylammonium)propane"[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of EGFR mRNA"22129739
C0493251,2-dithiol-3-thione"1,2-dithiol-3-thione results in decreased expression of EGFR mRNA"19162173
C0407561,2-naphthoquinone"1,2-naphthoquinone results in increased phosphorylation of and results in increased activity of EGFR protein"24067727
C49402214,15-eicosa-5-enoic acid"14,15-eicosa-5-enoic acid inhibits the reaction [11,12-epoxy-5,8,14-eicosatrienoic acid results in increased phosphorylation of and results in increased activity of EGFR protein]"20804500
C49402214,15-eicosa-5-enoic acid"14,15-eicosa-5-enoic acid results in decreased phosphorylation of and results in decreased activity of EGFR protein"20804500
C5696701-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one"EGFR gene mutant form results in increased susceptibility to 1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one"23136191
C5532941-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one"1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]"26455392
C5532941-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one"1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]"26455392
C5532941-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one"1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]"26455392
C5532941-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one"1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]"26455392
C5179431-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone"EGFR protein promotes the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone results in increased expression of MIR21 mRNA]"25969534
C5179431-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone"[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased phosphorylation of and results in increased activity of EGFR protein"22645130
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased expression of EGFR mRNA"22698814
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased expression of EGFR protein"21705713
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased expression of EGFR protein modified form"21705713
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"CTNNB1 gene mutant form affects the susceptibility to [1,4-bis(2-(3,5-dichloropyridyloxy))benzene affects the expression of EGFR protein]"21705713
C0602291-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione"1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]"15177934
C0512461-methylanthracene[1-methylanthracene co-treated with fluoranthene] results in increased expression of EGFR mRNA28329830
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"EGFR gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"23136191
C4172072,2',4,6,6'-pentachlorobiphenyl"2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of EGFR protein"16778083
C4172072,2',4,6,6'-pentachlorobiphenyl"WHI P154 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of EGFR protein]"16778083
C0939732-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [EGFR protein binds to GPER1 protein]19749156
C0939732-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein]21568938
C0939732-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased expression of EGFR mRNA18332871
C0939732-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased expression of EGFR protein18332871
C4049102,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane"2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in increased phosphorylation of EGFR protein"28426875
C4049102,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane"2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [FSHB protein affects the expression of EGFR mRNA]"19414516
C1202272-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide"2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide results in decreased phosphorylation of EGFR protein"16261397
C0388902,3,4,7,8-pentachlorodibenzofuran"2,3,4,7,8-pentachlorodibenzofuran results in decreased activity of EGFR protein"2718174
C0131862,3-pentanedione"2,3-pentanedione results in increased expression of EGFR mRNA"25710175
C0140242,4,5,2',4',5'-hexachlorobiphenyl"2,4,5,2',4',5'-hexachlorobiphenyl affects the localization of EGFR protein"19632255
C0140242,4,5,2',4',5'-hexachlorobiphenyl"2,4,5,2',4',5'-hexachlorobiphenyl binds to EGFR protein"29329451
C0140242,4,5,2',4',5'-hexachlorobiphenyl"2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [EGF protein binds to EGFR protein]"29329451
C0140242,4,5,2',4',5'-hexachlorobiphenyl"2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]"29329451
C0140242,4,5,2',4',5'-hexachlorobiphenyl"2,4,5,2',4',5'-hexachlorobiphenyl results in increased phosphorylation of EGFR protein"19632255
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]15177934
C4086042-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole affects the phosphorylation of EGFR protein19010935
C0112692,5-hexanedione"2,5-hexanedione results in increased expression of EGFR mRNA"16141653
C0237042-acetamidoethanethiol2-acetamidoethanethiol analog results in decreased phosphorylation of EGFR protein20058253
C0495842-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of EGFR mRNA"8603490
C0495842-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine"[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [[[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK1 protein] co-treated with [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK3 protein]] results in increased phosphorylation of ELK1 protein]"18056474
C4843272'-benzoyloxycinnamaldehyde2'-benzoyloxycinnamaldehyde results in increased phosphorylation of EGFR protein14660655
C4843272'-benzoyloxycinnamaldehydeAcetylcysteine inhibits the reaction [2'-benzoyloxycinnamaldehyde results in increased phosphorylation of EGFR protein]14660655
C4843272'-benzoyloxycinnamaldehydeGlutathione inhibits the reaction [2'-benzoyloxycinnamaldehyde results in increased phosphorylation of EGFR protein]14660655
C5850042-monochloropropanediol2-monochloropropanediol results in increased expression of EGFR mRNA28522335
C0299552-nitrotoluene2-nitrotoluene results in decreased expression of EGFR mRNA15618236
C5609053-(2-(dimethylamino)isopropoxy)-1-hydroxybenzo(b)naphtho(2,3-d)furan-6,11-dione"3-(2-(dimethylamino)isopropoxy)-1-hydroxybenzo(b)naphtho(2,3-d)furan-6,11-dione results in decreased activity of EGFR protein"21600193
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl binds to EGFR protein"29329451
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [EGF protein binds to EGFR protein]"29329451
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]"29329451
C4727913-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid results in increased expression of EGFR mRNA16788091
C5005303-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide"3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide results in increased expression of EGFR protein"21349818
C5005303-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide"3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide results in increased expression of and results in increased phosphorylation of EGFR protein"21349818
C495482(3-chloro-4-fluoro-phenyl)-(6-(4-diethylaminomethyl-piperidin-1yl)-pyrimido(5,4-d)pyrimidin-4-yl)amine"(3-chloro-4-fluoro-phenyl)-(6-(4-diethylaminomethyl-piperidin-1yl)-pyrimido(5,4-d)pyrimidin-4-yl)amine results in decreased activity of EGFR protein"22573732
C0020104-(2-aminoethyl)benzenesulfonylfluoride4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of EGFR protein]23376140
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of EGFR protein]"18346929
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"[4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased activity of EGFR protein] results in decreased susceptibility to [Copper binds to Clioquinol]"18346929
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein"18346929
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline analog results in decreased activity of EGFR protein"11822173
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of EGFR protein]"16908449
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [betulinic acid results in increased phosphorylation of EGFR protein]"16077934
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of EGFR protein]"18346929
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]"12915106|1690844
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein]"19133285
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]"15177934
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein]"12972402|1598003
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Zinc Sulfate results in increased phosphorylation of EGFR protein]"16410015
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased activity of EGFR protein"11822173|1595569
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein"18346929
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"[4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK1 protein]"18346929
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"[4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK3 protein]"18346929
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein]"26464147
C0888604-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased activity of EGFR protein"12839940|1507257
C5831264-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid"4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid inhibits the reaction [AM 251 results in increased expression of EGFR protein]"27423937
C5831264-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid"4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid results in decreased expression of EGFR protein"27423937
C575425(4-(4'-chloro-2'-fluoro)phenylamino)-6,7-dimethylquinazoline"(4-(4'-chloro-2'-fluoro)phenylamino)-6,7-dimethylquinazoline results in decreased activity of EGFR protein"22573732
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of EGFR mRNA"18648102
C0909424-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]15525798
C5830744,4'-hexafluorisopropylidene diphenol"4,4'-hexafluorisopropylidene diphenol results in increased expression of EGFR mRNA"27567155
C4339384557 W4557 W results in decreased activity of EGFR protein17093206
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFR mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA"27188386
C1081234-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [arsenic trioxide results in increased phosphorylation of EGFR protein]"22532027
C1081234-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]"25856345
C1081234-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Zinc co-treated with EGFR protein] results in increased activity of RAS protein]"11983694
C1081234-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein]"11983694
C1081234-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein]"17116659
C1081234-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein]"15849355
C0006035004'-methoxy-1-naphthylfenoterol4'-methoxy-1-naphthylfenoterol inhibits the reaction [AM 251 results in increased expression of EGFR protein]27423937
C0006035004'-methoxy-1-naphthylfenoterol4'-methoxy-1-naphthylfenoterol results in decreased expression of EGFR protein27423937
C1201954-nitroquinolone-1-oxide[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein26464283
C1201954-nitroquinolone-1-oxide[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the localization of EGFR protein modified form26464283
C1201954-nitroquinolone-1-oxidehelioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein]26464283
C0175724-nitrotoluene4-nitrotoluene results in decreased expression of EGFR protein15618236
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of EGFR protein16671086
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneAtenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of EGFR protein]16671086
C0022024-oxoretinoic acid4-oxoretinoic acid results in decreased expression of EGFR mRNA15982314
C1052604-tert-octylphenol4-tert-octylphenol results in increased expression of EGFR mRNA17011747
C0126064-vinyl-1-cyclohexene dioxide4-vinyl-1-cyclohexene dioxide affects the expression of EGFR mRNA20829426
C4805415-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one"5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein"21266357
C4805415-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one"[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]"21266357
C4805415-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one"TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]"21266357
C5130035-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione"5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in decreased expression of EGFR mRNA"17409431
C4449195-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione"[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased susceptibility to 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione"20433816
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFR mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA"27188386
C4750936-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime"6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]"25625231
C53242964Cu-DOTA-cetuximab64Cu-DOTA-cetuximab binds to EGFR protein18454685|1870360
C1001016-chrysenamine6-chrysenamine inhibits the reaction [EGF protein binds to EGFR protein]6309801
C0538766-isopropoxy-9-oxoxanthene-2-carboxylic acid[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]19407222
C0538766-isopropoxy-9-oxoxanthene-2-carboxylic acid[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of EGFR protein19407222
C1078756-(methylamino)pyrido(3,4-d)pyrimidine"6-(methylamino)pyrido(3,4-d)pyrimidine results in decreased activity of EGFR protein"15572027
C1078756-(methylamino)pyrido(3,4-d)pyrimidine"6-(methylamino)pyrido(3,4-d)pyrimidine results in decreased activity of EGFR protein"15952178
C0030017-ketocholesterol7-ketocholesterol results in increased phosphorylation of EGFR protein20466046
C469552A 419259A 419259 inhibits the reaction [GRP protein results in increased phosphorylation of EGFR protein]15342401
D000082AcetaminophenAcetaminophen results in decreased expression of EGFR mRNA21420995
D000082AcetaminophenAcetaminophen results in increased expression of EGFR mRNA29067470
D000082AcetaminophenAcetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein28123000
D000082AcetaminophenAcetaminophen affects the localization of EGFR protein28123000
D000082Acetaminophen[Acetaminophen results in decreased abundance of Glutathione] which results in increased phosphorylation of and results in increased activity of EGFR protein28123000
D000082AcetaminophenAcetaminophen results in decreased expression of EGFR mRNA24126418
D000082AcetaminophenAcetaminophen results in decreased expression of EGFR protein15618236
D000082AcetaminophenAcetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein28123000
D000082AcetaminophenAcetylcysteine inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein]28123000
D000082AcetaminophenCanertinib inhibits the reaction [Acetaminophen affects the localization of EGFR protein]28123000
D000082AcetaminophenCanertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein]28123000
D000082Acetaminophen[Clofibrate co-treated with Acetaminophen] affects the expression of EGFR mRNA17585979
D000082AcetaminophenPPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of EGFR mRNA]17585979
C056165acetovanilloneacetovanillone inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein]26514923
D000111AcetylcysteineAcetylcysteine inhibits the reaction [2'-benzoyloxycinnamaldehyde results in increased phosphorylation of EGFR protein]14660655
D000111AcetylcysteineAcetylcysteine inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein]26514923
D000111AcetylcysteineAcetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of EGFR protein]10640773
D000111AcetylcysteineAcetylcysteine inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein]28123000
D000111Acetylcysteine"Acetylcysteine inhibits the reaction [Asbestos, Crocidolite results in increased activity of EGFR protein]"15520183
D000111AcetylcysteineAcetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of EGFR mRNA]23948867
D000111AcetylcysteineAcetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]23948867
D000111AcetylcysteineAcetylcysteine inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of and results in increased activity of EGFR protein]17942915
D000111AcetylcysteineAcetylcysteine inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein]21220312
D000111AcetylcysteineAcetylcysteine inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein]15849355
D000111Acetylcysteine"Acetylcysteine inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein]"26368632
D000111AcetylcysteineAcetylcysteine inhibits the reaction [EDN1 protein results in increased phosphorylation of and results in increased activity of EGFR protein]16261333
D000171AcroleinAcrolein results in increased activity of EGFR protein11329622
D000171AcroleinAcrolein results in increased phosphorylation of EGFR protein11329622|1553174
D000171AcroleinEGFR protein affects the reaction [Acrolein results in increased expression of MUC5AC mRNA]15531749
D000171Acroleintyrphostin AG 1478 inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]15531749
D000171AcroleinAcrolein results in increased phosphorylation of EGFR protein20153347
D000171AcroleinAcrolein results in increased phosphorylation of EGFR protein20359552
D000171AcroleinMevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]]20359552
D000171AcroleinSimvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]20359552
D020106AcrylamideAcrylamide analog affects the phosphorylation of EGFR protein11462982
D020106AcrylamideAcrylamide analog results in decreased phosphorylation of EGFR protein10753475
D020106AcrylamideAcrylamide results in increased expression of EGFR protein24508477
D020106AcrylamideCurcumin inhibits the reaction [Acrylamide results in increased expression of EGFR protein]24508477
D020106Acrylamideepigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of EGFR protein]24508477
C058956acteosideacteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]21756928
C058956acteosideacteoside promotes the reaction [TGFA protein affects the localization of EGFR protein]21967610
C058956acteosideacteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]21967610
C058956acteosideacteoside results in decreased phosphorylation of EGFR protein21756928|2196761
C058956acteoside[acteoside co-treated with TNF protein] results in decreased phosphorylation of EGFR protein23527233
C058956acteosideacteoside inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]21967610
C058956acteosideacteoside inhibits the reaction [TGFA protein results in increased phosphorylation of EGFR protein]21967610
C058956acteoside[leptomycin B co-treated with TGFA protein co-treated with acteoside] affects the localization of EGFR protein modified form21967610
D000242Cyclic AMP[Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]17295779
D000242Cyclic AMPCyclic AMP analog inhibits the reaction [Cimetidine inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]17295779
D000255Adenosine TriphosphateAdenosine Triphosphate results in increased phosphorylation of EGFR protein26104857
D000255Adenosine Triphosphatesodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of EGFR protein]26104857
C489254AEE 788AEE 788 results in decreased activity of EGFR protein16940797
C522924afatinibafatinib results in decreased activity of EGFR protein21322567|2224213
C522924afatinibafatinib results in decreased activity of EGFR protein mutant form21322567
C522924afatinibafatinib results in decreased phosphorylation of EGFR protein28787001
C016601afimoxifeneEGFR protein results in decreased susceptibility to afimoxifene18351453
C016601afimoxifeneEGFR results in decreased susceptibility to afimoxifene21233418
C412373AG 1879AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein]19151764
C412373AG 1879AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C412373AG 1879AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C412373AG 1879AG 1879 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C412373AG 1879AG 1879 inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]20660715
C412373AG 1879AG 1879 inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C412373AG 1879AG 1879 inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C412373AG 1879AG 1879 inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C412373AG 1879AG 1879 inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of and results in increased activity of EGFR protein]18346929
C412373AG 1879AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C412373AG 1879AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C412373AG 1879AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C412373AG 1879AG 1879 inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]27087131
C412373AG 1879AG 1879 inhibits the reaction [Nicotine results in increased phosphorylation of EGFR protein]14569062
C412373AG 1879AG 1879 inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein]25303742
C412373AG 1879AG 1879 inhibits the reaction [Particulate Matter results in increased phosphorylation of EGFR protein]17028263
C412373AG 1879AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein]19151764
C412373AG 1879AG 1879 inhibits the reaction [Vehicle Emissions results in increased phosphorylation of EGFR protein]17028263
C412373AG 1879AG 1879 inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein]12915106|1598003
C412373AG 1879[AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein]21205633
C412373AG 1879AG 1879 inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]14737115
C412373AG 1879AG 1879 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of EGFR protein]14737115
C412373AG 1879AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein]19151764
C412373AG 1879AG 1879 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein]20660715
C412373AG 1879AG 1879 inhibits the reaction [SRC protein promotes the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein]]18295415
C430898AGN 194204AGN 194204 inhibits the reaction [CREBBP protein binds to EGFR promoter]21080969
C430898AGN 194204AGN 194204 inhibits the reaction [NCOA1 protein binds to EGFR promoter]21080969
C430898AGN 194204AGN 194204 results in decreased expression of EGFR protein15318936|2108096
C430898AGN 194204CREBBP protein inhibits the reaction [AGN 194204 results in decreased expression of EGFR protein]21080969
C430898AGN 194204NCOA1 protein inhibits the reaction [AGN 194204 results in decreased expression of EGFR protein]21080969
C430898AGN 194204AGN 194204 results in decreased expression of EGFR mRNA15302862
C046926AH 23848[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]19407222
C046926AH 23848[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of EGFR protein19407222
C031143AICA ribonucleotideAICA ribonucleotide inhibits the reaction [EGFR protein results in increased import of Deoxyglucose]19625624
D000450AldosteroneAldosterone results in increased expression of EGFR mRNA11507004
C103303alitretinoinalitretinoin results in decreased expression of EGFR mRNA15982314
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in increased expression of EGFR mRNA28522335
C095512alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide"alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Bile Acids and Salts results in increased expression of EGFR protein]"21127259
C095512alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide"alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]"18995957
C011512alpha-naphthoflavonealpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of EGFR protein]17934341
C005277alpha-naphthyl thioureaalpha-naphthyl thiourea results in increased expression of EGFR mRNA10755703
D000526AlprenololAG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D000526AlprenololAG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D000526AlprenololAG 1879 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D000526AlprenololAlprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]18787115
D000526AlprenololAlprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]18787115
D000526AlprenololAlprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]18787115
D000526Alprenolol[Alprenolol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein18787115
D000526AlprenololARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D000526AlprenololARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D000526AlprenololARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D000526AlprenololARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D000526AlprenololHBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D000526AlprenololHBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D000526AlprenololHBEGF protein promotes the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D000526AlprenololN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D000526AlprenololN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D000526AlprenololN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D000526AlprenololPropranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D000526AlprenololPropranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]18787115
D000526Alprenololtyrphostin AG 1478 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D000526Alprenololtyrphostin AG 1478 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D000526Alprenololtyrphostin AG 1478 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D000537Aluminum OxideAluminum Oxide results in increased expression of EGFR mRNA19464052
D000538Aluminum SilicatesAluminum Silicates results in increased expression of EGFR protein16335828
C103505AM 251"4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid inhibits the reaction [AM 251 results in increased expression of EGFR protein]"27423937
C103505AM 2514'-methoxy-1-naphthylfenoterol inhibits the reaction [AM 251 results in increased expression of EGFR protein]27423937
C103505AM 251AM 251 results in increased expression of EGFR protein27423937
D000638AmiodaroneAmiodarone results in decreased expression of EGFR mRNA24535564
D000643Ammonium ChlorideAmmonium Chloride affects the expression of EGFR mRNA16483693
D000643Ammonium ChlorideAmmonium Chloride results in decreased expression of EGFR protein16483693
D000880AnthraquinonesAnthraquinones analog results in decreased activity of EGFR protein27473261
D000903Antibiotics, Antineoplastic"EGFR protein affects the susceptibility to Antibiotics, Antineoplastic"15981280
C061374antimoniteantimonite results in increased expression of EGFR protein17400267
D000970Antineoplastic AgentsAntineoplastic Agents results in decreased expression of EGFR protein23125191
D000970Antineoplastic AgentsAntineoplastic Agents results in decreased expression of EGFR protein modified form23125191
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of EGFR mRNA24449571
D016718Arachidonic Acid"5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [Arachidonic Acid results in increased phosphorylation of and results in increased activity of EGFR protein]"15525798
D001115Arecoline[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein26464283
D001115Arecoline[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the localization of EGFR protein modified form26464283
D001115Arecolinehelioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein]26464283
D001151ArsenicArsenic results in increased expression of EGFR mRNA19945496
D001151ArsenicArsenic results in increased expression of EGFR protein alternative form17453740
C025657arsenic acidarsenic acid results in increased phosphorylation of EGFR protein14674888
C025657arsenic acidEGFR protein affects the reaction [arsenic acid results in increased activity of MAPK1 protein]14674888
C025657arsenic acidEGFR protein affects the reaction [arsenic acid results in increased activity of MAPK3 protein]14674888
C006632arsenic trioxide"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [arsenic trioxide results in increased phosphorylation of EGFR protein]"22532027
C006632arsenic trioxidearsenic trioxide results in decreased expression of EGFR mRNA20435036
C006632arsenic trioxidearsenic trioxide results in decreased expression of EGFR protein20435036|2302945
C006632arsenic trioxidearsenic trioxide results in increased expression of EGFR mRNA22521957
C006632arsenic trioxidearsenic trioxide results in increased phosphorylation of and results in increased activity of EGFR protein15961274|2354826
C006632arsenic trioxidearsenic trioxide results in increased phosphorylation of EGFR protein22532027
C006632arsenic trioxideErlotinib Hydrochloride inhibits the reaction [arsenic trioxide results in increased phosphorylation of and results in increased activity of EGFR protein]23548265
C006632arsenic trioxideNCF2 mutant form inhibits the reaction [arsenic trioxide results in increased phosphorylation of EGFR protein]22532027
C006632arsenic trioxide[arsenic trioxide co-treated with huachansu] results in decreased expression of EGFR protein21434348
C006632arsenic trioxidearsenic trioxide results in decreased expression of EGFR protein23029451
C015001arsenitearsenite results in decreased degradation of EGFR protein17400267
C015001arsenitearsenite results in increased expression of EGFR protein17400267
C015001arsenitearsenite results in increased methylation of EGFR promoter23974009
C015001arsenitearsenite results in increased phosphorylation of EGFR protein14674888|1740026
C015001arseniteEGFR protein affects the reaction [arsenite results in increased activity of MAPK1 protein]14674888
C015001arseniteEGFR protein affects the reaction [arsenite results in increased activity of MAPK3 protein]14674888
D001194AsbestosAsbestos results in increased phosphorylation of EGFR protein26368632
D017639Asbestos, Amosite"Asbestos, Amosite results in decreased phosphorylation of EGFR protein"15626777
D017639Asbestos, Amosite"Asbestos, Amosite results in increased expression of EGFR mRNA"22251266
D017636Asbestos, Amphibole"Asbestos, Amphibole results in increased expression of EGFR mRNA"22251266
D017638Asbestos, Crocidolite"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of EGFR protein]"16908449
D017638Asbestos, Crocidolite"Asbestos, Crocidolite binds to EGFR protein"23672436
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in decreased activity of and results in decreased phosphorylation of EGFR protein"15626777
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in increased activity of EGFR protein"21762757
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in increased expression of EGFR protein"21570478
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in increased phosphorylation of EGFR protein"16908449
D017638Asbestos, Crocidolite"CAT protein inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of EGFR protein]"16908449
D017638Asbestos, Crocidolite"Cytochalasin B inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein]"15626777
D017638Asbestos, Crocidolite"Cytochalasin D inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein]"15626777
D017638Asbestos, Crocidolite"Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in decreased activity of and results in decreased phosphorylation of EGFR protein]"15626777
D017638Asbestos, Crocidolite"EGFR protein affects the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK1 protein]"16908449
D017638Asbestos, Crocidolite"EGFR protein affects the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK3 protein]"16908449
D017638Asbestos, Crocidolite"Phytic Acid inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein]"15626777
D017638Asbestos, Crocidolite"SOD1 protein inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of EGFR protein]"16908449
D017638Asbestos, Crocidolite"Acetylcysteine inhibits the reaction [Asbestos, Crocidolite results in increased activity of EGFR protein]"15520183
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in increased activity of EGFR protein"15520183
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in increased phosphorylation of EGFR protein"14737115
D017638Asbestos, Crocidolite"EGFR protein promotes the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]"12154012
D017638Asbestos, Crocidolite"EGFR protein promotes the reaction [Asbestos, Crocidolite results in increased expression of JUN mRNA]"12154012
D017638Asbestos, Crocidolite"Acetylcysteine inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein]"26368632
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in increased expression of EGFR mRNA"10783328
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in increased expression of EGFR protein"26368632
D017638Asbestos, Crocidolite"Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein]"26368632
D001205Ascorbic AcidAscorbic Acid results in decreased expression of EGFR mRNA21919647
D001241AspirinAspirin results in increased expression of EGFR mRNA15456535
D001262AtenololAtenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of EGFR protein]16671086
D000069059Atorvastatin CalciumAtorvastatin Calcium inhibits the reaction [Phenylephrine results in increased expression of and results in increased phosphorylation of and results in increased activity of EGFR protein]18360054
D001280AtrazineAtrazine inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]29329451
D001280AtrazineAtrazine results in increased expression of EGFR mRNA22378314
D001285AtropineAtropine inhibits the reaction [Parathion results in increased expression of EGFR protein]17390078
C006680baicaleinbaicalein inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]25625231
C038044baicalinbaicalin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]25625231
C060988baohuoside Ibaohuoside I inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]25119583
C060988baohuoside Ibaohuoside I results in decreased phosphorylation of EGFR protein25119583
D001507BeclomethasoneBeclomethasone results in increased activity of EGFR protein22573732
C030935benz(a)anthraceneAHR protein affects the reaction [benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]]6309801
C030935benz(a)anthracenebenz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]6309801
C037689benzamidebenzamide analog results in decreased activity of EGFR protein15186837
C032157benzamidinebenzamidine analog results in decreased activity of EGFR protein15186837
D001554BenzeneBenzene results in decreased expression of EGFR mRNA17905399
C030233benzo(a)pyrene-1,6-quinone"benzo(a)pyrene-1,6-quinone results in increased phosphorylation of EGFR protein"19166869
C018003benzo(a)pyrene-3,6-quinone"benzo(a)pyrene-3,6-quinone results in increased phosphorylation of EGFR protein"19166869
C006703benzo(b)fluoranthenebenzo(b)fluoranthene affects the localization of and results in increased expression of EGFR protein21776270
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in decreased expression of EGFR mRNA26377693
D019817Benzoic AcidBenzoic Acid analog inhibits the reaction [EGF protein promotes the reaction [STAT3 protein binds to EGFR protein]]26088127
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of EGFR mRNA19181443
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased phosphorylation of EGFR protein19181443
D001564Benzo(a)pyreneEGFR protein results in increased susceptibility to Benzo(a)pyrene8608954
D001564Benzo(a)pyreneAHR protein affects the reaction [Benzo(a)pyrene inhibits the reaction [EGF protein binds to EGFR protein]]6309801
D001564Benzo(a)pyreneBenzo(a)pyrene inhibits the reaction [EGF protein binds to EGFR protein]6309801
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of EGFR mRNA19770486|2180369
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of EGFR mRNA"19150397
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of EGFR protein"22457794
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"EGFR mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of AKT1 protein]"22457794
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"EGFR mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of MAPK1 protein]"22457794
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"EGFR mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of MAPK3 protein]"22457794
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"MUC1 mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of EGFR protein]"22457794
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide inhibits the reaction [EGF protein binds to EGFR protein]"6309801
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]17146438
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [MUC1 affects the expression of EGFR protein]22457794
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [platycodin D results in decreased expression of EGFR protein]28711525
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of EGFR protein]20332299
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of EGFR protein]20332299
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGFR protein20332299
D004958Estradiol[AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein21185374
D004958EstradiolEGF protein inhibits the reaction [[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 mRNA]18629630
D004958EstradiolEGF protein inhibits the reaction [[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 protein]18629630
D004958EstradiolEGF protein promotes the reaction [Estradiol results in increased phosphorylation of EGFR protein]20005069
D004958Estradiol[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 mRNA18629630
D004958Estradiol[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 protein18629630
D004958Estradiol[Estradiol co-treated with ESR1 protein] results in decreased expression of EGFR mRNA19347870
D004958Estradiol[Estradiol co-treated with ESR1 protein] results in decreased expression of EGFR protein19347870
D004958Estradiol[Estradiol co-treated with ESR2 protein] results in decreased expression of EGFR mRNA19347870
D004958Estradiol[Estradiol co-treated with ESR2 protein] results in decreased expression of EGFR protein19347870
D004958Estradiol[Estradiol co-treated with IGF1R mutant form] results in increased expression of EGFR mRNA23094148
D004958Estradiol[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EGFR mRNA19619570
D004958EstradiolEstradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]21185374
D004958EstradiolEstradiol results in decreased expression of EGFR mRNA20005069
D004958EstradiolEstradiol results in decreased expression of EGFR protein20005069
D004958EstradiolEstradiol results in increased activity of EGFR protein15802018
D004958EstradiolEstradiol results in increased expression of EGFR mRNA19619570
D004958EstradiolEstradiol results in increased phosphorylation of EGFR protein20005069|2118537
D004958EstradiolICI 164384 inhibits the reaction [[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 mRNA]18629630
D004958Estradiol[Parathion co-treated with Estradiol] results in increased expression of EGFR protein17622325
D004958Estradiol[Progesterone co-treated with Estradiol] results in increased expression of EGFR mRNA18692832
D004958Estradioltyrphostin AG 1478 inhibits the reaction [[AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein]21185374
D004958Estradioltyrphostin AG 1478 inhibits the reaction [Estradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]]21185374
D004958Estradioltyrphostin AG 1478 inhibits the reaction [Estradiol results in increased phosphorylation of EGFR protein]21185374
D004958EstradiolESR1 protein promotes the reaction [Estradiol results in increased expression of EGFR mRNA]25210133
D004958EstradiolEstradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]22414604
D004958EstradiolEstradiol promotes the reaction [Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]]22414604
D004958EstradiolEstradiol results in increased expression of EGFR mRNA25210133
D004958EstradiolProgesterone promotes the reaction [Estradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]]22414604
D004958EstradiolDactinomycin inhibits the reaction [Estradiol results in increased expression of EGFR protein]8888411
D004958EstradiolEstradiol results in decreased expression of EGFR mRNA20068009
D004958EstradiolEstradiol results in increased expression of EGFR protein8888411
C002070betulinic acid"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [betulinic acid results in increased phosphorylation of EGFR protein]"16077934
C002070betulinic acidbetulinic acid results in increased phosphorylation of EGFR protein16077934
D001647Bile Acids and Salts"alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Bile Acids and Salts results in increased expression of EGFR protein]"21127259
D001647Bile Acids and SaltsBile Acids and Salts results in increased expression of EGFR protein21127259
C088060bisindolylmaleimidebisindolylmaleimide inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]15177934
C070515bisindolylmaleimide Ibisindolylmaleimide I inhibits the reaction [irinotecan metabolite results in increased phosphorylation of EGFR protein]15723263
C070515bisindolylmaleimide Ibisindolylmaleimide I inhibits the reaction [irinotecan results in increased phosphorylation of EGFR protein]15723263
C006780bisphenol Abisphenol A results in decreased expression of EGFR mRNA20678512
C006780bisphenol Abisphenol A results in increased expression of EGFR mRNA29275510
C006780bisphenol Abisphenol A results in increased phosphorylation of EGFR protein28426875
C006780bisphenol AGW 583340 inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein]28426875
C006780bisphenol Abisphenol A results in decreased expression of EGFR mRNA26063408
C006780bisphenol Abisphenol A results in increased expression of EGFR mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of EGFR gene28505145
C471992bosutinibbosutinib results in decreased activity of EGFR protein18385429
C000595192BP-1-102BP-1-102 analog inhibits the reaction [EGF protein promotes the reaction [STAT3 protein binds to EGFR protein]]26088127
D0151248-Bromo Cyclic Adenosine Monophosphate8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGFR mRNA22079614
D0200011-Butanol1-Butanol inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein]15525798
D0200011-Butanol1-Butanol inhibits the reaction [EGF protein binds to and results in increased degradation of EGFR protein]11134345
D0200011-Butanol1-Butanol inhibits the reaction [EGF protein binds to and results in increased localization of EGFR protein]11134345
C048491butaprost[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased susceptibility to butaprost21268125
D002083Butylated HydroxyanisoleButylated Hydroxyanisole inhibits the reaction [Particulate Matter results in increased phosphorylation of EGFR protein]17028263
D002083Butylated HydroxyanisoleButylated Hydroxyanisole inhibits the reaction [Vehicle Emissions results in increased phosphorylation of EGFR protein]17028263
D002083Butylated HydroxyanisoleButylated Hydroxyanisole inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein]21220312
C027561butylbenzyl phthalatebutylbenzyl phthalate results in increased phosphorylation of EGFR protein22552774
C027561butylbenzyl phthalatefulvestrant inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of EGFR protein]22552774
D020122tert-Butylhydroperoxide"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein]"17116659
D020122tert-ButylhydroperoxideSB 203580 inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein]17116659
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in increased phosphorylation of EGFR protein17116659
D020122tert-Butylhydroperoxidetyrphostin AG 1478 inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein]17116659
D002101Cacodylic AcidCacodylic Acid results in increased expression of EGFR mRNA16122865
D002104Cadmiumacetovanillone inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein]26514923
D002104CadmiumAcetylcysteine inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein]26514923
D002104CadmiumCadmium results in increased activity of EGFR protein25343777
D002104CadmiumCadmium results in increased phosphorylation of EGFR protein26514923
D002104Cadmiumdiphenyleneiodonium inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein]26514923
D002104CadmiumEGFR mutant form inhibits the reaction [Cadmium results in increased phosphorylation of MAPK1 protein]26006730
D002104CadmiumEGFR mutant form inhibits the reaction [Cadmium results in increased phosphorylation of MAPK3 protein]26006730
D002104Cadmiumtyrphostin AG 1478 inhibits the reaction [Cadmium results in increased activity of EGFR protein]25343777
D002104Cadmiumtyrphostin AG 1478 inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein]26514923
D002104CadmiumCadmium results in decreased expression of EGFR mRNA22666406
D019256Cadmium ChlorideCadmium Chloride results in increased expression of EGFR21605009
D019256Cadmium ChlorideCadmium Chloride results in increased expression of EGFR mRNA18560533|2647268
D019256Cadmium ChlorideCadmium Chloride results in increased phosphorylation of EGFR protein25118938|2638518
D019256Cadmium ChlorideEGFR mutant form inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]25744307
D019256Cadmium ChlorideEGFR mutant form inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]25744307
D019256Cadmium ChlorideEGFR protein promotes the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]26385184
D019256Cadmium ChlorideEGFR protein promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]26385184
D019256Cadmium ChlorideEGFR protein promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]26385184
D019256Cadmium ChlorideNOTCH1 mutant form inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]25118938
D019256Cadmium Chloridetyrphostin AG 1478 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]26385184
D019256Cadmium Chloride[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein]23673518
D019256Cadmium Chloride4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of EGFR protein]23376140
D019256Cadmium ChlorideAcetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of EGFR mRNA]23948867
D019256Cadmium ChlorideAcetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]23948867
D019256Cadmium ChlorideCadmium Chloride promotes the reaction [EGFR protein binds to SRC protein]23376140
D019256Cadmium ChlorideCadmium Chloride promotes the reaction [EGFR protein binds to STAT3 protein]23376140
D019256Cadmium Chloride[[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein23376140
D019256Cadmium Chloride[[[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein] which results in increased activity of STAT3 protein23376140
D019256Cadmium Chloride[[[[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein] which results in increased activity of STAT3 protein] promotes the reaction [STAT3 protein binds to STAT3 protein]23376140
D019256Cadmium ChlorideCadmium Chloride results in increased expression of EGFR mRNA23948867
D019256Cadmium ChlorideCadmium Chloride results in increased phosphorylation of and results in increased activity of EGFR protein23376140
D019256Cadmium ChlorideCadmium Chloride results in increased phosphorylation of EGFR protein23948867
D019256Cadmium Chloridegefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]23948867
D019256Cadmium Chloride[SU 6656 results in decreased activity of SRC protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of EGFR protein]23376140
D019256Cadmium Chloride[[tyrphostin AG 1478 results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]23376140
D019256Cadmium Chloride[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased expression of MT2 protein]23376140
D019256Cadmium Chloride[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]23376140
D019256Cadmium Chloride[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]23376140
D019256Cadmium ChlorideCadmium Chloride results in increased phosphorylation of EGFR protein19233221
D019256Cadmium ChlorideKN 93 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]19233221
D019256Cadmium Chloridetyrphostin AG 1478 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]19233221
D002118CalciumCalcium affects the phosphorylation of and affects the expression of EGFR protein8393775
C031293calcium silicatecalcium silicate results in increased activity of EGFR protein21762757
C420268CanertinibCanertinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]18927496
C420268CanertinibCanertinib results in decreased activity of EGFR protein21322567
C420268CanertinibCanertinib results in decreased activity of EGFR protein mutant form21322567
C420268CanertinibCanertinib results in decreased phosphorylation of EGFR protein15956251
C420268CanertinibCanertinib inhibits the reaction [Acetaminophen affects the localization of EGFR protein]28123000
C420268CanertinibCanertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein]28123000
D002211CapsaicinAG 1879 inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]20660715
D002211CapsaicinCapsaicin inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]21462327
D002211CapsaicinCapsaicin results in decreased expression of EGFR protein19855437
D002211CapsaicinCapsaicin results in increased phosphorylation of EGFR protein20619260|2066071
D002211CapsaicinN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]20660715
D002211Capsaicintyrphostin AG 1478 inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]20619260|2066071
D002211CapsaicinAG 1879 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein]20660715
D002211CapsaicinEGFR gene mutant form inhibits the reaction [Capsaicin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]]20660715
D002211CapsaicinEGFR gene mutant form inhibits the reaction [Capsaicin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]]20660715
D002211CapsaicinEGFR gene mutant form inhibits the reaction [Capsaicin results in increased expression of PTGS2 protein]20660715
D002211CapsaicinEGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of AREG mRNA]20660715
D002211CapsaicinEGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of AKT1 protein]20660715
D002211CapsaicinEGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK1 protein]20660715
D002211CapsaicinEGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK3 protein]20660715
D002211Capsaicin[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein20660715
D002211Capsaicintyrphostin AG 1478 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein]20660715
D002211CapsaicinCapsaicin results in decreased expression of EGFR protein14521749
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of EGFR mRNA17484886|2747729
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of EGFR protein27477297
D002251Carbon TetrachlorideNFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA]]27477297
D002251Carbon TetrachlorideNFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR protein]]27477297
D002251Carbon Tetrachloridetetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA]27477297
D002251Carbon Tetrachloridetetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR protein]27477297
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of EGFR mRNA16644059|1800664
D002251Carbon TetrachlorideCurcumin inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA]18006644
C043211carvedilolAG 1879 inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C043211carvedilolAG 1879 inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C043211carvedilolAG 1879 inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C043211carvedilolARRB1 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C043211carvedilolARRB1 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C043211carvedilolARRB2 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C043211carvedilolARRB2 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C043211carvedilolcarvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]18787115
C043211carvedilolcarvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]18787115
C043211carvedilolcarvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]18787115
C043211carvedilol[carvedilol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein18787115
C043211carvedilolHBEGF protein inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C043211carvedilolHBEGF protein inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C043211carvedilolHBEGF protein promotes the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C043211carvedilolN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C043211carvedilolN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C043211carvedilolN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C043211carvedilolPropranolol inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C043211carvedilolPropranolol inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]18787115
C043211carvediloltyrphostin AG 1478 inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C043211carvediloltyrphostin AG 1478 inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C043211carvediloltyrphostin AG 1478 inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C054133casticincasticin results in decreased expression of EGFR protein28444820
D000068579Celecoxib[Celecoxib co-treated with sulindac sulfone] results in decreased expression of EGFR protein17908994
D000068579Celecoxib[Celecoxib co-treated with sulindac sulfone] results in decreased expression of EGFR protein modified form17908994
D000068579CelecoxibCelecoxib promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein]15309881
D002706ChlordanChlordan inhibits the reaction [EGF protein binds to EGFR protein]29329451
D002706ChlordanChlordan inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]29329451
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFR mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of EGFR mRNA26272509
D002734Chlorophyll"Chlorophyll inhibits the reaction [dibenzo(a,l)pyrene results in increased expression of EGFR mRNA]"22079312
D002737ChloropreneChloroprene results in increased expression of EGFR mRNA23125180
D002738ChloroquineChloroquine inhibits the reaction [EGF protein results in decreased expression of EGFR protein]20332299
D002738ChloroquineChloroquine inhibits the reaction [MUC1 affects the expression of EGFR protein]22457794
D002738ChloroquineChloroquine inhibits the reaction [sulindac sulfide results in decreased expression of EGFR protein]20332299
D002738ChloroquineChloroquine inhibits the reaction [sulindac sulfone results in decreased expression of EGFR protein]20332299
D002738ChloroquineChloroquine results in decreased expression of EGFR protein20332299
D004390ChlorpyrifosChlorpyrifos results in increased phosphorylation of EGFR protein26514924
D002784Cholesterol"[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of EGFR mRNA"22129739
C002415cholesterol alpha-oxidecholesterol alpha-oxide results in increased phosphorylation of EGFR protein20466046
C074702chromium hexavalent ionchromium hexavalent ion results in decreased expression of EGFR mRNA18053681
C074702chromium hexavalent ionchromium hexavalent ion results in increased expression of EGFR mRNA19616015
C074702chromium hexavalent ionchromium hexavalent ion results in increased phosphorylation of EGFR protein25477514
C043561chrysinchrysin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]25625231
C039671ciglitazoneciglitazone inhibits the reaction [CREBBP protein binds to EGFR promoter]21080969
C039671ciglitazoneciglitazone inhibits the reaction [NCOA1 protein binds to EGFR promoter]21080969
C039671ciglitazoneciglitazone results in decreased expression of EGFR protein21080969
C039671ciglitazoneCREBBP protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]21080969
C039671ciglitazoneNCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]21080969
C039671ciglitazoneEGFR affects the reaction [ciglitazone results in increased activity of MAPK1]16616945
C039671ciglitazoneEGFR affects the reaction [ciglitazone results in increased activity of MAPK3]16616945
D002922CiguatoxinsCiguatoxins affects the expression of EGFR mRNA18353800
D002927CimetidineCimetidine inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]17295779
D002927Cimetidine[Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]17295779
D002927CimetidineCimetidine inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]17295779
D002927CimetidineCyclic AMP analog inhibits the reaction [Cimetidine inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]17295779
C019304ciprofibrateciprofibrate results in decreased expression of EGFR protein2404574
D007464Clioquinol"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of EGFR protein]"18346929
D007464Clioquinol"[4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased activity of EGFR protein] results in decreased susceptibility to [Copper binds to Clioquinol]"18346929
D007464Clioquinol[Clioquinol binds to Copper] which results in decreased expression of EGFR protein18346929
D007464Clioquinol"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of EGFR protein]"18346929
D007464Clioquinol"[4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK1 protein]"18346929
D007464Clioquinol"[4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK3 protein]"18346929
D007464ClioquinolAG 1879 inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of and results in increased activity of EGFR protein]18346929
D007464Clioquinol[[Clioquinol binds to Copper] which results in increased activity of SRC protein] which results in increased phosphorylation of and results in increased activity of EGFR protein18346929
D007464Clioquinol[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein18346929
D007464Clioquinol[FN1 protein co-treated with [Clioquinol binds to Copper]] results in increased expression of EGFR protein18346929
D007464ClioquinolFN1 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein]18346929
D007464ClioquinolITGA2 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein]18346929
D007464ClioquinolITGA5 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein]18346929
D002994ClofibrateClofibrate inhibits the reaction [CREBBP protein binds to EGFR promoter]21080969
D002994ClofibrateClofibrate inhibits the reaction [NCOA1 protein binds to EGFR promoter]21080969
D002994ClofibrateClofibrate results in decreased expression of EGFR protein21080969
D002994ClofibrateCREBBP protein inhibits the reaction [Clofibrate results in decreased expression of EGFR protein]21080969
D002994ClofibrateNCOA1 protein inhibits the reaction [Clofibrate results in decreased expression of EGFR protein]21080969
D002994Clofibrate[Clofibrate co-treated with Acetaminophen] affects the expression of EGFR mRNA17585979
D002994ClofibrateClofibrate results in decreased expression of EGFR mRNA17585979
D002994ClofibratePPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of EGFR mRNA]17585979
D002994ClofibrateClofibrate results in decreased expression of EGFR protein2404574
C034456CMF regimenEGFR protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]18768436
C018021cobaltous chloridecobaltous chloride results in increased expression of EGFR mRNA19376846
C018021cobaltous chloridecobaltous chloride results in decreased expression of EGFR mRNA24386269
D003042CocaineCocaine results in decreased expression of EGFR mRNA18000554
D003300Copper"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of EGFR protein]"18346929
D003300Copper"[4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased activity of EGFR protein] results in decreased susceptibility to [Copper binds to Clioquinol]"18346929
D003300Copper[Clioquinol binds to Copper] which results in decreased expression of EGFR protein18346929
D003300Copper"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of EGFR protein]"18346929
D003300Copper"[4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK1 protein]"18346929
D003300Copper"[4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK3 protein]"18346929
D003300CopperAG 1879 inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of and results in increased activity of EGFR protein]18346929
D003300Copper[[Clioquinol binds to Copper] which results in increased activity of SRC protein] which results in increased phosphorylation of and results in increased activity of EGFR protein18346929
D003300Copper[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein18346929
D003300Copper[Copper binds to neocuproine] which results in increased phosphorylation of EGFR protein18346929
D003300Copper[Copper binds to Oxyquinoline] which results in increased phosphorylation of EGFR protein18346929
D003300Copper[Copper binds to pyrrolidine dithiocarbamic acid] which results in increased phosphorylation of EGFR protein18346929
D003300Copper[FN1 protein co-treated with [Clioquinol binds to Copper]] results in increased expression of EGFR protein18346929
D003300CopperFN1 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein]18346929
D003300CopperITGA2 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein]18346929
D003300CopperITGA5 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein]18346929
D003300Copper[NSC 689534 binds to Copper] which results in increased expression of EGFR mRNA20971185
D003300Copper[Thiosemicarbazones binds to Copper] which results in increased phosphorylation of EGFR protein20931265
D003300CopperCopper results in decreased expression of EGFR mRNA17205981
D019327Copper SulfateCopper Sulfate results in increased phosphorylation of EGFR protein10564177
C551994crizotinibEGFR protein mutant form results in decreased susceptibility to crizotinib22235099
C551994crizotinibEGFR protein promotes the reaction [EGF protein results in decreased susceptibility to crizotinib]22553343
C551994crizotinibEGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]22553343
C551994crizotinibEGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]22553343
C551994crizotinibEGFR protein results in decreased susceptibility to crizotinib21791641
C551994crizotinib[EGFR protein results in increased phosphorylation of EGFR protein] which results in decreased susceptibility to crizotinib22277784
D003471CuprizoneCuprizone results in increased expression of EGFR mRNA26577399
D003474CurcuminCurcumin analog results in decreased expression of EGFR mRNA26409325
D003474CurcuminCurcumin inhibits the reaction [Acrylamide results in increased expression of EGFR protein]24508477
D003474CurcuminCurcumin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]10851300|1512942
D003474CurcuminCurcumin promotes the reaction [Folfox protocol results in decreased expression of EGFR protein]17918158
D003474CurcuminCurcumin promotes the reaction [Folfox protocol results in decreased phosphorylation of and results in decreased activity of EGFR protein]17918158
D003474CurcuminCurcumin results in decreased expression of and results in decreased activity of EGFR protein10851300
D003474CurcuminCurcumin results in decreased expression of EGFR mRNA15486348|1871936
D003474CurcuminCurcumin results in decreased expression of EGFR protein17918158|1871936
D003474CurcuminCurcumin results in decreased phosphorylation of and results in decreased activity of EGFR protein17918158
D003474CurcuminCurcumin results in decreased phosphorylation of EGFR protein15486348
D003474CurcuminFluorouracil promotes the reaction [Curcumin results in decreased expression of EGFR protein]17918158
D003474CurcuminFluorouracil promotes the reaction [Curcumin results in decreased phosphorylation of and results in decreased activity of EGFR protein]17918158
D003474CurcuminCurcumin inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA]18006644
D003474CurcuminCurcumin results in decreased expression of EGFR mRNA18332871
D003474CurcuminCurcumin results in decreased expression of EGFR protein18332871
D003474CurcuminCurcumin results in decreased phosphorylation of EGFR protein17372590|1833287
D003474CurcuminCurcumin results in decreased expression of EGFR18462866
D003513CycloheximideCycloheximide results in increased expression of EGFR mRNA15228094
D003513Cycloheximide"Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein]"26368632
D003520CyclophosphamideEGFR protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with Fluorouracil]15981280
D016572CyclosporineCyclosporine results in increased expression of EGFR mRNA20106945
D016572CyclosporineCyclosporine results in decreased expression of EGFR mRNA19770486
C017160cypermethrincypermethrin binds to EGFR protein22048644
C017160cypermethrincypermethrin results in decreased expression of EGFR mRNA22048644
C017160cypermethrincypermethrin results in decreased expression of EGFR protein22048644
C017160cypermethrincypermethrin results in decreased phosphorylation of EGFR protein22048644
D003571Cytochalasin B"Cytochalasin B inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein]"15626777
D015638Cytochalasin D"Cytochalasin D inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein]"15626777
D003609DactinomycinDactinomycin inhibits the reaction [Estradiol results in increased expression of EGFR protein]8888411
D003609DactinomycinDactinomycin inhibits the reaction [Methoxychlor results in increased expression of EGFR protein]8888411
C004742daidzein[daidzein co-treated with ESR1 protein] results in decreased expression of EGFR mRNA19347870
C004742daidzein[daidzein co-treated with ESR1 protein] results in decreased expression of EGFR protein19347870
C004742daidzein[daidzein co-treated with ESR2 protein] results in decreased expression of EGFR mRNA19347870
C004742daidzein[daidzein co-treated with ESR2 protein] results in decreased expression of EGFR protein19347870
D000069439DasatinibDasatinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]20664932
D000069439DasatinibDasatinib results in decreased phosphorylation of EGFR protein19398150
D000069439DasatinibEGFR gene mutant form results in increased susceptibility to Dasatinib16740687
D000069439Dasatinib[EGFR gene mutant form results in increased susceptibility to Dasatinib] which results in decreased phosphorylation of STAT3 protein16740687
C014347decitabinedecitabine results in increased expression of EGFR mRNA19151715
D003676Deferoxamine"Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in decreased activity of and results in decreased phosphorylation of EGFR protein]"15626777
C107676deguelindeguelin metabolite results in decreased expression of EGFR protein19139008
C107676deguelindeguelin results in decreased expression of EGFR protein19139008
D003687DehydroepiandrosteroneEGFR protein promotes the reaction [Dehydroepiandrosterone results in increased expression of MIR21 mRNA]25969534
C017185delphinidindelphinidin results in decreased phosphorylation of EGFR protein18618485
D003840Deoxycholic AcidDeoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein22223758
D003840Deoxycholic AcidDeoxycholic Acid results in increased activity of EGFR protein16213893
D003840Deoxycholic AcidDeoxycholic Acid results in increased phosphorylation of EGFR protein14747693
D003840Deoxycholic AcidEGFR protein results in decreased susceptibility to Deoxycholic Acid12507930
D003840Deoxycholic AcidErlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]22223758
D003840Deoxycholic AcidUrsodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of EGFR protein]14747693
D003840Deoxycholic AcidDeoxycholic Acid results in increased activity of EGFR protein14747693
D003847DeoxyglucoseAICA ribonucleotide inhibits the reaction [EGFR protein results in increased import of Deoxyglucose]19625624
D003847DeoxyglucoseEGFR protein mutant form results in increased import of Deoxyglucose19625624
D003907DexamethasoneDexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]]10807665
D003907DexamethasoneDexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]10807665
D003907DexamethasoneDexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to HRAS protein]]10807665
D003907DexamethasoneDexamethasone promotes the reaction [EGFR protein binds to ANXA1 protein modified form]10807665
D003907DexamethasoneMifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]]]10807665
D003907DexamethasoneMifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]]10807665
D003907DexamethasoneMifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to HRAS protein]]]10807665
D003907DexamethasoneMifepristone inhibits the reaction [Dexamethasone promotes the reaction [EGFR protein binds to ANXA1 protein modified form]]10807665
D003907DexamethasoneDexamethasone results in decreased phosphorylation of and results in decreased activity of EGFR protein15556944
C042577diallyl trisulfidediallyl trisulfide results in decreased expression of EGFR protein23754639
D003976DiazinonDiazinon affects the expression of EGFR mRNA22546817
C041517dibenzo(a,l)pyrene"Chlorophyll inhibits the reaction [dibenzo(a,l)pyrene results in increased expression of EGFR mRNA]"22079312
C041517dibenzo(a,l)pyrene"dibenzo(a,l)pyrene results in increased expression of EGFR mRNA"22079312
D003993Dibutyl PhthalateDibutyl Phthalate results in increased phosphorylation of EGFR protein22552774
D003993Dibutyl Phthalatefulvestrant inhibits the reaction [Dibutyl Phthalate results in increased phosphorylation of EGFR protein]22552774
D003993Dibutyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA25607892
D002945Cisplatin[Cisplatin co-treated with Fluorouracil] results in decreased expression of EGFR mRNA15737843
D002945Cisplatin[Cisplatin co-treated with Quercetin] results in increased expression of EGFR mRNA27514524
D002945CisplatinCisplatin promotes the reaction [HER3 protein binds to EGFR protein]20726858
D002945CisplatinCisplatin results in increased phosphorylation of and results in increased uptake of EGFR protein21431282
D002945CisplatinCisplatin results in increased phosphorylation of EGFR protein20726858
D002945CisplatinEGFR gene mutant form results in increased susceptibility to [gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]21541241
D002945CisplatinEGFR mRNA results in decreased susceptibility to Cisplatin18337622
D002945CisplatinEGFR protein affects the susceptibility to Cisplatin21431282
D002945CisplatinEGFR protein results in increased susceptibility to Cisplatin21324906
D002945CisplatinEGFR results in decreased susceptibility to Cisplatin21849418|2190913
D002945CisplatinEGFR results in increased susceptibility to [Cisplatin co-treated with docetaxel co-treated with Fluorouracil]21947696
D002945Cisplatin[ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to Cisplatin21478906
D002945CisplatinLRIG1 protein inhibits the reaction [Cisplatin results in increased phosphorylation of and affects the localization of EGFR protein]21431282
D002945Cisplatin[TNFSF10 protein co-treated with Cisplatin] results in decreased expression of EGFR protein21252285
D002945CisplatinCisplatin promotes the reaction [PRKDC protein binds to EGFR protein]21266349
D003633Dichlorodiphenyl Dichloroethylene[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA25607892
D004008DiclofenacDiclofenac results in increased expression of EGFR mRNA26934552
C000944dicrotophosdicrotophos results in increased expression of EGFR mRNA28302478
D004026DieldrinDieldrin affects the expression of EGFR mRNA22546817
D004041Dietary FatsDietary Fats results in decreased expression of EGFR mRNA15238619|2260994
D004051Diethylhexyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA25607892
D004051Diethylhexyl PhthalateDiethylhexyl Phthalate results in decreased expression of EGFR protein2404574
D004052DiethylnitrosamineAcetylcysteine inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of and results in increased activity of EGFR protein]17942915
D004052DiethylnitrosamineCTNNB1 protein promotes the reaction [Diethylnitrosamine results in decreased expression of EGFR protein]20583210
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with Piperonyl Butoxide] results in decreased expression of EGFR mRNA20101389
D004052DiethylnitrosamineDiethylnitrosamine results in decreased expression of EGFR protein20583210
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of EGFR mRNA27058323
D004052DiethylnitrosamineDiethylnitrosamine results in increased phosphorylation of and results in increased activity of EGFR protein17942915
D004052Diethylnitrosamineepigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of EGFR mRNA]27058323
D004052DiethylnitrosamineMET protein inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of and results in increased activity of EGFR protein]17942915
D004052Diethylnitrosaminetheaflavin inhibits the reaction [Diethylnitrosamine results in increased expression of EGFR mRNA]27058323
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EGFR protein8403215
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of EGFR mRNA28943392
D004052DiethylnitrosamineDiethylnitrosamine results in decreased expression of EGFR mRNA15660382|1963824
D004052DiethylnitrosamineDiethylnitrosamine results in decreased expression of EGFR protein15660382
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of EGFR mRNA17011747
D002117CalcitriolCalcitriol results in increased expression of EGFR mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in increased expression of EGFR mRNA21592394
D002117CalcitriolCalcitriol results in increased expression of and binds to EGFR protein3498716
D01506416,16-Dimethylprostaglandin E2"EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein]"15578100
C007517diphenyleneiodoniumdiphenyleneiodonium inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein]26514923
C007517diphenyleneiodoniumdiphenyleneiodonium inhibits the reaction [EDN1 protein results in increased phosphorylation of and results in increased activity of EGFR protein]16391241
C031291diphenyliodoniumdiphenyliodonium inhibits the reaction [EDN1 protein results in increased phosphorylation of and results in increased activity of EGFR protein]16261333
D004177DipyroneDipyrone promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein]15309881
D004280DobutamineAG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D004280DobutamineAG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D004280DobutamineAG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D004280DobutamineARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D004280DobutamineARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D004280DobutamineARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D004280DobutamineARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D004280DobutamineDobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]18787115
D004280DobutamineDobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]18787115
D004280DobutamineDobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]18787115
D004280DobutamineHBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D004280DobutamineHBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D004280DobutamineHBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D004280DobutamineN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D004280DobutamineN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D004280DobutamineN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D004280DobutaminePropranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D004280DobutaminePropranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]18787115
D004280Dobutaminetyrphostin AG 1478 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
D004280Dobutaminetyrphostin AG 1478 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
D004280Dobutaminetyrphostin AG 1478 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D004280DobutamineEGFR gene mutant form results in decreased susceptibility to Dobutamine18599591
C067311docetaxelABCB1 protein affects the reaction [EGFR protein results in decreased susceptibility to docetaxel]24888374
C067311docetaxelEGFR protein results in decreased susceptibility to docetaxel24888374
C067311docetaxelEGFR results in increased susceptibility to [Cisplatin co-treated with docetaxel co-treated with Fluorouracil]21947696
C067311docetaxelEGFR results in increased susceptibility to docetaxel21681119
C067311docetaxelgefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to docetaxel]24888374
D004317DoxorubicinDoxorubicin results in increased phosphorylation of EGFR protein17974986
D004317DoxorubicinEGFR protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with Fluorouracil]15981280
D004317Doxorubicin[[gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin17938326
D004317DoxorubicinDoxorubicin results in increased expression of EGFR mRNA25896364
D004317DoxorubicinDoxorubicin results in increased phosphorylation of EGFR protein17974986
D004317DoxorubicinDoxorubicin results in increased phosphorylation of and results in increased activity of EGFR protein15843167
D004365Drugs, Chinese Herbal"Drugs, Chinese Herbal inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]"25856345
D004365Drugs, Chinese Herbal"Drugs, Chinese Herbal results in decreased activity of EGFR protein"25856345
C058249ebastineebastine results in increased activity of EGFR protein22573732
D0151175,8,11,14-Eicosatetraynoic Acid"5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein]"15525798
D0151175,8,11,14-Eicosatetraynoic Acid"5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [Arachidonic Acid results in increased phosphorylation of and results in increased activity of EGFR protein]"15525798
C413879EKB 569EKB 569 results in decreased activity of EGFR protein21322567|2224213
C413879EKB 569EKB 569 results in decreased activity of EGFR protein mutant form21322567
D015251EpirubicinEGFR protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]18768436
C045651epigallocatechin gallateepigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of EGFR protein]24508477
C045651epigallocatechin gallateepigallocatechin gallate inhibits the reaction [EGF protein binds to EGFR protein]17616711
C045651epigallocatechin gallateepigallocatechin gallate inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]17616711
C045651epigallocatechin gallateepigallocatechin gallate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]17616711
C045651epigallocatechin gallateepigallocatechin gallate results in increased expression of EGFR mRNA22079256
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EGFR mRNA22079256
C045651epigallocatechin gallate[Raloxifene Hydrochloride co-treated with epigallocatechin gallate] results in decreased phosphorylation of EGFR protein18371987
C045651epigallocatechin gallateepigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of EGFR mRNA]27058323
C109476epoxiconazole[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA25607892
D060754Equol[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased chemical synthesis of Oxygen]21300668
D060754Equol[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein]21300668
D060754Equol[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]21300668
D060754Equol[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]21300668
C083174erioniteerionite results in increased expression of EGFR protein26368632
D000069347Erlotinib HydrochlorideEGFR gene mutant form results in increased susceptibility to [gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]21541241
D000069347Erlotinib HydrochlorideEGFR protein affects the susceptibility to Erlotinib Hydrochloride21080748
D000069347Erlotinib HydrochlorideEGFR protein mutant form affects the susceptibility to Erlotinib Hydrochloride21080748
D000069347Erlotinib HydrochlorideEGFR protein mutant form results in decreased susceptibility to Erlotinib Hydrochloride16407879
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride inhibits the reaction [arsenic trioxide results in increased phosphorylation of and results in increased activity of EGFR protein]23548265
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]25625231
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]26455392
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]26455392
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]26455392
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]26455392
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein]28101945
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]19168569
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]22223758
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]21787763
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride results in decreased activity of and results in decreased phosphorylation of EGFR protein23548265
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride results in decreased activity of EGFR protein12907618|2108074
D000069347Erlotinib Hydrochloride[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein23548265
D000069347Erlotinib Hydrochloride[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein23548265
D000069347Erlotinib Hydrochloride[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein23548265
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride results in decreased glycosylation of and results in decreased expression of EGFR protein22223758
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride results in decreased phosphorylation of EGFR protein16891461|2309936
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride binds to EGFR protein22048644
D000069347Erlotinib HydrochlorideErlotinib Hydrochloride results in decreased activity of EGFR protein16891461|1898099
C025483estradiol-17 beta-glucuronideEGFR protein promotes the reaction [estradiol-17 beta-glucuronide affects the localization of and results in decreased activity of ABCC2 protein]25813982
C025483estradiol-17 beta-glucuronideestradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of EGFR protein25813982
C025483estradiol-17 beta-glucuronidetyrphostin AG 1478 inhibits the reaction [estradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of EGFR protein]25813982
C074283estradiol 3-benzoateestradiol 3-benzoate results in increased expression of EGFR protein15778002
D004967EstrogensEstrogens results in increased expression of EGFR mRNA14647453
D004967Estrogens[Estrogens co-treated with Progesterone] results in increased expression of EGFR mRNA21258428
D004967Estrogens[Estrogens co-treated with Progesterone] results in increased expression of EGFR protein21258428
D004967EstrogensEstrogens results in increased expression of EGFR mRNA21258428
D004967EstrogensEstrogens results in increased expression of EGFR protein21258428
D004970EstroneEstrone inhibits the reaction [LEPR gene mutant form inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]1753381
D004970EstroneEstrone inhibits the reaction [LEPR gene mutant form results in decreased expression of EGFR mRNA]1753381
D000431Ethanol[Ethanol co-treated with CYP2E1 protein] results in increased phosphorylation of EGFR protein22222162
D000431EthanolEthanol results in decreased expression of EGFR mRNA19167417
D000431EthanolEthanol results in increased expression of EGFR mRNA15353170
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of EGFR mRNA17555576
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of EGFR mRNA17942748
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of EGFR protein2197011|2786453
D004997Ethinyl EstradiolEthinyl Estradiol results in increased stability of EGFR protein2197011
C024565ethylene dichlorideethylene dichloride results in decreased expression of EGFR mRNA28189721
D005038EthylnitrosoureaEthylnitrosourea results in increased mutagenesis of EGFR gene15366372|1672432
D005047EtoposideEtoposide results in decreased expression of EGFR mRNA15228094
D005047EtoposideEtoposide results in decreased expression of EGFR protein15228094
D005054EugenolEugenol results in decreased expression of EGFR protein15618236
D005054EugenolEugenol results in increased expression of EGFR mRNA15618236
D000068338EverolimusEverolimus results in increased expression of EGFR mRNA28711525
D000068338EverolimusEverolimus results in increased expression of EGFR protein28711525
D000068338Everolimusplatycodin D inhibits the reaction [Everolimus results in increased expression of EGFR protein]28711525
C049639evodiamineEGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]19854188
C049639evodiamineEGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]19854188
C049639evodiamineEGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of PLCG1 protein]19854188
C049639evodiamineEGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of PRKCA protein]19854188
C049639evodiamineevodiamine results in increased phosphorylation of EGFR protein19854188
C049639evodiaminetyrphostin AG 1478 inhibits the reaction [evodiamine results in increased phosphorylation of EGFR protein]19854188
C471268FD137 nitrosourea[FD137 nitrosourea inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]] which results in decreased expression of FOS mRNA14991862
C471268FD137 nitrosourea[FD137 nitrosourea metabolite inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]] which results in decreased expression of FOS mRNA14991862
C471268FD137 nitrosoureaFD137 nitrosourea results in decreased activity of EGFR protein14991862
C540355fenamidonefenamidone results in increased expression of EGFR mRNA27029645
D011345FenofibrateFenofibrate results in decreased expression of EGFR mRNA11798191
C000499ferric oxideferric oxide analog results in increased phosphorylation of EGFR protein24068039
C007738fluoranthene[1-methylanthracene co-treated with fluoranthene] results in increased expression of EGFR mRNA28329830
D0150732-Acetylaminofluorene2-Acetylaminofluorene affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]10900465
D0150732-Acetylaminofluorene2-Acetylaminofluorene results in decreased expression of EGFR mRNA22213190
D005472Fluorouracil[Cisplatin co-treated with Fluorouracil] results in decreased expression of EGFR mRNA15737843
D005472FluorouracilEGFR gene polymorphism affects the susceptibility to [oxaliplatin co-treated with Fluorouracil]16098254
D005472FluorouracilEGFR gene polymorphism results in decreased susceptibility to Fluorouracil19217205
D005472FluorouracilEGFR protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with Fluorouracil]15981280
D005472FluorouracilEGFR protein affects the susceptibility to Fluorouracil16836928|1716937
D005472FluorouracilEGFR results in increased susceptibility to [Cisplatin co-treated with docetaxel co-treated with Fluorouracil]21947696
D005472FluorouracilFluorouracil promotes the reaction [Curcumin results in decreased expression of EGFR protein]17918158
D005472FluorouracilFluorouracil promotes the reaction [Curcumin results in decreased phosphorylation of and results in decreased activity of EGFR protein]17918158
D005472FluorouracilFluorouracil results in decreased expression of EGFR protein17918158|1798267
D005472FluorouracilFluorouracil results in decreased phosphorylation of and results in decreased activity of EGFR protein17918158
D005472FluorouracilFluorouracil results in increased phosphorylation of EGFR protein18794807
D005472FluorouracilTP53 protein affects the reaction [Fluorouracil results in decreased expression of EGFR protein]17982676
D005473Fluoxetine[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein19662385
D005473Fluoxetine[[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein19662385
D005473Fluoxetine[[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein19662385
D005473FluoxetineFluoxetine results in increased phosphorylation of EGFR protein18758753
D005473FluoxetineN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein]18758753
D005473Fluoxetinetyrphostin AG 1478 inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein]18758753
D005478FlurandrenoloneFlurandrenolone results in increased activity of EGFR protein22573732
D005485FlutamideFlutamide results in decreased expression of EGFR mRNA24136188
C410216Folfox protocolCurcumin promotes the reaction [Folfox protocol results in decreased expression of EGFR protein]17918158
C410216Folfox protocolCurcumin promotes the reaction [Folfox protocol results in decreased phosphorylation of and results in decreased activity of EGFR protein]17918158
C410216Folfox protocolFolfox protocol results in decreased expression of EGFR protein17918158
C410216Folfox protocolFolfox protocol results in decreased phosphorylation of and results in decreased activity of EGFR protein17918158
D005620Freund's Adjuvant[Urethane co-treated with Freund's Adjuvant] results in increased expression of EGFR mRNA12400877
C070081fulvestrantfulvestrant inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of EGFR protein]22552774
C070081fulvestrantfulvestrant inhibits the reaction [Dibutyl Phthalate results in increased phosphorylation of EGFR protein]22552774
C039281furanfuran results in decreased expression of EGFR mRNA25539665
C037032galangingalangin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]25625231
D005707Gallic Acid[Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]27634460
D005707Gallic AcidGallic Acid inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]27087131|2763446
D005707Gallic AcidSRC protein modified form affects the reaction [Gallic Acid inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]]27087131
D005707Gallic AcidSRC protein modified form inhibits the reaction [Gallic Acid inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]]27087131
C106014geduningedunin results in decreased expression of EGFR protein17010675
C419708gefitinibEGFR gene mutant form affects the susceptibility to gefitinib18271929
C419708gefitinibEGFR gene mutant form promotes the reaction [gefitinib results in decreased expression of SQSTM1 protein]27639429
C419708gefitinibEGFR gene mutant form promotes the reaction [gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]27639429
C419708gefitinibEGFR gene mutant form results in decreased susceptibility to gefitinib16740687
C419708gefitinibEGFR gene mutant form results in increased susceptibility to gefitinib16115929|2763942
C419708gefitinibEGFR gene polymorphism results in increased susceptibility to gefitinib18625569
C419708gefitinibEGFR protein affects the susceptibility to gefitinib15976335|1624382
C419708gefitinibEGFR protein mutant form results in decreased susceptibility to gefitinib17290066
C419708gefitinibEGFR protein mutant form results in increased susceptibility to gefitinib16824645|1727002
C419708gefitinib[gefitinib co-treated with oxaliplatin] results in decreased phosphorylation of EGFR protein13680161
C419708gefitinibgefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]17898861
C419708gefitinibgefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]16243822|1892749
C419708gefitinibgefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]21787763
C419708gefitinibgefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]21787763
C419708gefitinibgefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to docetaxel]24888374
C419708gefitinibgefitinib inhibits the reaction [gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]17146438
C419708gefitinibgefitinib inhibits the reaction [irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein]15723263
C419708gefitinibgefitinib inhibits the reaction [irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein]15723263
C419708gefitinibgefitinib promotes the reaction [EGF protein binds to EGFR protein]21787763
C419708gefitinibgefitinib promotes the reaction [EGFR protein binds to EGFR protein]21787763
C419708gefitinib[gefitinib promotes the reaction [EGFR protein binds to EGFR protein]] which results in decreased activity of EGFR protein21787763
C419708gefitinibgefitinib promotes the reaction [IGF1R protein binds to EGFR protein]17473213
C419708gefitinibgefitinib results in decreased activity of EGFR protein17938326|2054969
C419708gefitinibgefitinib results in decreased activity of [EGFR protein binds to EGFR protein]17898861
C419708gefitinibgefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]17898861
C419708gefitinib[gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein17938326
C419708gefitinib[[gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin17938326
C419708gefitinibgefitinib results in decreased expression of EGFR protein modified form19288272
C419708gefitinibgefitinib results in decreased phosphorylation of EGFR protein13680161|1467915
C419708gefitinib[ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to gefitinib21478906
C419708gefitinibKRAS protein affects the reaction [EGFR protein affects the susceptibility to gefitinib]28739874
C419708gefitinibgefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]23948867
C419708gefitinibgefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]15841081
C419708gefitinib[gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene20935109
C419708gefitinibgefitinib results in decreased phosphorylation of and results in decreased activity of EGFR protein20935109
C419708gefitinibgefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]29228391
C419708gefitinibgefitinib results in decreased activity of EGFR protein29228391
C419708gefitinibgefitinib results in decreased expression of EGFR protein modified form15660382
C419708gefitinibgefitinib results in decreased phosphorylation of EGFR protein18375820
C419708gefitinibgefitinib affects the activity of EGFR protein23061908
C419708gefitinibgefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]15202007
C419708gefitinibgefitinib results in decreased activity of EGFR protein12906920|1463900
C001277geldanamycingeldanamycin promotes the reaction [Sulfasalazine results in decreased expression of EGFR protein]20007406
C001277geldanamycingeldanamycin results in decreased expression of EGFR protein20007406
C001277geldanamycingeldanamycin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]]9664232
C001277geldanamycingeldanamycin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]]9605431
C056507gemcitabinebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]17146438
C056507gemcitabineEGFR gene mutant form results in increased susceptibility to [gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]21541241
C056507gemcitabinegefitinib inhibits the reaction [gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]17146438
C056507gemcitabinegemcitabine promotes the reaction [HER3 protein binds to EGFR protein]20726858
C056507gemcitabinegemcitabine results in decreased expression of EGFR mRNA20103597
C056507gemcitabinegemcitabine results in decreased expression of EGFR protein17146438
C056507gemcitabinegemcitabine results in increased degradation of EGFR protein17146438
C056507gemcitabinegemcitabine results in increased expression of EGFR mRNA17146438
C056507gemcitabinegemcitabine results in increased phosphorylation of EGFR protein17146438|2072685
D019833Genistein[Genistein co-treated with ESR1 protein] results in decreased expression of EGFR mRNA19347870
D019833Genistein[Genistein co-treated with ESR1 protein] results in decreased expression of EGFR protein19347870
D019833Genistein[Genistein co-treated with ESR2 protein] results in decreased expression of EGFR mRNA19347870
D019833Genistein[Genistein co-treated with ESR2 protein] results in decreased expression of EGFR protein19347870
D019833GenisteinGenistein results in decreased expression of EGFR mRNA15257099
D019833GenisteinGenistein results in decreased expression of EGFR mRNA11880592
D019833GenisteinGenistein results in increased expression of EGFR protein15781664
D019833Genistein[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Genistein results in increased secretion of Testosterone]19059320
D005839GentamicinsGentamicins results in increased expression of EGFR mRNA22061828
C097367ginsenoside Rg3EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]25824408
C097367ginsenoside Rg3ginsenoside Rg3 affects the phosphorylation of EGFR protein25824408
C097367ginsenoside Rg3ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]25824408
C097367ginsenoside Rg3ginsenoside Rg3 results in decreased expression of and affects the localization of EGFR protein25824408
D005897GlafenineGlafenine results in decreased expression of EGFR mRNA24136188
D005978GlutathioneGlutathione inhibits the reaction [2'-benzoyloxycinnamaldehyde results in increased phosphorylation of EGFR protein]14660655
D005978Glutathione[Acetaminophen results in decreased abundance of Glutathione] which results in increased phosphorylation of and results in increased activity of EGFR protein28123000
D005978Glutathione[phorone results in decreased abundance of Glutathione] which results in increased phosphorylation of and results in increased activity of EGFR protein28123000
C081021Go 6976Go 6976 inhibits the reaction [irinotecan metabolite results in increased phosphorylation of EGFR protein]15723263
C081021Go 6976Go 6976 inhibits the reaction [irinotecan results in increased phosphorylation of EGFR protein]15723263
C081021Go 6976Go 6976 inhibits the reaction [EGF protein binds to and results in increased localization of EGFR protein]11134345
D006046Gold[Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]27634460
D017612Gold CompoundsGold Compounds results in decreased expression of and results in decreased phosphorylation of EGFR protein20209498
C551538GW 583340GW 583340 inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein]28426875
C551538GW 583340GW 583340 results in decreased phosphorylation of EGFR protein28426875
C505802helioxanthin[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the localization of EGFR protein modified form26464283
C505802helioxanthinhelioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein]26464283
D006493HeparinHeparin results in decreased expression of EGFR mRNA16475731
D006493HeparinHeparin results in decreased expression of EGFR protein16475731
D006493HeparinHeparin results in increased phosphorylation of EGFR protein16556679
C089796hexabromocyclododecanehexabromocyclododecane results in increased phosphorylation of EGFR protein26718265
C089796hexabromocyclododecane[hexabromocyclododecane co-treated with FSHB protein] results in increased phosphorylation of EGFR protein24071787
D006581Hexachlorobenzene[AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein]21205633
D006581HexachlorobenzeneHexachlorobenzene results in increased phosphorylation of and results in increased expression of EGFR protein23462309
D006581HexachlorobenzeneHexachlorobenzene results in increased phosphorylation of EGFR protein21205633
D006581Hexachlorobenzene[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK1 protein]21205633
D006581Hexachlorobenzene[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK3 protein]21205633
D006581Hexachlorobenzene[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of STAT5B protein]21205633
D006581Hexachlorobenzene[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased susceptibility to Hexachlorobenzene21205633
D006581HexachlorobenzeneHexachlorobenzene affects the reaction [AHR protein affects the expression of EGFR mRNA]28923513
D006581HexachlorobenzeneHexachlorobenzene results in increased expression of EGFR mRNA28923513
D006581HexachlorobenzeneAG 1879 inhibits the reaction [SRC protein promotes the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein]]18295415
D006581HexachlorobenzeneHexachlorobenzene promotes the reaction [EGFR protein binds to SRC protein]18295415|2224512
D006581HexachlorobenzeneHexachlorobenzene promotes the reaction [Methylnitrosourea promotes the reaction [EGFR protein binds to SRC protein]]22245120
D006581HexachlorobenzeneHexachlorobenzene promotes the reaction [Methylnitrosourea results in increased phosphorylation of EGFR protein]22245120
D006581HexachlorobenzeneHexachlorobenzene results in increased phosphorylation of and results in decreased expression of EGFR protein22245120
D006581HexachlorobenzeneHexachlorobenzene results in increased phosphorylation of EGFR protein18295415
D006581HexachlorobenzeneMethylnitrosourea promotes the reaction [Hexachlorobenzene promotes the reaction [EGFR protein binds to SRC protein]]22245120
D006581HexachlorobenzeneMethylnitrosourea promotes the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein]22245120
D006581HexachlorobenzeneSRC protein promotes the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein]18295415
D006632HistamineEGFR protein affects the reaction [Histamine results in increased secretion of MMP1 protein]17656145
D017313FenretinideFenretinide results in increased expression of EGFR mRNA16570282
D017313FenretinideFenretinide results in decreased expression of EGFR mRNA28973697
C545813huachansu[arsenic trioxide co-treated with huachansu] results in decreased expression of EGFR protein21434348
D006820Hyaluronic Acid[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]21520325
D006820Hyaluronic AcidEGFR protein affects the chemical synthesis of and affects the localization of Hyaluronic Acid21520325
D006820Hyaluronic Acid[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [EGF protein results in increased chemical synthesis of Hyaluronic Acid]21520325
D006851Hydrochloric AcidCelecoxib promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein]15309881
D006851Hydrochloric AcidDipyrone promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein]15309881
D006851Hydrochloric AcidHydrochloric Acid results in increased expression of EGFR protein15309881
D006851Hydrochloric AcidPiroxicam promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein]15309881
D006861Hydrogen PeroxideHydrogen Peroxide results in increased expression of EGFR mRNA26846883
D006861Hydrogen PeroxideAcetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of EGFR protein]10640773
D006861Hydrogen PeroxideEGFR mutant form inhibits the reaction [Hydrogen Peroxide results in increased expression of MMP9 mRNA]26514923
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of EGFR protein21179406
D006861Hydrogen PeroxideHydrogen Peroxide results in increased phosphorylation of and results in increased activity of EGFR protein10640773
D006861Hydrogen PeroxideAG 1879 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of EGFR protein]14737115
D006861Hydrogen PeroxideHydrogen Peroxide results in increased phosphorylation of EGFR protein14737115
D006861Hydrogen PeroxideHydrogen Peroxide results in increased phosphorylation of EGFR protein19885844
D006877Hydroxamic AcidsHydroxamic Acids analog inhibits the reaction [EGF protein promotes the reaction [STAT3 protein binds to EGFR protein]]26088127
D006997Hypochlorous AcidHypochlorous Acid results in increased phosphorylation of and results in increased activity of EGFR protein18156441
C051781ICI 164384ICI 164384 inhibits the reaction [[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 mRNA]18629630
C531470icotinibEGFR gene mutant form promotes the reaction [icotinib results in decreased expression of SQSTM1 protein]27639429
C531470icotinibEGFR gene mutant form promotes the reaction [icotinib results in increased cleavage of and results in increased activity of CASP3 protein]27639429
C531470icotinibEGFR gene mutant form results in increased susceptibility to icotinib27639429
C016517indole-3-carbinolindole-3-carbinol results in decreased expression of EGFR protein18025290
D007213IndomethacinIndomethacin results in increased expression of EGFR protein17977527
D007213Indomethacinmalabaricone B promotes the reaction [Indomethacin results in increased expression of EGFR protein]17977527
D007213Indomethacinmalabaricone C promotes the reaction [Indomethacin results in increased expression of EGFR protein]17977527
C051890irinotecanbisindolylmaleimide I inhibits the reaction [irinotecan metabolite results in increased phosphorylation of EGFR protein]15723263
C051890irinotecanbisindolylmaleimide I inhibits the reaction [irinotecan results in increased phosphorylation of EGFR protein]15723263
C051890irinotecangefitinib inhibits the reaction [irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein]15723263
C051890irinotecangefitinib inhibits the reaction [irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein]15723263
C051890irinotecanGo 6976 inhibits the reaction [irinotecan metabolite results in increased phosphorylation of EGFR protein]15723263
C051890irinotecanGo 6976 inhibits the reaction [irinotecan results in increased phosphorylation of EGFR protein]15723263
C051890irinotecanirinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein15723263
C051890irinotecanirinotecan results in increased phosphorylation of and results in increased activity of EGFR protein15723263
C051890irinotecanrottlerin inhibits the reaction [irinotecan metabolite results in increased phosphorylation of EGFR protein]15723263
C051890irinotecanrottlerin inhibits the reaction [irinotecan results in increased phosphorylation of EGFR protein]15723263
C051890irinotecanirinotecan metabolite results in decreased activity of EGFR protein15723263
C051890irinotecanirinotecan results in decreased activity of EGFR protein15723263
D007545IsoproterenolIsoproterenol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]18787115
D007545IsoproterenolIsoproterenol results in increased expression of EGFR mRNA20003209
C016527isoquercitrinisoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]26109002
C561695(+)-JQ1 compound[EGFR gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in decreased expression of MYC protein26455392
C561695(+)-JQ1 compound[EGFR gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in increased activity of CASP3 protein26455392
C561695(+)-JQ1 compound[EGFR gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in increased activity of CASP7 protein26455392
C471998JTE 013JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of EGFR protein]26518876
C471998JTE 013JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]26518876
C107086KB R7785KB R7785 inhibits the reaction [CXCL8 protein results in increased phosphorylation of and results in increased activity of EGFR protein]15300588
C107086KB R7785KB R7785 inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased activity of EGFR protein]15300588
C107086KB R7785KB R7785 results in decreased phosphorylation of EGFR protein16240219
D007654KetoconazoleKetoconazole inhibits the reaction [EGF protein results in increased uptake of and results in increased degradation of EGFR protein]23125191
C072105KN 93KN 93 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]19233221
D064747LansoprazoleLansoprazole results in increased expression of EGFR protein9881512
C490728lapatinibEGFR protein affects the susceptibility to lapatinib28739874
C490728lapatinibKRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]28739874
C490728lapatiniblapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]28739874
C490728lapatiniblapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]28739874
C490728lapatiniblapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]28739874
C490728lapatiniblapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]28739874
C490728lapatiniblapatinib results in decreased activity of EGFR protein15665275|1719253
C490728lapatinibpirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]28739874
C490728lapatinibpirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]28739874
C490728lapatiniblapatinib results in decreased activity of EGFR protein16091755|2179497
C490728lapatinib[lapatinib results in decreased activity of EGFR protein] which results in decreased susceptibility to EGF protein21794976
D007854LeadLead results in decreased expression of EGFR protein17298174
C008261lead acetate"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein]"19133285
C008261lead acetateEGFR mutant form inhibits the reaction [lead acetate results in increased activity of PRKCA protein]19133285
C008261lead acetateEGFR mutant form inhibits the reaction [lead acetate results in increased phosphorylation of SRC protein]19133285
C008261lead acetatelead acetate results in increased phosphorylation of EGFR protein19133285
C008261lead acetatetyrphostin AG 1478 inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein]19133285
C008261lead acetatelead acetate results in decreased expression of EGFR protein17298174
C017461lead nitrateEGFR mutant form affects the reaction [lead nitrate results in increased expression of PLA2G4A mRNA]20850495
C017461lead nitrateEGFR mutant form affects the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]20850495
C017461lead nitrateEGFR mutant form affects the reaction [lead nitrate results in increased secretion of Dinoprostone]20850495
C017461lead nitrateEGFR promotes the reaction [lead nitrate results in increased expression of PLA2G4A mRNA]20850495
C017461lead nitratelead nitrate results in increased phosphorylation of EGFR protein20850495
C017461lead nitratetyrphostin AG 1478 inhibits the reaction [lead nitrate results in increased phosphorylation of EGFR protein]20850495
C045463leflunomideleflunomide results in increased expression of EGFR mRNA28988120
C038753leptomycin B[leptomycin B co-treated with TGFA protein co-treated with acteoside] affects the localization of EGFR protein modified form21967610
C038753leptomycin B[leptomycin B co-treated with TGFA protein co-treated with polydatin] affects the localization of EGFR protein modified form21967610
C038753leptomycin B[leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein21967610
C038753leptomycin B[leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein modified form21967610
C038753leptomycin B[leptomycin B co-treated with TGFA protein co-treated with resveratrol] affects the localization of EGFR protein modified form21967610
C038753leptomycin B[leptomycin B co-treated with TGFA protein co-treated with Rutin] affects the localization of EGFR protein modified form21967610
C038753leptomycin Bleptomycin B promotes the reaction [TGFA protein affects the localization of EGFR protein]21967610
C018584linaloollinalool results in increased expression of EGFR mRNA19922762
D008044Linuron[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA25607892
D008044LinuronLinuron results in decreased expression of EGFR mRNA12730624
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in increased expression of EGFR mRNA"24972896
C482199lipopolysaccharide, E coli O55-B5"[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of EGFR mRNA"18930950
D008070LipopolysaccharidesLipopolysaccharides results in increased phosphorylation of EGFR protein21874253|2309936
D008070LipopolysaccharidesQuercetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of EGFR protein]23099361
D008070LipopolysaccharidesTLR4 mutant form promotes the reaction [Lipopolysaccharides results in increased phosphorylation of EGFR protein]21874253
D018021Lithium Chloride[Lithium Chloride results in decreased activity of and results in increased phosphorylation of GSK3B protein] which results in increased expression of EGFR mRNA22493441
D018021Lithium Chloride[Lithium Chloride results in decreased activity of and results in increased phosphorylation of GSK3B protein] which results in increased expression of EGFR protein22493441
D018021Lithium ChlorideLithium Chloride results in increased expression of EGFR mRNA22493441
D018021Lithium ChlorideLithium Chloride results in increased expression of EGFR protein22493441
D018021Lithium ChlorideN-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride results in increased expression of EGFR mRNA]22493441
D008148LovastatinLovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]12942316
D008148LovastatinLovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]19760159
D017997Leukotriene C4Leukotriene C4 results in increased expression of EGFR mRNA12388339
D047311LuteolinEGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of EGFR protein]12168845
D047311LuteolinEGFR protein affects the susceptibility to Luteolin12168845
D047311LuteolinLuteolin affects the activity of and results in decreased phosphorylation of EGFR protein12168845
D047311LuteolinLuteolin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]15135307
D047311LuteolinLuteolin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]10556937|2292644
D047311LuteolinLuteolin results in decreased expression of EGFR mRNA22926442
D047311LuteolinLuteolin results in decreased phosphorylation of and results in increased activity of EGFR protein15135307
C032881lysophosphatidic acidGNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]23127547
C032881lysophosphatidic acidlysophosphatidic acid results in increased phosphorylation of EGFR protein23127547
C032881lysophosphatidic acidPertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]23127547
C032881lysophosphatidic acidresveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]23127547
D008274MagnesiumMagnesium inhibits the reaction [Ofloxacin results in increased phosphorylation of EGFR protein]23274517
D015636Magnesium Chloride[Magnesium Chloride co-treated with EGF protein] results in increased activity of EGFR protein2354210
D058185Magnetite Nanoparticles[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of EGFR mRNA26378955
C071788malabaricone Bmalabaricone B promotes the reaction [Indomethacin results in increased expression of EGFR protein]17977527
C071787malabaricone Cmalabaricone C promotes the reaction [Indomethacin results in increased expression of EGFR protein]17977527
C025340manganese chloride[manganese chloride co-treated with EGF protein] results in increased activity of EGFR protein2354210
C025340manganese chloridemanganese chloride results in increased activity of EGFR protein2354210
D008555MelittenMelitten results in increased activity of EGFR protein22613720
D008627Mercuric ChlorideMercuric Chloride results in increased expression of EGFR mRNA10901180
D008727MethotrexateEGFR mRNA results in decreased susceptibility to Methotrexate16918715
D008727MethotrexateMethotrexate results in increased expression of EGFR mRNA18803016
D008731MethoxychlorMethoxychlor results in increased phosphorylation of EGFR protein28426875
D008731MethoxychlorDactinomycin inhibits the reaction [Methoxychlor results in increased expression of EGFR protein]8888411
D008731MethoxychlorMethoxychlor results in increased expression of EGFR protein8888411
D008746Methylazoxymethanol AcetateMethylazoxymethanol Acetate results in increased expression of EGFR mRNA28349193
D008748MethylcholanthreneMethylcholanthrene results in decreased expression of EGFR mRNA29094188
C005223methyleugenolmethyleugenol results in decreased expression of EGFR protein15618236
C002950methylformamidemethylformamide analog results in decreased expression of EGFR mRNA17040096
C002950methylformamidemethylformamide results in decreased expression of EGFR mRNA17040096
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of EGFR mRNA28001369
C004925methylmercuric chloridemethylmercuric chloride results in increased phosphorylation of EGFR protein28958600
D008767Methylmercury CompoundsMethylmercury Compounds results in decreased expression of EGFR protein17298174
D008767Methylmercury CompoundsMethylmercury Compounds results in decreased expression of EGFR protein17298174
D008769MethylnitronitrosoguanidineMethylnitronitrosoguanidine affects the localization of EGFR protein15708576
D008769MethylnitronitrosoguanidineMethylnitronitrosoguanidine inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]15708576
D008770MethylnitrosoureaHexachlorobenzene promotes the reaction [Methylnitrosourea promotes the reaction [EGFR protein binds to SRC protein]]22245120
D008770MethylnitrosoureaHexachlorobenzene promotes the reaction [Methylnitrosourea results in increased phosphorylation of EGFR protein]22245120
D008770Methylnitrosourea[Methylnitrosourea co-treated with Testosterone] results in increased expression of and results in increased phosphorylation of EGFR protein25164625
D008770MethylnitrosoureaMethylnitrosourea promotes the reaction [EGFR protein binds to SRC protein]22245120
D008770MethylnitrosoureaMethylnitrosourea promotes the reaction [Hexachlorobenzene promotes the reaction [EGFR protein binds to SRC protein]]22245120
D008770MethylnitrosoureaMethylnitrosourea promotes the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein]22245120
D008770MethylnitrosoureaMethylnitrosourea results in increased phosphorylation of and results in decreased expression of EGFR protein22245120
D008770MethylnitrosoureaQuercetin inhibits the reaction [[Methylnitrosourea co-treated with Testosterone] results in increased expression of and results in increased phosphorylation of EGFR protein]25164625
D015741MetriboloneMetribolone results in increased phosphorylation of and results in increased activity of EGFR protein17272394
D008798Mevalonic AcidMevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]]20359552
D015735MifepristoneMifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]]]10807665
D015735MifepristoneMifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]]10807665
D015735MifepristoneMifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to HRAS protein]]]10807665
D015735MifepristoneMifepristone inhibits the reaction [Dexamethasone promotes the reaction [EGFR protein binds to ANXA1 protein modified form]]10807665
D015735MifepristoneMifepristone results in decreased expression of EGFR mRNA18591650|2597220
C575143Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrinMn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin results in decreased phosphorylation of EGFR protein24635018
C406082monomethylarsonous acidEGFR protein affects the reaction [monomethylarsonous acid results in increased expression of PTGS2 protein]17093206
C406082monomethylarsonous acidmonomethylarsonous acid results in decreased expression of EGFR mRNA20886546
C406082monomethylarsonous acidmonomethylarsonous acid results in increased expression of EGFR mRNA19945496
C406082monomethylarsonous acidmonomethylarsonous acid results in increased expression of EGFR protein17093206
C040015myricetinmyricetin promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]18995957
C040015myricetinmyricetin results in decreased phosphorylation of EGFR protein18995957
C570404N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide"N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide results in decreased activity of EGFR protein"22003817
C063509N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamideN-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride results in increased expression of EGFR mRNA]22493441
C092152N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide"N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide inhibits the reaction [ELANE protein results in increased phosphorylation of EGFR protein]"17456367
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]20660715
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein]12972402
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide"N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Asbestos, Serpentine results in increased activity of EGFR protein]"16571779
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein]18758753
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein]21568938
C078131N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide affects the reaction [PTPN11 protein affects the reaction [EDN1 protein results in increased phosphorylation of and results in increased activity of EGFR protein]]16261333
C487932N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamideN-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide results in decreased activity of EGFR protein21322567|2224213
C487932N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamideN-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide results in decreased activity of EGFR protein mutant form21322567
C415243N-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)acrylamideN-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)acrylamide results in decreased phosphorylation of EGFR protein10987266
C465666N-(4-((4,5-dichloro-2-fluorophenyl)amino)quinazolin-6-yl)acrylamide"N-(4-((4,5-dichloro-2-fluorophenyl)amino)quinazolin-6-yl)acrylamide binds to and results in decreased phosphorylation of EGFR protein"12209961
C465666N-(4-((4,5-dichloro-2-fluorophenyl)amino)quinazolin-6-yl)acrylamide"N-(4-((4,5-dichloro-2-fluorophenyl)amino)quinazolin-6-yl)acrylamide results in decreased phosphorylation of EGFR protein"12573320
C452423N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amineEGFR affects the susceptibility to N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine15604279
C452423N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amineN-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine results in decreased activity of EGFR protein15596048
C452423N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amineN-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine results in decreased phosphorylation of EGFR protein21350000
C452423N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amineN-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine results in decreased activity of EGFR protein15604279|1694079
D037742Nanotubes, Carbon"Nanotubes, Carbon affects the expression of EGFR mRNA"23845593
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of EGFR mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of EGFR mRNA"25554681|2562005
C031721naphthalene[gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene20935109
C073873naphtho(1,2-b)furan-4,5-dione"naphtho(1,2-b)furan-4,5-dione inhibits the reaction [EGF protein binds to and results in increased activity of EGFR protein]"23064031
C073873naphtho(1,2-b)furan-4,5-dione"[naphtho(1,2-b)furan-4,5-dione inhibits the reaction [EGF protein binds to and results in increased activity of EGFR protein]] which results in decreased expression of MMP9"23064031
C073873naphtho(1,2-b)furan-4,5-dione"naphtho(1,2-b)furan-4,5-dione inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]"23064031
C005273naringeninnaringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR protein]25866363
C005274naringinnaringin inhibits the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein]22766066
C051752nefazodonenefazodone results in decreased expression of EGFR mRNA24136188
C002701neocuproine[Copper binds to neocuproine] which results in increased phosphorylation of EGFR protein18346929
D019829NevirapineNevirapine results in decreased expression of EGFR mRNA19152342
C119536nickel acetateMUC1 mutant form inhibits the reaction [nickel acetate results in increased phosphorylation of EGFR protein]25053108
C119536nickel acetatenickel acetate results in decreased expression of and results in decreased phosphorylation of EGFR protein22210268
C119536nickel acetatenickel acetate results in decreased expression of EGFR mRNA22210268
C119536nickel acetatenickel acetate results in increased phosphorylation of EGFR protein25053108
C022838nickel chloridenickel chloride results in increased expression of EGFR protein26026961
C022838nickel chlorideRECK protein inhibits the reaction [nickel chloride results in increased expression of EGFR protein]26026961
C022838nickel chloridenickel chloride affects the expression of EGFR mRNA22546817
C017557nickel subsulfidenickel subsulfide results in increased expression of EGFR mRNA21086188
C029938nickel sulfate[TGFA protein binds to and affects the activity of EGFR protein] which results in decreased susceptibility to nickel sulfate19131640
D009534NiclosamideNiclosamide results in decreased phosphorylation of EGFR protein28426875
D009538NicotineAG 1879 inhibits the reaction [Nicotine results in increased phosphorylation of EGFR protein]14569062
D009538NicotineNicotine results in increased phosphorylation of EGFR protein14569062
D009538NicotineNicotine results in decreased expression of EGFR mRNA11478936
C500716N-isobutyl-N-(4-methoxyphenylsulfonyl)glycylhydroxamic acidN-isobutyl-N-(4-methoxyphenylsulfonyl)glycylhydroxamic acid inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein]12972402
C562238N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide"ILK protein inhibits the reaction [N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of EGFR mRNA]"21823616
C562238N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide"ILK protein inhibits the reaction [N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of EGFR protein]"21823616
C562238N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide"N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of EGFR mRNA"21823616
C562238N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide"N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of EGFR protein"21823616
C001870nonachlornonachlor binds to EGFR protein29329451
C001870nonachlornonachlor inhibits the reaction [EGF protein binds to EGFR protein]29329451
C001870nonachlornonachlor inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]29329451
C510003nordynordy inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]17377739
D009638NorepinephrineEGFR protein inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]19168439
C558013NSC 689534[NSC 689534 binds to Copper] which results in increased expression of EGFR mRNA20971185
C501177NVP-AEW541NVP-AEW541 inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]20664932
C516714NVP-TAE684[EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein] which results in decreased susceptibility to NVP-TAE68422843788
C516714NVP-TAE684EGFR protein results in decreased susceptibility to NVP-TAE68421791641
C025589ochratoxin Aochratoxin A results in increased phosphorylation of EGFR protein23172667
D015242OfloxacinCYBB protein affects the reaction [Ofloxacin results in increased phosphorylation of EGFR protein]23274517
D015242OfloxacinMagnesium inhibits the reaction [Ofloxacin results in increased phosphorylation of EGFR protein]23274517
D015242OfloxacinOfloxacin results in increased phosphorylation of EGFR protein23274517
D015242OfloxacinRAC1 protein affects the reaction [Ofloxacin results in increased phosphorylation of EGFR protein]23274517
D000069463Olive OilOlive Oil analog affects the expression of EGFR mRNA17349074
C000603933osimertinibosimertinib results in decreased activity of EGFR protein28237877
D010047OvalbuminOvalbumin results in increased expression of EGFR mRNA12388339
C030110oxaliplatinEGFR gene polymorphism affects the susceptibility to [oxaliplatin co-treated with Fluorouracil]16098254
C030110oxaliplatin[gefitinib co-treated with oxaliplatin] results in decreased phosphorylation of EGFR protein13680161
C030110oxaliplatinoxaliplatin results in increased phosphorylation of EGFR protein16243822
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of EGFR mRNA25729387
D010076OxazepamOxazepam results in decreased expression of EGFR mRNA15618236
D010076OxazepamOxazepam results in decreased expression of EGFR protein15618236
C029341oxophenylarsineoxophenylarsine inhibits the reaction [EGF protein binds to and affects the localization of EGFR protein]12093727
D010100Oxygen[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased chemical synthesis of Oxygen]21300668
D010121OxytocinOxytocin results in increased expression of EGFR protein modified form23707249
D010126OzoneAG 1879 inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein]25303742
D010126OzoneAHR protein affects the reaction [Ozone results in increased phosphorylation of EGFR protein]19536146
D010126OzoneOzone results in increased phosphorylation of EGFR protein19536146|2530374
D010126OzoneProtein Kinase Inhibitors inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein]25303742
D010126Ozone"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein]"26464147
D010126OzoneOzone results in increased phosphorylation of EGFR protein26464147
D017239PaclitaxelPaclitaxel promotes the reaction [HER3 protein binds to EGFR protein]20726858
D017239PaclitaxelPaclitaxel results in decreased expression of EGFR mRNA18058816
D017239PaclitaxelPaclitaxel results in increased phosphorylation of EGFR protein16211241|2072685
D017239Paclitaxel[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein16413505
D010269ParaquatParaquat results in decreased expression of EGFR protein17298174
D010278ParathionAtropine inhibits the reaction [Parathion results in increased expression of EGFR protein]17390078
D010278Parathion[Parathion co-treated with Estradiol] results in increased expression of EGFR protein17622325
D010278ParathionParathion results in increased expression of EGFR protein17390078|1762232
D017374Paroxetine[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein19662385
D017374Paroxetine[[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein19662385
D017374Paroxetine[[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein19662385
D052638Particulate MatterAG 1879 inhibits the reaction [Particulate Matter results in increased phosphorylation of EGFR protein]17028263
D052638Particulate MatterButylated Hydroxyanisole inhibits the reaction [Particulate Matter results in increased phosphorylation of EGFR protein]17028263
D052638Particulate MatterEGFR protein affects the reaction [Particulate Matter results in increased secretion of AR protein]24555532
D052638Particulate MatterEGFR protein affects the reaction [Particulate Matter results in increased secretion of CXCL8 protein]24555532
D052638Particulate MatterEGFR protein affects the reaction [Particulate Matter results in increased secretion of TGFA protein]24555532
D052638Particulate MatterErlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein]28101945
D052638Particulate MatterParticulate Matter analog results in increased expression of EGFR mRNA24910982
D052638Particulate MatterParticulate Matter analog results in increased phosphorylation of EGFR protein28101945
D052638Particulate MatterParticulate Matter results in decreased expression of EGFR mRNA24769257
D052638Particulate MatterParticulate Matter results in increased phosphorylation of EGFR protein17028263|1892683
D052638Particulate MatterParticulate Matter analog results in increased phosphorylation of EGFR protein28101945
D052638Particulate MatterParticulate Matter results in increased phosphorylation of EGFR protein27158778|2737705
C000610380p-carboxymethylphenyl 1,1-bis(3'-indolyl)-1-(p-carboxymethylphenyl)methane"p-carboxymethylphenyl 1,1-bis(3'-indolyl)-1-(p-carboxymethylphenyl)methane results in decreased expression of EGFR protein"26035713
C509204PD168393PD168393 affects the localization of EGFR protein21967610
C509204PD168393PD168393 affects the localization of EGFR protein modified form21967610
C509204PD168393[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein16413505
C509204PD168393PD168393 inhibits the reaction [resveratrol results in increased phosphorylation of EGFR protein]23527233
C509204PD168393PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein]21967610
C509204PD168393PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]21967610
C509204PD168393PD168393 results in decreased phosphorylation of EGFR protein21967610|2352723
C509204PD168393PD168393 inhibits the reaction [[resveratrol co-treated with TNF protein] results in increased phosphorylation of EGFR protein]23527233
C509204PD168393PD168393 results in decreased activity of EGFR protein21967610
C509204PD168393[PD168393 results in decreased activity of EGFR protein] which results in decreased susceptibility to TGFA protein21967610
C086401pentabromodiphenyl etherpentabromodiphenyl ether results in increased phosphorylation of EGFR protein24184330
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in increased phosphorylation of EGFR protein28288859
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in increased expression of EGFR mRNA21251948
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in increased expression of EGFR protein21251948
C023036perfluorooctanoic acidEstradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]22414604
C023036perfluorooctanoic acidEstradiol promotes the reaction [Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]]22414604
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of EGFR protein22414604
C023036perfluorooctanoic acidperfluorooctanoic acid results in increased expression of EGFR protein20118188
C023036perfluorooctanoic acidProgesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]22414604
C023036perfluorooctanoic acidProgesterone promotes the reaction [Estradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]]22414604
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of EGFR mRNA16221955
D037342Pertussis ToxinPertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]23127547
C076715pervanadatepervanadate results in increased phosphorylation of EGFR protein18926838
D010575PesticidesPesticides results in increased methylation of EGFR gene28396702
C525726PF 00299804PF 00299804 inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]27491023
D015232DinoprostoneDinoprostone results in increased phosphorylation of EGFR protein17805209
D015232DinoprostoneEGFR mutant form affects the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]20850495
D015232DinoprostoneEGFR mutant form affects the reaction [lead nitrate results in increased secretion of Dinoprostone]20850495
D015232DinoprostoneEGFR protein results in increased secretion of Dinoprostone16213893
D010634PhenobarbitalPhenobarbital inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]25625231
D010634PhenobarbitalNR1I3 protein affects the reaction [Phenobarbital results in decreased expression of EGFR mRNA]19482888
D010634PhenobarbitalPhenobarbital affects the expression of EGFR mRNA19136022|2309116
D010634PhenobarbitalPhenobarbital inhibits the reaction [EGF protein binds to EGFR protein]6309801
D010634PhenobarbitalPhenobarbital results in decreased expression of EGFR mRNA19482888
D010634PhenobarbitalPhenobarbital inhibits the reaction [EGF protein binds to EGFR protein]10828207
D010634PhenobarbitalPhenobarbital results in decreased expression of EGFR mRNA19162173
D010634PhenobarbitalPhenobarbital binds to and results in decreased activity of EGFR protein25949234
D010634Phenobarbital[Phenobarbital binds to and results in decreased activity of EGFR protein] which affects the localization of NR1I3 protein25949234
D010656PhenylephrineAtorvastatin Calcium inhibits the reaction [Phenylephrine results in increased expression of and results in increased phosphorylation of and results in increased activity of EGFR protein]18360054
D010656PhenylephrinePhenylephrine results in increased expression of and results in increased phosphorylation of and results in increased activity of EGFR protein18360054
D010656Phenylephrine[EGF protein binds to EGFR protein] promotes the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]16760267
D010656Phenylephrine[EGF protein binds to EGFR protein] promotes the reaction [Phenylephrine results in increased phosphorylation of MAPK3 protein]16760267
D010656PhenylephrinePhenylephrine results in increased phosphorylation of EGFR protein14676212
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of EGFR mRNA26272509
C018637phorone[phorone results in decreased abundance of Glutathione] which results in increased phosphorylation of and results in increased activity of EGFR protein28123000
C008890phosphoramidonphosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]15177934
D010833Phytic Acid"Phytic Acid inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein]"15626777
D010862PilocarpinePilocarpine results in decreased expression of EGFR mRNA17971868
D010882Piperonyl Butoxide[Diethylnitrosamine co-treated with Piperonyl Butoxide] results in decreased expression of EGFR mRNA20101389
C093844pirfenidonelapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]28739874
C093844pirfenidonelapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]28739874
C093844pirfenidonepirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]28739874
C093844pirfenidone[pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]] which results in decreased phosphorylation of PTPN3 protein28739874
C093844pirfenidone[pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]] which results in increased phosphorylation of EGFR protein28739874
C093844pirfenidonepirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]28739874
C093844pirfenidonepirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]28739874
C093844pirfenidonepirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]28739874
C006253pirinixic acidpirinixic acid affects the expression of EGFR mRNA19136022
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of EGFR mRNA19710929
C006253pirinixic acid[pirinixic acid co-treated with PPARA] results in decreased expression of EGFR mRNA20813756
C006253pirinixic acidpirinixic acid results in decreased expression of EGFR mRNA11798191|1530286
C006253pirinixic acidPPARA protein promotes the reaction [pirinixic acid results in decreased expression of EGFR mRNA]20059764
C006253pirinixic acidpirinixic acid results in decreased expression of EGFR protein2404574
D010894PiroxicamPiroxicam results in decreased expression of EGFR mRNA21858171
D010894PiroxicamPiroxicam promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein]15309881
C410026PKI 166PKI 166 results in decreased activity of and results in decreased phosphorylation of EGFR protein12912971
D010936Plant ExtractsPlant Extracts results in decreased expression of EGFR mRNA23557933
D010936Plant ExtractsPlant Extracts results in increased phosphorylation of EGFR protein25051199
D028321Plant PreparationsPlant Preparations results in decreased expression of EGFR mRNA24973489
C108953platycodin Dbenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [platycodin D results in decreased expression of EGFR protein]28711525
C108953platycodin Dplatycodin D inhibits the reaction [Everolimus results in increased expression of EGFR protein]28711525
C108953platycodin Dplatycodin D results in decreased expression of EGFR protein23867902|2871152
C108953platycodin Dplatycodin D inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]23867902
D011084Polycyclic Aromatic HydrocarbonsPolycyclic Aromatic Hydrocarbons results in increased expression of EGFR mRNA24910982
C058229polydatinpolydatin inhibits the reaction [TGFA protein affects the localization of EGFR protein]21967610
C058229polydatin[leptomycin B co-treated with TGFA protein co-treated with polydatin] affects the localization of EGFR protein modified form21967610
C058229polydatinpolydatin inhibits the reaction [EGFR protein affects the expression of CCL2 mRNA]21967610
C058229polydatinpolydatin inhibits the reaction [EGFR protein affects the expression of CCL2 protein]21967610
C058229polydatinpolydatin inhibits the reaction [EGFR protein affects the expression of CXCL10 mRNA]21967610
C058229polydatinpolydatin inhibits the reaction [EGFR protein affects the expression of CXCL10 protein]21967610
C545373ponatinibponatinib results in decreased activity of EGFR protein mutant form19878872
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EGFR mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of EGFR mRNA22079256
D011319PrimaquinePrimaquine inhibits the reaction [EGF protein results in increased uptake of and results in increased degradation of EGFR protein]23125191
C045362prochloraz[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA25607892
C035988procymidone[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA25607892
D011374Progesterone[Progesterone co-treated with Estradiol] results in increased expression of EGFR mRNA18692832
D011374ProgesteroneProgesterone promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]16175315
D011374ProgesteroneProgesterone results in increased expression of EGFR protein16175315
D011374Progesterone[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]21520325
D011374ProgesteroneEstradiol promotes the reaction [Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]]22414604
D011374ProgesteroneProgesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]22414604
D011374ProgesteroneProgesterone promotes the reaction [Estradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]]22414604
D011374Progesterone[Estrogens co-treated with Progesterone] results in increased expression of EGFR mRNA21258428
D011374Progesterone[Estrogens co-treated with Progesterone] results in increased expression of EGFR protein21258428
D011374ProgesteroneProgesterone results in increased expression of EGFR mRNA18591650
D011374ProgesteroneEGFR protein affects the chemical synthesis of Progesterone21520325
D011433PropranololPropranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D011433PropranololPropranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]18787115
D011433PropranololPropranolol inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D011433PropranololPropranolol inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]18787115
D011433PropranololPropranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
D011433PropranololPropranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]18787115
D011441PropylthiouracilPropylthiouracil results in increased expression of EGFR mRNA24780913
D047428Protein Kinase InhibitorsProtein Kinase Inhibitors inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein]25303742
C028025protoporphyrin IXprotoporphyrin IX results in decreased expression of EGFR protein23624237
C043680ptaquilosideptaquiloside results in decreased expression of EGFR mRNA23274088
C107773pterostilbenepterostilbene inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR protein]19447859
D011710PyocyaninePyocyanine results in increased phosphorylation of EGFR protein24015256
C513428pyrachlostrobinpyrachlostrobin results in increased expression of EGFR mRNA27029645
C432165pyrazolanthronepyrazolanthrone results in decreased expression of EGFR mRNA15923621
C432165pyrazolanthronepyrazolanthrone results in decreased expression of EGFR protein15923621
C432165pyrazolanthronepyrazolanthrone results in decreased expression of EGFR mRNA18332871
C432165pyrazolanthronepyrazolanthrone results in decreased expression of EGFR protein18332871
C014175pyrazolo(3,4-d)pyrimidine"pyrazolo(3,4-d)pyrimidine analog affects the expression of EGFR mRNA"21152443
C014175pyrazolo(3,4-d)pyrimidine"pyrazolo(3,4-d)pyrimidine analog results in decreased expression of EGFR protein"21152443
C014175pyrazolo(3,4-d)pyrimidine"pyrazolo(3,4-d)pyrimidine analog results in decreased expression of EGFR protein"21152443
C020972pyrrolidine dithiocarbamic acid[Copper binds to pyrrolidine dithiocarbamic acid] which results in increased phosphorylation of EGFR protein18346929
D011794Quercetin[Cisplatin co-treated with Quercetin] results in increased expression of EGFR mRNA27514524
D011794QuercetinEGF protein inhibits the reaction [Quercetin results in decreased phosphorylation of EGFR protein]12168845
D011794QuercetinEGFR protein affects the susceptibility to Quercetin12168845
D011794QuercetinQuercetin affects the activity of and results in decreased phosphorylation of EGFR protein12168845
D011794QuercetinQuercetin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]15135307
D011794QuercetinQuercetin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]10556937
D011794QuercetinQuercetin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]21756928
D011794QuercetinQuercetin results in decreased expression of EGFR mRNA21308698
D011794QuercetinQuercetin results in decreased phosphorylation of and results in increased activity of EGFR protein15135307
D011794QuercetinQuercetin results in decreased phosphorylation of EGFR protein18618485|2130869
D011794QuercetinQuercetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of EGFR protein]23099361
D011794QuercetinQuercetin inhibits the reaction [[Methylnitrosourea co-treated with Testosterone] results in increased expression of and results in increased phosphorylation of EGFR protein]25164625
D011794Quercetin[leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein21967610
D011794Quercetin[leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein modified form21967610
D011794QuercetinQuercetin inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]21967610
D011794QuercetinQuercetin promotes the reaction [TGFA protein affects the localization of EGFR protein]21967610
D011794QuercetinQuercetin promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]21967610
D011799QuinazolinesQuinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK1 protein]21075094
D011799QuinazolinesQuinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK3 protein]21075094
D011799QuinazolinesQuinazolines analog results in decreased phosphorylation of EGFR protein10753475
D015125Oxyquinoline[Copper binds to Oxyquinoline] which results in increased phosphorylation of EGFR protein18346929
D020849Raloxifene Hydrochloride[Raloxifene Hydrochloride co-treated with epigallocatechin gallate] results in decreased phosphorylation of EGFR protein18371987
D020849Raloxifene HydrochlorideRaloxifene Hydrochloride results in increased phosphorylation of EGFR protein24782323
D017382Reactive Oxygen Species[[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein23376140
D017382Reactive Oxygen Species[[[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein] which results in increased activity of STAT3 protein23376140
D017382Reactive Oxygen Species[[[[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein] which results in increased activity of STAT3 protein] promotes the reaction [STAT3 protein binds to STAT3 protein]23376140
D017382Reactive Oxygen SpeciesEGFR protein affects the reaction [Reactive Oxygen Species affects the phosphorylation of SHC1 protein]19168439
D017382Reactive Oxygen SpeciesReactive Oxygen Species results in increased activity of EGFR protein24635018
C059514resveratrolAR protein affects the reaction [[resveratrol binds to EGFR protein] which results in decreased phosphorylation of EGFR protein]20729295
C059514resveratrolEGF protein inhibits the reaction [resveratrol results in decreased phosphorylation of EGFR protein]20729295
C059514resveratrolPD168393 inhibits the reaction [resveratrol results in increased phosphorylation of EGFR protein]23527233
C059514resveratrolresveratrol affects the localization of EGFR protein23527233
C059514resveratrolresveratrol affects the localization of EGFR protein modified form23527233
C059514resveratrolresveratrol binds to EGFR protein20729295
C059514resveratrol[resveratrol binds to EGFR protein] which results in decreased phosphorylation of EGFR protein20729295
C059514resveratrolresveratrol inhibits the reaction [EGR protein results in increased phosphorylation of EGFR protein]23127547
C059514resveratrolresveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]23127547
C059514resveratrolresveratrol inhibits the reaction [TGFA protein affects the localization of EGFR protein]21967610
C059514resveratrolresveratrol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]16343977
C059514resveratrolresveratrol results in decreased expression of and results in decreased phosphorylation of EGFR protein25063218
C059514resveratrolresveratrol results in decreased expression of EGFR mRNA25667456
C059514resveratrolresveratrol results in decreased expression of EGFR protein24514079
C059514resveratrolresveratrol results in decreased phosphorylation of EGFR protein20729295|2352723
C059514resveratrolresveratrol results in increased activity of EGFR protein15802018
C059514resveratrolresveratrol results in increased degradation of EGFR protein23527233
C059514resveratrolresveratrol results in increased phosphorylation of EGFR protein23527233
C059514resveratrolresveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]26100520
C059514resveratrolresveratrol promotes the reaction [ursolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]]26100520
C059514resveratrolresveratrol results in decreased expression of EGFR mRNA23525482
C059514resveratrolursolic acid promotes the reaction [resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]]26100520
C059514resveratrol[leptomycin B co-treated with TGFA protein co-treated with resveratrol] affects the localization of EGFR protein modified form21967610
C059514resveratrolPD168393 inhibits the reaction [[resveratrol co-treated with TNF protein] results in increased phosphorylation of EGFR protein]23527233
C059514resveratrol[resveratrol co-treated with TNF protein] results in increased phosphorylation of EGFR protein23527233
C059514resveratrolresveratrol inhibits the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein]21942447
C059514resveratrolresveratrol inhibits the reaction [EGFR protein affects the expression of CCL2 mRNA]21967610
C059514resveratrolresveratrol inhibits the reaction [EGFR protein affects the expression of CCL2 protein]21967610
C059514resveratrolresveratrol inhibits the reaction [EGFR protein affects the expression of CXCL10 mRNA]21967610
C059514resveratrolresveratrol inhibits the reaction [EGFR protein affects the expression of CXCL10 protein]21967610
D015474IsotretinoinIsotretinoin results in decreased expression of EGFR mRNA15982314
C000589977rociletinibrociletinib results in decreased activity of EGFR protein28237877
C087123romidepsinromidepsin results in decreased expression of EGFR protein15014036
C089730rosiglitazonerosiglitazone results in increased phosphorylation of EGFR protein18507034
D012402RotenoneRotenone results in decreased expression of EGFR protein17555550
C085746rottlerinrottlerin inhibits the reaction [irinotecan metabolite results in increased phosphorylation of EGFR protein]15723263
C085746rottlerinrottlerin inhibits the reaction [irinotecan results in increased phosphorylation of EGFR protein]15723263
C085746rottlerinrottlerin inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]15177934
D012431RutinRutin inhibits the reaction [TGFA protein affects the localization of EGFR protein]21967610
D012431Rutin[leptomycin B co-treated with TGFA protein co-treated with Rutin] affects the localization of EGFR protein modified form21967610
D012431RutinRutin promotes the reaction [TGFA protein results in increased phosphorylation of EGFR protein]21967610
C093642SB 203580SB 203580 inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein]17116659
D012601Scopolamine HydrobromideScopolamine Hydrobromide results in decreased expression of EGFR mRNA12818353
C090142secoisolariciresinol diglucosidesecoisolariciresinol diglucoside results in decreased expression of EGFR mRNA19904759
D012643SeleniumSelenium results in decreased expression of EGFR mRNA17390030
D012645SelenomethionineSelenomethionine results in increased expression of EGFR mRNA17205524
D017632Asbestos, Serpentine"Asbestos, Serpentine results in decreased phosphorylation of EGFR protein"15626777
D017632Asbestos, Serpentine"Asbestos, Serpentine results in increased activity of EGFR protein"16571779
D017632Asbestos, Serpentine"N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Asbestos, Serpentine results in increased activity of EGFR protein]"16571779
D020280SertralineSertraline results in increased expression of EGFR mRNA24865413
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of EGFR mRNA25895662
D012822Silicon DioxideSilicon Dioxide analog results in increased phosphorylation of EGFR protein24844442
D012822Silicon DioxideSilicon Dioxide results in increased expression of EGFR mRNA21540303
D012822Silicon DioxideSilicon Dioxide results in increased expression of EGFR mRNA23221170
D019821SimvastatinMevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]]20359552
D019821SimvastatinSimvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]20359552
D020123SirolimusAG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein]19151764
D020123SirolimusAG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein]19151764
D020123SirolimusAG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein]19151764
D020123SirolimusSirolimus results in increased phosphorylation of and results in increased activity of EGFR protein19151764
D020123Sirolimus[Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein19151764
D020123Sirolimus[Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein19151764
D020123Sirolimus[Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of EGFR protein19151764
D012906SmokeSmoke results in decreased expression of EGFR mRNA21095227
D012906SmokeSmoke results in decreased nitrosation of EGFR protein21652289
C009277sodium arsenatesodium arsenate results in increased expression of EGFR mRNA21795629
C017947sodium arseniteEGFR mutant form inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein]15734884
C017947sodium arseniteErlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]19168569
C017947sodium arsenitesodium arsenite affects the methylation of EGFR gene28589171
C017947sodium arsenitesodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of EGFR protein]26104857
C017947sodium arsenitesodium arsenite results in decreased expression of EGFR mRNA28595984
C017947sodium arsenitesodium arsenite results in increased activity of and results in increased phosphorylation of EGFR protein15734884
C017947sodium arsenitesodium arsenite results in increased activity of EGFR protein19414066
C017947sodium arsenitesodium arsenite results in increased expression of EGFR mRNA12016162
C017947sodium arsenitesodium arsenite results in increased expression of EGFR protein25907674
C017947sodium arsenite[sodium arsenite results in increased expression of EGFR protein] which results in increased phosphorylation of PCNA protein25907674
C017947sodium arsenitesodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein11723127|1550445
C017947sodium arsenitesodium arsenite results in increased phosphorylation of EGFR protein10564177|1194366
C017947sodium arseniteSU 6656 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein]15504454
C017947sodium arsenitetyrphostin AG 1478 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein]15504454
C017947sodium arsenitetyrphostin AG 1478 inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]28974440
C017947sodium arsenitesodium arsenite affects the expression of EGFR mRNA16507464
C017947sodium arsenitesodium arsenite promotes the reaction [SRC protein binds to EGFR protein]11723127
C017947sodium arsenitesodium arsenite results in decreased expression of EGFR mRNA19822182
C017947sodium arsenitesodium arsenite results in decreased expression of EGFR protein16507464
C017947sodium arsenitesodium arsenite results in increased expression of EGFR mRNA17077188|9846968
C017947sodium arsenitesodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein11723127
C017947sodium arsenite[EGF protein results in decreased expression of EGFR protein] inhibits the reaction [sodium arsenite results in increased activity of MAPK1 protein]9710602
C017947sodium arsenite[EGF protein results in decreased expression of EGFR protein] inhibits the reaction [sodium arsenite results in increased activity of MAPK3 protein]9710602
C017947sodium arsenitegefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]29228391
C017947sodium arseniteHBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]29228391
C017947sodium arseniteHBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of EGFR protein]29228391
C017947sodium arsenitesodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein]9710602
C017947sodium arsenitesodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein29228391
C017947sodium arsenitesodium arsenite results in decreased phosphorylation of EGFR protein29228391
C017947sodium arsenitesodium arsenite results in increased phosphorylation of EGFR protein9710602
C017947sodium arseniteSuramin inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]9710602
C017947sodium arsenitetyrphostin AG 1478 inhibits the reaction [sodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein]]9710602
C017947sodium arsenitetyrphostin AG 1478 inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]9710602
D012965Sodium Chloride2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein]21568938
D012965Sodium ChlorideN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein]21568938
D012965Sodium ChlorideSodium Chloride results in increased phosphorylation of EGFR protein21568938
D012965Sodium Chloridetyrphostin AG 1478 inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein]21568938
D012965Sodium Chloridewortmannin inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein]21568938
D012972Sodium HydroxideEGFR SNP affects the susceptibility to Sodium Hydroxide27206134
D018038Sodium SeleniteSodium Selenite results in decreased expression of EGFR mRNA23274088
D053260SootSoot results in increased expression of EGFR mRNA22461453|2655175
C471405sorafenibsorafenib results in decreased expression of EGFR mRNA26409325
C060506sphingosine 1-phosphateJTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of EGFR protein]26518876
C060506sphingosine 1-phosphatesphingosine 1-phosphate results in increased phosphorylation of EGFR protein26518876
D019311StaurosporineStaurosporine inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]15177934
D013267StilbenesStilbenes analog results in decreased expression of and results in decreased phosphorylation of EGFR protein25063218
D010042OuabainOuabain results in decreased phosphorylation of EGFR protein28795476
C416927SU 6656SU 6656 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein]15504454
C416927SU 6656[SU 6656 results in decreased activity of SRC protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of EGFR protein]23376140
C416927SU 6656[[tyrphostin AG 1478 results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]23376140
D004113Succimer[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of EGFR mRNA26378955
D012460Sulfasalazinegeldanamycin promotes the reaction [Sulfasalazine results in decreased expression of EGFR protein]20007406
D012460Sulfasalazine[Sulfasalazine co-treated with tripterine] affects the expression of EGFR protein20007406
D012460Sulfasalazine[Sulfasalazine co-treated with tripterine] results in decreased expression of EGFR protein20007406
C025462sulindac sulfidebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of EGFR protein]20332299
C025462sulindac sulfideChloroquine inhibits the reaction [sulindac sulfide results in decreased expression of EGFR protein]20332299
C025462sulindac sulfidesulindac sulfide results in decreased expression of EGFR protein20332299
C025462sulindac sulfidesulindac sulfide results in decreased phosphorylation of EGFR protein20332299
C025462sulindac sulfidesulindac sulfide results in increased phosphorylation of EGFR protein20332299
C025462sulindac sulfidesulindac sulfide results in increased ubiquitination of EGFR protein20332299
C025463sulindac sulfonebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of EGFR protein]20332299
C025463sulindac sulfoneChloroquine inhibits the reaction [sulindac sulfone results in decreased expression of EGFR protein]20332299
C025463sulindac sulfonesulindac sulfone results in decreased expression of EGFR protein20332299
C025463sulindac sulfonesulindac sulfone results in decreased phosphorylation of EGFR protein20332299
C025463sulindac sulfonesulindac sulfone results in increased phosphorylation of EGFR protein20332299
C025463sulindac sulfonesulindac sulfone results in increased ubiquitination of EGFR protein20332299
C025463sulindac sulfone[Celecoxib co-treated with sulindac sulfone] results in decreased expression of EGFR protein17908994
C025463sulindac sulfone[Celecoxib co-treated with sulindac sulfone] results in decreased expression of EGFR protein modified form17908994
D013498SuraminSuramin inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]9710602
C467766taiwanin Ctaiwanin C results in decreased phosphorylation of EGFR protein26537528
D013629Tamoxifen[EGF protein results in increased activity of EGFR protein] which results in decreased susceptibility to Tamoxifen24758408
D013629TamoxifenEGFR mutant form inhibits the reaction [[EGF protein results in increased activity of EGFR protein] which results in decreased susceptibility to Tamoxifen]24758408|2475840
D013629TamoxifenEGFR protein results in decreased susceptibility to Tamoxifen15665275|1600058
D013629Tamoxifen[Tamoxifen co-treated with ESR1 protein] results in decreased expression of EGFR mRNA19347870
D013629Tamoxifen[Tamoxifen co-treated with ESR1 protein] results in decreased expression of EGFR protein19347870
D013629Tamoxifen[Tamoxifen co-treated with ESR2 protein] results in increased expression of EGFR mRNA19347870
D013629Tamoxifen[Tamoxifen co-treated with ESR2 protein] results in increased expression of EGFR protein19347870
D013629TamoxifenTamoxifen results in increased expression of EGFR mRNA20005069
D013629TamoxifenTamoxifen results in increased expression of EGFR protein20005069
D013629TamoxifenTamoxifen affects the expression of EGFR mRNA17555576
C112765tanespimycintanespimycin results in decreased expression of EGFR protein17010675
C112765tanespimycintanespimycin results in increased degradation of and results in decreased expression of EGFR protein16061882
D013656Taurocholic AcidJTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]26518876
D013656Taurocholic AcidS1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]26518876
D013656Taurocholic AcidTaurocholic Acid results in increased phosphorylation of EGFR protein26518876
D016593Terfenadine"11,12-epoxy-5,8,14-eicosatrienoic acid inhibits the reaction [Terfenadine analog results in decreased phosphorylation of EGFR protein]"19289568
D016593TerfenadineTerfenadine analog results in decreased phosphorylation of EGFR protein19289568
D013739Testosterone[Testosterone co-treated with Calcitriol] results in increased expression of EGFR mRNA21592394
D013739TestosteroneTestosterone results in increased expression of EGFR mRNA21592394
D013739TestosteroneTestosterone results in increased expression of EGFR mRNA21669218
D013739Testosterone[Methylnitrosourea co-treated with Testosterone] results in increased expression of and results in increased phosphorylation of EGFR protein25164625
D013739TestosteroneQuercetin inhibits the reaction [[Methylnitrosourea co-treated with Testosterone] results in increased expression of and results in increased phosphorylation of EGFR protein]25164625
D013739TestosteroneTestosterone results in increased phosphorylation of and results in increased activity of EGFR protein17272394
D013739TestosteroneTestosterone results in increased phosphorylation of EGFR protein21177760
D013739Testosterone[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Genistein results in increased secretion of Testosterone]19059320
D013739TestosteroneTestosterone results in increased activity of EGFR protein20403869
C020806tetrabromobisphenol Atetrabromobisphenol A results in increased phosphorylation of EGFR protein26718265
D013749Tetrachlorodibenzodioxinalpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of EGFR protein]17934341
D013749TetrachlorodibenzodioxinEGFR protein affects the susceptibility to Tetrachlorodibenzodioxin9163677
D013749TetrachlorodibenzodioxinEGFR protein promotes the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of AKT1 protein]11309286
D013749TetrachlorodibenzodioxinEGFR protein promotes the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK1 protein]11309286
D013749TetrachlorodibenzodioxinEGFR protein promotes the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK3 protein]11309286
D013749Tetrachlorodibenzodioxin[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EGFR mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]2033054
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of EGFR1336723
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of EGFR mRNA19619570|9163677
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of EGFR protein9787404
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of EGFR protein17934341
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased phosphorylation of EGFR protein20971882|2697137
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased activity of EGFR protein9707505
D013749TetrachlorodibenzodioxinCSK protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]]9664232
D013749Tetrachlorodibenzodioxingeldanamycin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]]9664232
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of EGFR mRNA21570461|2637764
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]6309801|9664232
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of EGFR mRNA14708085|1977048
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of EGFR mRNA17942748|2116763
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of EGFR protein2305375|9787404
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]8430419
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased phosphorylation of EGFR protein8430419|8470122
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin results in increased phosphorylation of EGFR protein] inhibits the reaction [EGF protein binds to EGFR protein]8430419
D013749Tetrachlorodibenzodioxin[Diethylnitrosamine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EGFR protein8403215
D013749Tetrachlorodibenzodioxingeldanamycin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]]9605431
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of EGFR mRNA22298810
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]9605431
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of and affects the localization of EGFR protein11752688
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of EGFR mRNA20959002
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of EGFR protein8403215
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased phosphorylation of EGFR protein10401681|1559292
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [[AHR protein binds to CYP1A1 gene] which results in increased expression of CYP1A1 mRNA]]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [[AHR protein binds to FLG gene] which results in increased expression of FLG mRNA]]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FLG2 mRNA]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FLG mRNA]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FLG protein]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of HRNR mRNA]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCE3A mRNA]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCE3E mRNA]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RPTN mRNA]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of S100A12 mRNA]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of S100A7 mRNA]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of S100A9 mRNA]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SPRR1A mRNA]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SPRR2A mRNA]21835898
D013749Tetrachlorodibenzodioxin[EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SPRR2B mRNA]21835898
C005806tetrachloroisophthalonitriletetrachloroisophthalonitrile results in decreased phosphorylation of EGFR protein28426875
D013752TetracyclineTetracycline results in decreased expression of EGFR mRNA24489787
D013755Tetradecanoylphorbol Acetatenaringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR protein]25866363
D013755Tetradecanoylphorbol Acetatepterostilbene inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR protein]19447859
D013755Tetradecanoylphorbol AcetateTetradecanoylphorbol Acetate results in increased expression of EGFR protein19447859|2586636
D013755Tetradecanoylphorbol AcetateAG 1879 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein]20660715
D013755Tetradecanoylphorbol AcetateEGFR gene mutant form inhibits the reaction [Capsaicin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]]20660715
D013755Tetradecanoylphorbol AcetateEGFR gene mutant form inhibits the reaction [Capsaicin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]]20660715
D013755Tetradecanoylphorbol AcetateEGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of AREG mRNA]20660715
D013755Tetradecanoylphorbol AcetateEGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of AKT1 protein]20660715
D013755Tetradecanoylphorbol AcetateEGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK1 protein]20660715
D013755Tetradecanoylphorbol AcetateEGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK3 protein]20660715
D013755Tetradecanoylphorbol Acetateresveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]26100520
D013755Tetradecanoylphorbol Acetateresveratrol promotes the reaction [ursolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]]26100520
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein20660715
D013755Tetradecanoylphorbol AcetateTetradecanoylphorbol Acetate inhibits the reaction [EGF protein binds to EGFR protein]6309801
D013755Tetradecanoylphorbol AcetateTetradecanoylphorbol Acetate results in increased expression of EGFR26100520
D013755Tetradecanoylphorbol AcetateTetradecanoylphorbol Acetate results in increased phosphorylation of EGFR protein26513295
D013755Tetradecanoylphorbol Acetatetyrphostin AG 1478 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein]20660715
D013755Tetradecanoylphorbol Acetateursolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]26100520
D013755Tetradecanoylphorbol Acetateursolic acid promotes the reaction [resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]]26100520
C017953tetramethylpyrazineNFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA]]27477297
C017953tetramethylpyrazineNFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR protein]]27477297
C017953tetramethylpyrazinetetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA]27477297
C017953tetramethylpyrazinetetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR protein]27477297
C020809tetrathiomolybdatetetrathiomolybdate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]18480265
D019284ThapsigarginThapsigargin results in increased expression of EGFR protein24648495
C056068theaflavintheaflavin inhibits the reaction [Diethylnitrosamine results in increased expression of EGFR mRNA]27058323
D013853Thioacetamide[Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of EGFR mRNA28943392
D013853ThioacetamideThioacetamide results in decreased expression of EGFR mRNA23411599
D013859ThiocarbamatesThiocarbamates results in decreased expression of and results in decreased phosphorylation of EGFR protein20209498
D013882Thiosemicarbazones[Thiosemicarbazones binds to Copper] which results in increased phosphorylation of EGFR protein20931265
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in decreased expression of EGFR mRNA28065790
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased expression of EGFR mRNA27865774
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased phosphorylation of and results in increased activity of EGFR protein22457794
D014051Toluene 2,4-Diisocyanate"EGFR protein affects the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CCL5 protein]"16908450
D014051Toluene 2,4-Diisocyanate"EGFR protein affects the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]"16908450
D014051Toluene 2,4-Diisocyanate"EGFR protein affects the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CXCL8 protein]"16908450
D019772TopotecanTopotecan results in decreased expression of EGFR mRNA15923621
D019772TopotecanTopotecan results in decreased expression of EGFR protein15923621
D019772TopotecanTopotecan results in decreased phosphorylation of EGFR protein15923621
D019772Topotecan[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased susceptibility to Topotecan15923621
D019772TopotecanTopotecan results in decreased expression of EGFR protein15923621
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of EGFR mRNA25729387
D014212TretinoinTretinoin metabolite results in decreased expression of EGFR mRNA15982314
D014212TretinoinTretinoin results in decreased expression of EGFR protein15970678|1647392
D014212TretinoinTretinoin results in increased expression of EGFR mRNA21934132
D014212TretinoinHBEGF protein promotes the reaction [Tretinoin results in increased phosphorylation of EGFR protein]16357442
D014212TretinoinTretinoin results in increased expression of EGFR mRNA16604517
D014212TretinoinTretinoin results in increased phosphorylation of EGFR protein16357442
D014223TriamtereneEGFR gene SNP affects the susceptibility to Triamterene25622337
D014241TrichloroethyleneTrichloroethylene results in decreased expression of EGFR mRNA15363585|1944899
D014241TrichloroethyleneTrichloroethylene results in increased methylation of EGFR gene27618143
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of EGFR mRNA24935251|2627250
C050414tripterine[Sulfasalazine co-treated with tripterine] affects the expression of EGFR protein20007406
C050414tripterine[Sulfasalazine co-treated with tripterine] results in decreased expression of EGFR protein20007406
C050414tripterinetripterine results in decreased expression of EGFR protein17010675
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of EGFR mRNA"26179874
C080163trovafloxacin"[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of EGFR mRNA"18930950
C101044tyrphostin AG 1478tyrphostin AG 1478 results in decreased phosphorylation of EGFR protein19151764
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]15531749
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [[AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein]21185374
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]26385184
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Cadmium results in increased activity of EGFR protein]25343777
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein]26514923
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]20619260|2066071
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]18787115
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]18787115
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]18787115
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]16472761|2585634
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [EGFR protein binds to GPER1 protein]19749156
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Estradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]]21185374
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Estradiol results in increased phosphorylation of EGFR protein]21185374
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein]19133285
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [lead nitrate results in increased phosphorylation of EGFR protein]20850495
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]15177934
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein]15504454
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]28974440
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Win 55212-2 results in increased phosphorylation of EGFR protein]20619260
C101044tyrphostin AG 1478tyrphostin AG 1478 results in decreased activity of EGFR protein27071941
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein]23673518
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased chemical synthesis of Oxygen]21300668
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein]21300668
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]21300668
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]21300668
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]21520325
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]21520325
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK1 protein]21205633
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK3 protein]21205633
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of STAT5B protein]21205633
C101044tyrphostin AG 1478"[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased susceptibility to 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione"20433816
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased susceptibility to FSHB protein21520325
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased susceptibility to Hexachlorobenzene21205633
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased susceptibility to Topotecan15923621
C101044tyrphostin AG 1478tyrphostin AG 1478 results in decreased phosphorylation of EGFR protein15923621|1861848
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [evodiamine results in increased phosphorylation of EGFR protein]19854188
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein]18758753
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein]21220312
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein]21568938
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein]20660715
C101044tyrphostin AG 1478tyrphostin AG 1478 results in decreased activity of EGFR protein12794006
C101044tyrphostin AG 1478[[tyrphostin AG 1478 results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]23376140
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased expression of MT2 protein]23376140
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]23376140
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]23376140
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased expression of BIRC5 protein21268125
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased phosphorylation of STAT3 protein21268125
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased susceptibility to butaprost21268125
C101044tyrphostin AG 1478tyrphostin AG 1478 results in decreased phosphorylation of and results in decreased activity of EGFR protein21268125
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein]17116659
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein]15849355
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]19233221
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]]16261333
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]]16261333
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [estradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of EGFR protein]25813982
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [LHB protein results in increased phosphorylation of EGFR protein]15459120
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [sodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein]]9710602
C101044tyrphostin AG 1478tyrphostin AG 1478 inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]9710602
C101044tyrphostin AG 1478tyrphostin AG 1478 results in decreased activity of EGFR protein15574683
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [Genistein results in increased secretion of Testosterone]19059320
C101044tyrphostin AG 1478tyrphostin AG 1478 binds to EGFR protein22048644
C101044tyrphostin AG 1478tyrphostin AG 1478 results in decreased activity of EGFR protein12154034|1456906
C101044tyrphostin AG 1478"[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [[[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK1 protein] co-treated with [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK3 protein]] results in increased phosphorylation of ELK1 protein]"18056474
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] inhibits the reaction [EGF protein results in increased chemical synthesis of Hyaluronic Acid]21520325
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] results in decreased activity of [OXT protein binds to and results in increased activity of OXTR protein]12955084
C101044tyrphostin AG 1478[tyrphostin AG 1478 results in decreased activity of EGFR protein] which results in decreased susceptibility to EGF protein21520325
C113580U 0126U 0126 inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]26455392
C113580U 0126U 0126 inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]26455392
C113580U 0126U 0126 inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]26455392
C113580U 0126U 0126 inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]26455392
C113580U 0126U 0126 inhibits the reaction [EGFR protein promotes the reaction [EGF protein results in increased phosphorylation of AKT1 protein]]24758408
C113580U 0126U 0126 inhibits the reaction [EGFR protein promotes the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]]24758408
C113580U 0126U 0126 inhibits the reaction [EGFR protein promotes the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]]24758408
C113580U 0126U 0126 inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]15177934
D014520UrethaneUrethane results in decreased expression of EGFR mRNA28818685
D014520UrethaneIFNG protein promotes the reaction [Urethane results in increased expression of EGFR mRNA]12810352
D014520Urethane[Urethane co-treated with Freund's Adjuvant] results in increased expression of EGFR mRNA12400877
D014520UrethaneUrethane results in increased expression of EGFR mRNA12400877
D014544Uridine TriphosphateUridine Triphosphate results in increased phosphorylation of EGFR protein14676212
D014580Ursodeoxycholic AcidUrsodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of EGFR protein]14747693
C005466ursolic acidresveratrol promotes the reaction [ursolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]]26100520
C005466ursolic acidursolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]26100520
C005466ursolic acidursolic acid promotes the reaction [resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]]26100520
C406224valdecoxibvaldecoxib results in decreased expression of EGFR mRNA24136188
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased methylation of EGFR gene29154799
D014635Valproic AcidValproic Acid results in increased expression of EGFR mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in decreased expression of EGFR mRNA24535564
C034028vanadyl sulfatevanadyl sulfate results in increased phosphorylation of EGFR protein10564177|1194366
D001335Vehicle EmissionsAG 1879 inhibits the reaction [Vehicle Emissions results in increased phosphorylation of EGFR protein]17028263
D001335Vehicle EmissionsButylated Hydroxyanisole inhibits the reaction [Vehicle Emissions results in increased phosphorylation of EGFR protein]17028263
D001335Vehicle EmissionsEGFR protein affects the reaction [Vehicle Emissions results in increased secretion of AR protein]24555532
D001335Vehicle EmissionsEGFR protein affects the reaction [Vehicle Emissions results in increased secretion of CXCL8 protein]24555532
D001335Vehicle EmissionsEGFR protein affects the reaction [Vehicle Emissions results in increased secretion of TGFA protein]24555532
D001335Vehicle EmissionsVehicle Emissions results in increased phosphorylation of EGFR protein17028263|1892683
D001335Vehicle EmissionsVehicle Emissions results in decreased expression of EGFR mRNA19165385
C521013veliparibEGFR protein results in decreased susceptibility to veliparib21912620
C521013veliparibveliparib affects the localization of EGFR protein21719137
C025643vinclozolin[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA25607892
D014801Vitamin AVitamin A deficiency results in increased expression of EGFR mRNA7519440
D014810Vitamin EVitamin E results in decreased expression of EGFR mRNA19244175
D024483Vitamin K 3Vitamin K 3 results in increased phosphorylation of EGFR protein15843167
C111237vorinostatvorinostat results in decreased phosphorylation of EGFR protein20531243
C111237vorinostatvorinostat results in decreased expression of EGFR mRNA21389970
C111237vorinostatvorinostat results in decreased expression of EGFR protein21389970
D014873Water PollutantsWater Pollutants results in decreased expression of EGFR mRNA23591932
C113888WHI P154"WHI P154 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of EGFR protein]"16778083
C113888WHI P154WHI P154 results in decreased activity of EGFR protein11173405
C118361WHI P180WHI P180 results in decreased activity of EGFR protein11173405
C070417Win 55212-2tyrphostin AG 1478 inhibits the reaction [Win 55212-2 results in increased phosphorylation of EGFR protein]20619260
C070417Win 55212-2Win 55212-2 results in increased phosphorylation of EGFR protein20619260
C009687wortmanninwortmannin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]25856345
C009687wortmanninwortmannin inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]15177934
C009687wortmanninwortmannin inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein]21568938
C571455WZ4002WZ4002 results in decreased activity of EGFR protein mutant form22553343
C523798YM 155EGF protein inhibits the reaction [YM 155 results in decreased phosphorylation of EGFR protein]28787001
C523798YM 155YM 155 results in decreased phosphorylation of EGFR protein28787001
D015032Zinc"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein]"12972402|1598003
D015032ZincAG 1879 inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein]12915106|1598003
D015032ZincHBEGF protein affects the reaction [Zinc results in increased phosphorylation of EGFR protein]12972402
D015032ZincN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein]12972402
D015032ZincN-isobutyl-N-(4-methoxyphenylsulfonyl)glycylhydroxamic acid inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein]12972402
D015032ZincZinc results in increased phosphorylation of and results in increased activity of EGFR protein16410015
D015032ZincZinc results in increased phosphorylation of EGFR protein12915106|1297240
D015032Zinc"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Zinc co-treated with EGFR protein] results in increased activity of RAS protein]"11983694
D015032Zinc"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein]"11983694
D015032Zinc[SRC protein results in increased phosphorylation of EGFR protein] affects the reaction [[Zinc co-treated with EGFR protein] results in increased activity of RAS protein]11983694
D015032Zinc[Zinc co-treated with EGFR protein] results in increased activity of RAS protein11983694
D015032ZincZinc promotes the reaction [EGFR protein binds to SRC protein]11983694
D015032ZincZinc results in increased phosphorylation of EGFR protein11983694
D015032ZincZinc deficiency results in decreased expression of EGFR mRNA12672911
C016837zinc chloridezinc chloride results in increased phosphorylation of EGFR protein21540303
D019287Zinc Sulfate"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Zinc Sulfate results in increased phosphorylation of EGFR protein]"16410015
D019287Zinc SulfateZinc Sulfate results in increased phosphorylation of and results in increased activity of EGFR protein16410015
D019287Zinc SulfateZinc Sulfate results in increased phosphorylation of EGFR protein10564177|1194366
D019287Zinc SulfateZinc Sulfate results in increased phosphorylation of EGFR protein19946718

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0001618virus receptor activity-IEA-  
GO:0003682chromatin binding-IDA20551055  
GO:0003690double-stranded DNA binding-NAS6325948  
GO:0004709MAP kinase kinase kinase activity-IBA21873635  
GO:0004709MAP kinase kinase kinase activity-NAS15542601  
GO:0004713protein tyrosine kinase activity-EXP17349580  
GO:0004713protein tyrosine kinase activity-IBA21873635  
GO:0004713protein tyrosine kinase activity-IDA17115032  17599051  
GO:0004713protein tyrosine kinase activity-IMP14702346  20878056  
GO:0004713protein tyrosine kinase activity-TAS16076471  
GO:0004714transmembrane receptor protein tyrosine kinase activity-IBA21873635  
GO:0004714transmembrane receptor protein tyrosine kinase activity-TAS-  
GO:0004888transmembrane signaling receptor activity-IBA21873635  
GO:0004888transmembrane signaling receptor activity-IDA7736574  
GO:0005006epidermal growth factor-activated receptor activity-IBA21873635  
GO:0005006epidermal growth factor-activated receptor activity-IDA12435727  17115032  
GO:0005006epidermal growth factor-activated receptor activity-IMP22732145  
GO:0005006epidermal growth factor-activated receptor activity-NAS2790960  6325948  
GO:0005088Ras guanyl-nucleotide exchange factor activity-TAS-  
GO:0005178integrin binding-IEA-  
GO:0005515protein binding-IPI2176151  2790960  7518560  7527043  7542744  7657591  
7685104  7693694  7797556  7993895  8034616  8305738  
8621392  8662998  8887653  8940013  9020117  9050838  
9355745  9419975  9506989  9544989  9852145  10026169  
10229072  10572067  10805725  11279102  11483589  11894095  
11896612  12070153  12177062  12297049  12297050  12577067  
12620237  14568990  14679214  14966128  15225635  15557335  
15581623  15590694  15620700  15657067  15677445  15962011  
16263120  16273093  16499958  16516204  16729043  16799092  
16843263  16914641  16954185  17115032  17126326  17148612  
17182860  17284441  17403676  17599051  17697999  17726113  
17909029  18046415  18273061  18455122  18602463  18776048  
18824549  19172738  19509291  19602593  19650109  19798056  
20029029  20308550  20403327  20551055  20562913  20624308  
20878056  20935677  21203579  21258405  21266349  21278786  
21278788  21349850  21376233  21439278  21706016  21822280  
22411794  22439932  22732145  22939624  23178489  23178716  
23273428  23397142  23436906  23520446  23597562  23636329  
23764002  23799367  23866081  23912460  24034250  24076656  
24135280  24189400  24557338  24658140  24780295  24947832  
25036637  25136068  25241761  25311788  25594178  25666625  
25796184  25873175  25970784  26280537  26551075  26751287  
27059931  27569582  28479384  29455656  
GO:0005516calmodulin binding-IEA-  
GO:0005524ATP binding-IEA-  
GO:0019899enzyme binding-IPI12009895  
GO:0019901protein kinase binding-IEA-  
GO:0019903protein phosphatase binding-IPI15899872  
GO:0030235nitric-oxide synthase regulator activitycontributes_toIDA12828935  
GO:0031434mitogen-activated protein kinase kinase binding-IBA21873635  
GO:0031625ubiquitin protein ligase binding-IPI23418353  
GO:0042802identical protein binding-IPI16777603  17148612  18042729  19563760  19650109  20007378  
20029029  20359299  21278786  21480528  21482778  22232519  
22579287  23273428  23374349  23436906  23636329  24135280  
GO:0045296cadherin binding-HDA25468996  
GO:0046934phosphatidylinositol-4,5-bisphosphate 3-kinase activity-TAS-  
GO:0046982protein heterodimerization activity-IDA10572067  
GO:0048408epidermal growth factor binding-IBA21873635  
GO:0048408epidermal growth factor binding-IEA-  
GO:0051015actin filament binding-IDA14702346  
GO ID GO Term Qualifier Evidence PubMed
GO:0000165MAPK cascade-TAS-  
GO:0000186activation of MAPKK activity-IEA-  
GO:0001503ossification-NAS12925580  
GO:0001892embryonic placenta development-IEA-  
GO:0001934positive regulation of protein phosphorylation-IDA20551055  
GO:0001942hair follicle development-IEA-  
GO:0006357regulation of transcription by RNA polymerase II-TAS-  
GO:0006412translation-IEA-  
GO:0006970response to osmotic stress-IEA-  
GO:0007165signal transduction-IDA10572067  
GO:0007165signal transduction-TAS-  
GO:0007166cell surface receptor signaling pathway-IDA7736574  
GO:0007173epidermal growth factor receptor signaling pathway-IDA7736574  12435727  
GO:0007173epidermal growth factor receptor signaling pathway-IMP20878056  
GO:0007173epidermal growth factor receptor signaling pathway-TAS-  
GO:0007202activation of phospholipase C activity-TAS12435727  
GO:0007275multicellular organism development-IBA21873635  
GO:0007435salivary gland morphogenesis-IEA-  
GO:0007494midgut development-IEA-  
GO:0007611learning or memory-ISS-  
GO:0007623circadian rhythm-IEA-  
GO:0008283cell proliferation-IDA17115032  
GO:0008284positive regulation of cell proliferation-IDA7736574  
GO:0008284positive regulation of cell proliferation-IMP27057632  
GO:0009968negative regulation of signal transduction-IBA21873635  
GO:0010750positive regulation of nitric oxide mediated signal transduction-IDA12828935  
GO:0010960magnesium ion homeostasis-IEA-  
GO:0014066regulation of phosphatidylinositol 3-kinase signaling-IMP26514923  
GO:0016101diterpenoid metabolic process-IEA-  
GO:0018108peptidyl-tyrosine phosphorylation-IDA22732145  
GO:0021795cerebral cortex cell migration-IEA-  
GO:0030154cell differentiation-IBA21873635  
GO:0030307positive regulation of cell growth-IDA15467833  
GO:0030324lung development-IEA-  
GO:0030335positive regulation of cell migration-IMP12435727  25678558  
GO:0031659positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle-IDA18483258  
GO:0032930positive regulation of superoxide anion generation-IEA-  
GO:0033138positive regulation of peptidyl-serine phosphorylation-IMP20878056  
GO:0033590response to cobalamin-IEA-  
GO:0033594response to hydroxyisoflavone-IEA-  
GO:0033674positive regulation of kinase activity-IBA21873635  
GO:0034614cellular response to reactive oxygen species-IMP26514923  
GO:0038083peptidyl-tyrosine autophosphorylation-IMP20878056  
GO:0038083peptidyl-tyrosine autophosphorylation-TAS22732145  
GO:0038128ERBB2 signaling pathway-TAS-  
GO:0042059negative regulation of epidermal growth factor receptor signaling pathway-TAS-  
GO:0042060wound healing-IEA-  
GO:0042177negative regulation of protein catabolic process-IDA17115032  
GO:0042327positive regulation of phosphorylation-IDA15082764  
GO:0042698ovulation cycle-IEA-  
GO:0042743hydrogen peroxide metabolic process-IEA-  
GO:0043006activation of phospholipase A2 activity by calcium-mediated signaling-TAS12435727  
GO:0043066negative regulation of apoptotic process-IBA21873635  
GO:0043066negative regulation of apoptotic process-IMP18070883  
GO:0043406positive regulation of MAP kinase activity-IDA10572067  
GO:0043410positive regulation of MAPK cascade-IBA21873635  
GO:0043586tongue development-IEA-  
GO:0045739positive regulation of DNA repair-IDA17115032  
GO:0045740positive regulation of DNA replication-IDA17115032  
GO:0045746negative regulation of Notch signaling pathway-TAS-  
GO:0045780positive regulation of bone resorption-IEA-  
GO:0045893positive regulation of transcription, DNA-templated-IMP26514923  
GO:0045907positive regulation of vasoconstriction-IEA-  
GO:0045930negative regulation of mitotic cell cycle-IEA-  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA20551055  
GO:0046328regulation of JNK cascade-IMP26514923  
GO:0046718viral entry into host cell-IEA-  
GO:0046777protein autophosphorylation-IMP18070883  
GO:0046854phosphatidylinositol phosphorylation-IEA-  
GO:0048143astrocyte activation-IEA-  
GO:0048146positive regulation of fibroblast proliferation-IEA-  
GO:0048546digestive tract morphogenesis-IEA-  
GO:0048661positive regulation of smooth muscle cell proliferation-IEA-  
GO:0048812neuron projection morphogenesis-IEA-  
GO:0050679positive regulation of epithelial cell proliferation-IDA10572067  
GO:0050729positive regulation of inflammatory response-IEA-  
GO:0050730regulation of peptidyl-tyrosine phosphorylation-IMP12435727  
GO:0050999regulation of nitric-oxide synthase activity-IDA12828935  
GO:0051205protein insertion into membrane-TAS12435727  
GO:0051592response to calcium ion-IEA-  
GO:0051897positive regulation of protein kinase B signaling-IMP17655843  
GO:0051897positive regulation of protein kinase B signaling-TAS-  
GO:0051968positive regulation of synaptic transmission, glutamatergic-IEA-  
GO:0060571morphogenesis of an epithelial fold-IEA-  
GO:0061024membrane organization-TAS-  
GO:0061029eyelid development in camera-type eye-IEA-  
GO:0070141response to UV-A-IDA18483258  
GO:0070372regulation of ERK1 and ERK2 cascade-IMP26514923  
GO:0070374positive regulation of ERK1 and ERK2 cascade-IBA21873635  
GO:0070374positive regulation of ERK1 and ERK2 cascade-IDA20551055  
GO:0070374positive regulation of ERK1 and ERK2 cascade-IMP21673316  
GO:0071230cellular response to amino acid stimulus-IEA-  
GO:0071260cellular response to mechanical stimulus-IEA-  
GO:0071276cellular response to cadmium ion-IMP26514923  
GO:0071364cellular response to epidermal growth factor stimulus-ISS-  
GO:0071392cellular response to estradiol stimulus-IDA20551055  
GO:0071549cellular response to dexamethasone stimulus-IEA-  
GO:0090263positive regulation of canonical Wnt signaling pathway-IMP20302655  
GO:0097421liver regeneration-IEA-  
GO:0097755positive regulation of blood vessel diameter-IEA-  
GO:0098609cell-cell adhesion-IMP12435727  
GO:1900020positive regulation of protein kinase C activity-IDA22732145  
GO:1901185negative regulation of ERBB signaling pathway-TAS-  
GO:1901224positive regulation of NIK/NF-kappaB signaling-IMP26514923  
GO:1902722positive regulation of prolactin secretion-IEA-  
GO:1903078positive regulation of protein localization to plasma membrane-IDA22732145  
GO:1903800positive regulation of production of miRNAs involved in gene silencing by miRNA-IMP21673316  
GO:1905208negative regulation of cardiocyte differentiation-IMP23069713  
GO:2000145regulation of cell motility-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-IEA-  
GO:0005615extracellular space-NAS9103388  
GO:0005634nucleus-IDA12828935  17115032  20551055  
GO:0005737cytoplasm-IBA21873635  
GO:0005737cytoplasm-IDA7588596  12435727  
GO:0005768endosome-IDA14702346  17182860  22732145  
GO:0005768endosomecolocalizes_withIDA16554368  
GO:0005789endoplasmic reticulum membrane-IEA-  
GO:0005886plasma membrane-IDA15465819  22732145  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0005925focal adhesion-HDA21423176  
GO:0009925basal plasma membrane-IBA21873635  
GO:0009986cell surface-IDA25666625  
GO:0010008endosome membrane-IDA22719997  
GO:0016020membrane-IDA12435727  
GO:0016021integral component of membrane-IEA-  
GO:0016323basolateral plasma membrane-IDA12646923  
GO:0016324apical plasma membrane-IEA-  
GO:0030122AP-2 adaptor complexcolocalizes_withTAS14702346  
GO:0030665clathrin-coated vesicle membrane-TAS-  
GO:0031901early endosome membrane-IDA17714434  
GO:0031965nuclear membrane-IEA-  
GO:0032991protein-containing complex-IDA20878056  
GO:0043235receptor complex-IBA21873635  
GO:0043235receptor complex-IDA23382219  
GO:0045121membrane raft-IDA12009895  
GO:0045202synapse-IEA-  
GO:0048471perinuclear region of cytoplasm-IEA-  
GO:0070435Shc-EGFR complex-ISS-  
GO:0097489multivesicular body, internal vesicle lumen-IDA17714434  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa04012ErbB signaling pathway
hsa04020Calcium signaling pathway
hsa04060Cytokine-cytokine receptor interaction
hsa04144Endocytosis
hsa04320Dorso-ventral axis formation
hsa04510Focal adhesion
hsa04520Adherens junction
hsa04540Gap junction
hsa04810Regulation of actin cytoskeleton
hsa04912GnRH signaling pathway
hsa05120Epithelial cell signaling in Helicobacter pylori infection
hsa05160Hepatitis C
hsa05200Pathways in cancer
hsa05212Pancreatic cancer
hsa05213Endometrial cancer
hsa05214Glioma
hsa05215Prostate cancer
hsa05218Melanoma
hsa05219Bladder cancer
hsa05223Non-small cell lung cancer
Reactome ID Reactome Term Evidence
R-HSA-1227986Signaling by ERBB2TAS
R-HSA-1227986Signaling by ERBB2IEA
R-HSA-1236382Constitutive Signaling by Ligand-Responsive EGFR Cancer VariantsTAS
R-HSA-1236394Signaling by ERBB4TAS
R-HSA-1250196SHC1 events in ERBB2 signalingIEA
R-HSA-1250196SHC1 events in ERBB2 signalingTAS
R-HSA-1251932PLCG1 events in ERBB2 signalingIEA
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-1266738Developmental BiologyTAS
R-HSA-157118Signaling by NOTCHTAS
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-1643685DiseaseTAS
R-HSA-1643713Signaling by EGFR in CancerTAS
R-HSA-177929Signaling by EGFRTAS
R-HSA-179812GRB2 events in EGFR signalingTAS
R-HSA-180292GAB1 signalosomeTAS
R-HSA-180336SHC1 events in EGFR signalingTAS
R-HSA-182971EGFR downregulationTAS
R-HSA-1963640GRB2 events in ERBB2 signalingIEA
R-HSA-1963642PI3K events in ERBB2 signalingTAS
R-HSA-199418Negative regulation of the PI3K/AKT networkTAS
R-HSA-199991Membrane TraffickingTAS
R-HSA-212436Generic Transcription PathwayTAS
R-HSA-212718EGFR interacts with phospholipase C-gammaTAS
R-HSA-2179392EGFR Transactivation by GastrinTAS
R-HSA-2219528PI3K/AKT Signaling in CancerTAS
R-HSA-2219530Constitutive Signaling by Aberrant PI3K in CancerTAS
R-HSA-372790Signaling by GPCRTAS
R-HSA-373760L1CAM interactionsTAS
R-HSA-388396GPCR downstream signallingTAS
R-HSA-416476G alpha (q) signalling eventsTAS
R-HSA-422475Axon guidanceTAS
R-HSA-445144Signal transduction by L1TAS
R-HSA-5637810Constitutive Signaling by EGFRvIIITAS
R-HSA-5637812Signaling by EGFRvIII in CancerTAS
R-HSA-5637815Signaling by Ligand-Responsive EGFR Variants in CancerTAS
R-HSA-5638302Signaling by Overexpressed Wild-Type EGFR in CancerTAS
R-HSA-5638303Inhibition of Signaling by Overexpressed EGFRTAS
R-HSA-5653656Vesicle-mediated transportTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5673001RAF/MAP kinase cascadeTAS
R-HSA-5683057MAPK family signaling cascadesTAS
R-HSA-5684996MAPK1/MAPK3 signalingTAS
R-HSA-6785631ERBB2 Regulates Cell MotilityTAS
R-HSA-6811558PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingTAS
R-HSA-73857RNA Polymerase II TranscriptionTAS
R-HSA-74160Gene expression (Transcription)TAS
R-HSA-881907Gastrin-CREB signalling pathway via PKC and MAPKTAS
R-HSA-8847993ERBB2 Activates PTK6 SignalingTAS
R-HSA-8848021Signaling by PTK6TAS
R-HSA-8856825Cargo recognition for clathrin-mediated endocytosisTAS
R-HSA-8856828Clathrin-mediated endocytosisTAS
R-HSA-8857538PTK6 promotes HIF1A stabilizationTAS
R-HSA-8863795Downregulation of ERBB2 signalingTAS
R-HSA-8864260Transcriptional regulation by the AP-2 (TFAP2) family of transcription factorsTAS
R-HSA-8866910TFAP2 (AP-2) family regulates transcription of growth factors and their receptorsTAS
R-HSA-9006925Intracellular signaling by second messengersTAS
R-HSA-9006927Signaling by Non-Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesIEA
R-HSA-9012852Signaling by NOTCH3TAS
R-HSA-9013507NOTCH3 Activation and Transmission of Signal to the NucleusTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28065467Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases. (2017 Jul)Rokutan-Kurata MClin Lung Cancer
26677401MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. (2015)Garajova IClin Epigenetics
26246248Impact of Smoking Cessation Treatment on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study. (2015)Pezzuto ARecent Pat Anticancer Drug Discov
28467510Prevalence and determinants of chronic kidney disease in northeast of Iran: Results of the Golestan cohort study. (2017)Sepanlou SGPLoS One
29786189[Renal Infarction: multicentric cases in Piedmont]. (2018 May)Motta DG Ital Nefrol
22305847Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. (2012 Feb)Dubin RAm Heart J
20723374[Detection and Its Clinical Significance of EGFR Gene Mutation and Gene Amplification in 187 Patients with Non-small Cell Lung Cancer.]. (2009 Dec 20)Liu HZhongguo Fei Ai Za Zhi
28364466Chronic Kidney Disease and Sleep Apnea Association of Kidney Disease With Obstructive Sleep Apnea in a Population Study of Men. (2017 Jan 1)Adams RJSleep
17097759Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. (2007 Jan)Tsurutani JLung Cancer
20935109EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. (2011 Mar 15)Harada CAm J Respir Crit Care Med
29608804Relationship between vitamin D receptor gene polymorphism and susceptibility to chronic kidney disease and periodontal disease in community-dwelling elderly. (2018 Apr 2)Yoshihara AJ Clin Periodontol
28514931Lung cancer in never-smokers - what are the differences? (2017 Jul)Dias MActa Oncol
18391747Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. (2008 Jun)Motoi NAm J Surg Pathol
28089453Serum uromodulin is a predictive biomarker for cardiovascular events and overall mortality in coronary patients. (2017 Mar 15)Leiherer AInt J Cardiol
21430413Chronic obstructive pulmonary disease and lung cancer: new molecular insights. (2011)Adcock IMRespiration
25217982Essential role of polymorphism of Gab1, EGFR, and EGF for the susceptibility of biliary tract cancer. (2014 Dec)Meng LQTumour Biol
24313652Classifying squamous cell carcinoma of the head and neck: prognosis, prediction and implications for therapy. (2014 Feb)Weiss JExpert Rev Anticancer Ther
27810687Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes. (2016 Dec)Ohara MDiabetes Res Clin Pract
21062932Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. (2010 Nov 15)Camidge DRClin Cancer Res
26955281The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. (2016)Zheng DOnco Targets Ther
26766989Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors. (2014 Mar)Wei ZThorac Cancer
19534585Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. (2009 Aug)Vincenzi BExpert Opin Biol Ther
25870798Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. (2015 Apr)Kohno TTransl Lung Cancer Res
22722787Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. (2012 May)Pietanza MCJ Thorac Oncol
23439505Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history. (2013)Furukawa MActa Med Okayama
25922704Correlation between familial cancer history and epidermal growth factor receptor mutations in Taiwanese never smokers with non-small cell lung cancer: a case-control study. (2015 Mar)Cheng PCJ Thorac Dis
20631996Determinants of plasma parathyroid hormone levels in young women. (2010 Sep)Paik JMCalcif Tissue Int
22572014Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer. (2012 Oct)Zhang LJChin J Cancer
19844277[Lung cancer in smokers and never-smokers]. (2009 Sep 24)Helland ATidsskr Nor Laegeforen
29682332Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? (2018)Pinto JAESMO Open
22277138Uric acid, hypertension, and chronic kidney disease among Alaska Eskimos: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. (2012 Feb)Jolly SEJ Clin Hypertens (Greenwich)
25384174Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations. (2015 Jan)Ebi HJ Thorac Oncol
22338650The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors. (2012)Krawczyk PChemotherapy
21933587Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer. (2011 Aug)Huang YSChin Med J (Engl)
25557162Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells. (2015 Mar)Pareja FCancer Cytopathol
22019276Self-reported sleep duration and prediction of proteinuria: a retrospective cohort study. (2012 Mar)Yamamoto RAm J Kidney Dis
16777389Acute effect of cigarette smoke on TNF-alpha release by macrophages mediated through the erk1/2 pathway. (2006 Jun)Demirjian LBiochim Biophys Acta
29173761Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma. (2017 Dec)Matsumura YLung Cancer
26493267Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naive non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. (2015 Oct 22)Choi YJBMC Cancer
18497061Steroid receptor and growth factor receptor expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection. (2008)Kerr A 2ndAdv Exp Med Biol
19443649Recovery of renal function in end-stage renal failure--comparison between peritoneal dialysis and haemodialysis. (2009 Sep)Macdonald JANephrol Dial Transplant
27542207Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells. (2016 Sep 20)Raja ROncotarget
27926474The association of thyroid function and the risk of kidney function decline: a population-based cohort study. (2016 Dec)Chaker LEur J Endocrinol
20709439Warfarin dosing in patients with impaired kidney function. (2010 Nov)Limdi NAAm J Kidney Dis
25226426Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib. (2015 Jan)Suleiman AAJ Thorac Oncol
28185793Establishment of an Adjusted Prognosis Analysis Model for Initially Diagnosed Non-Small-Cell Lung Cancer With Brain Metastases From Sun Yat-Sen University Cancer Center. (2017 May)Dinglin XXClin Lung Cancer
26700849A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells. (2015 Dec 23)Breinig MMol Syst Biol
23303019Expression of Epidermal Growth Factor (EGF) and its receptors (EGFR1 and EGFR2) in chronic bronchitis. (2012)Marinas AERom J Morphol Embryol
17387341Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. (2007 Apr 23)Satouchi MBr J Cancer
19596948Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. (2009 Jul)Garassino MCAnticancer Res
27371767Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation. (2016 Nov 10)Erdogan BBosn J Basic Med Sci
18362254Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate. (2008 Mar 24)Cirillo MArch Intern Med
26554909Genetic Polymorphism, Telomere Biology and Non-Small Lung Cancer Risk. (2015 Oct 20)Wei RJ Genet Genomics
26626139Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study. (2015 Dec 1)Niu YBMC Endocr Disord
17258495Advances in the biology of oral cancer. (2007 Jul)Tsantoulis PKOral Oncol
27646667[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement]. (2017 May)Caliez JRev Mal Respir
28104537Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% Expression in Lung Adenocarcinoma. (2017 May)Rangachari DJ Thorac Oncol
27933289The Association between Stress Measured by Allostatic Load Score and Physiologic Dysregulation in African Immigrants: The Africans in America Study. (2016)Bingham BAFront Public Health
27794398Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. (2016 Nov)Tanizaki JLung Cancer
26823874Association between EGFR polymorphisms and the risk of lung cancer. (2015)Liu CInt J Clin Exp Pathol
25867537Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung. (2015 Jun)Tjulandin SCurr Med Res Opin
27293837Surgical treatment of synchronous multiple primary lung cancers: a retrospective analysis of 122 patients. (2016 Jun)Liu MJ Thorac Dis
20061047The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. (2010 Sep)Chang MHLung Cancer
18845370Left ventricular hypertrophy in mild and moderate reduction in kidney function determined using cardiac magnetic resonance imaging and cystatin C: the multi-ethnic study of atherosclerosis (MESA). (2008 Nov)Moran AAm J Kidney Dis
29570930Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs. (2018 May)Tu CYMol Oncol
23752126Pulmonary CYP2A13 levels are associated with early occurrence of lung cancer-Its implication in mutagenesis of non-small cell lung carcinoma. (2013 Oct)Chiang HCCancer Epidemiol
16272456How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care. (2005 Oct)Kris MGOncologist
21605946Development of a multicomponent prediction model for acute esophagitis in lung cancer patients receiving chemoradiotherapy. (2011 Oct 1)De Ruyck KInt J Radiat Oncol Biol Phys
24482683Cognitive and kidney function: results from a British birth cohort reaching retirement age. (2014)Silverwood RJPLoS One
21863294Cigarette smoking, proteinuria, and renal function in middle-aged Japanese men from an occupational population. (2012 Mar)Noborisaka YEnviron Health Prev Med
17409862Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. (2006 Mar)Tsao ASJ Thorac Oncol
28826901Relation Between Calcified Atherosclerosis in the Renal Arteries and Kidney Function (from the Multi-Ethnic Study of Atherosclerosis). (2017 Oct 15)Vashishtha DAm J Cardiol
20479403Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. (2010 Jun 20)Sequist LVJ Clin Oncol
28956832Multiple Gene-Environment Interactions on the Angiogenesis Gene-Pathway Impact Rectal Cancer Risk and Survival. (2017 Sep 28)Sharafeldin NInt J Environ Res Public Health
23585689Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405). (2013 Jun)Akamatsu HJpn J Clin Oncol
29723088Molecular alterations associated with chronic exposure to cigarette smoke and chewing tobacco in normal oral keratinocytes. (2018 May 3)Rajagopalan PCancer Biol Ther
28210171Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer. (2016)Legius BLung Cancer (Auckl)
27669169Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. (2017 Mar 1)Chang ISAm J Respir Crit Care Med
23619604KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. (2013 Oct)Rekhtman NMod Pathol
28577939Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines. (2017 Jul)Zhang LLung Cancer
23686431Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation. (2013 Jul)Lee SMMol Cells
27203390GLK/MAP4K3 overexpression associates with recurrence risk for non-small cell lung cancer. (2016 Jul 5)Hsu CPOncotarget
24485957Association of Merkel cell polyomavirus infection with EGFR mutation status in Chinese non-small cell lung cancer patients. (2014 Mar)Xu SLung Cancer
29799009Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients. (2018 May 24)Wang CNat Commun
23887156ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. (2013 Sep)Sholl LMAm J Surg Pathol
22530966Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort. (2012 Apr 24)Vervloet MGBMC Nephrol
17112494Association of adiponectin and amino terminal proBNP in peripheral arterial disease. (2007 Feb)Dieplinger BClin Chim Acta
24097870EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. (2013 Dec 1)Behrens CClin Cancer Res
19181443Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway. (2009 Jun 8)Kometani TCancer Lett
25488863Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung. (2015 Feb)Qiong ZLung Cancer
28635230[The expression of programmed death receptor 1 in non-small cell lung cancer and its clinicopathological features and prognosis showed a connection with epidermal growth factor receptor gene mutations]. (2017 Jun 23)Yin HZhonghua Zhong Liu Za Zhi
25833149Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. (2015)de Melo ACOncology
17233840Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. (2007 Feb)Itaya TCancer Sci
261028103C.08: 24H CENTRAL BLOOD PRESSURE AND PULSE WAVE VELOCITY MONITORING IN NORMOTENSIVE, HYPERTENSIVE, WHITE COAT HYPERTENSION AND MASKED HYPERTENSION YOUNG ADULTS. (2015 Jun)Faria RAJ Hypertens
27008036Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer. (2016)Saber APLoS One
26487770Long-Term Renal Function after Endovascular Aneurysm Repair. (2015 Nov 6)Saratzis AClin J Am Soc Nephrol
26527886SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas. (2015)Zheng SOnco Targets Ther
26527887EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma. (2015)Ren YOnco Targets Ther
28468035[Clinicopathologic characteristics of epidermal growth factor receptor mutations in non-small cell lung cancer in Xinjiang region]. (2017 May 8)Shi YZhonghua Bing Li Xue Za Zhi
28468034[To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung]. (2017 May 8)Sun PLZhonghua Bing Li Xue Za Zhi
28468033[Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma]. (2017 May 8)Hou LKZhonghua Bing Li Xue Za Zhi
27532261Gefitinib, an EGFR Tyrosine Kinase inhibitor, Prevents Smoke-Mediated Ciliated Airway Epithelial Cell Loss and Promotes Their Recovery. (2016)Valencia-Gattas MPLoS One
28806935Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. (2017 Aug 15)Zhao LBMC Pulm Med
17580276Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. (2007 Jul)Sakuma YAm J Clin Pathol
17848274Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. (2007)Kumar BInt J Radiat Oncol Biol Phys
24331409KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. (2014 Feb)Maus MKLung Cancer
24179496Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. (2013 Nov)Takamochi KOncol Lett
25722296Factors Associated With Plasma IL-6 Levels During HIV Infection. (2015 Aug 15)Borges AHJ Infect Dis
26719713Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer. (2016)Gao YOnco Targets Ther
25726043Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. (2015 May)Fukuhara TLung Cancer
17711506LKB1 gene mutations in Japanese lung cancer patients. (2007 Nov)Onozato RCancer Sci
27293567Metabolic syndrome and other cardiovascular risk factors associated with the progression of IgA nephropathy. (2013 Aug)Kovacs TClin Kidney J
27160687Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. (2016 Jul)Ahn SJ Pathol Transl Med
26202550Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. (2015 Dec)Zheng DAnn Surg Oncol
29036821Estimated Glomerular Filtration Rate is not Associated with Alzheimer's Disease in a Northern Ireland Cohort. (2017)Paterson ENJ Alzheimers Dis
22978775Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. (2012 Oct)Biaoxue RCurr Med Res Opin
14581353Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. (2003 Oct 15)Miller CTClin Cancer Res
24760004Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing. (2014)Cai XPLoS One
26536196Clinical Implications of Variant ALK FISH Rearrangement Patterns. (2015 Nov)Gao XJ Thorac Oncol
26465607Serum Adiponectin and Glomerular Filtration Rate in Patients with Type 2 Diabetes. (2015)Ortega Moreno LPLoS One
26582224[Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma]. (2015 Nov)Zhang HZhongguo Fei Ai Za Zhi
23248420First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patients. (2012 Jul)Louis RAIndian J Med Paediatr Oncol
24685082[Relationship between human papilloma virus infection and expression of p16 and EGFR in head and neck squamous cell carcinoma and their prognostic significance]. (2014 Jan)Ma LZhonghua Zhong Liu Za Zhi
22171670Estimated glomerular filtration rate decline in 567 patients with acute stroke. (2012 Apr)Liu DScand J Urol Nephrol
261026781C.09: SERUM RESISTIN AS AN INDEPENDENT BIOMARKER ASSOCIATED WITH ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN ELDERLY HYPERTENSIVE, NON-DIABETIC PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD). (2015 Jun)Vlahakos DVJ Hypertens
25454007Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis. (2015 Mar)Zhang YClin Lung Cancer
26985396Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure. (2016)Choi JRAnn Occup Environ Med
28177140Serum Phosphate Is Associated With Fracture Risk: The Rotterdam Study and MrOS. (2017 Jun)Campos-Obando NJ Bone Miner Res
25766256Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. (2015 Jun)Esteban ECancer Epidemiol
28031832Effectiveness of afatinib in lung cancer with paralytic ileus due to peritoneal carcinomatosis. (2016 Nov)Kobayashi HRespirol Case Rep
23239743EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women. (2013 Mar)Chen KYCarcinogenesis
16091975The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors. (2005 Oct)Askari MDJ Cancer Res Clin Oncol
28988295Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma. (2018 Apr)Cao YInt J Clin Oncol
26766992Phase II trial of paclitaxel-carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown non-small cell lung cancer. (2014 Mar)Yang JThorac Cancer
16505411Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. (2006 Apr 10)Pham DJ Clin Oncol
18949411Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. (2008 Nov)Sasaki HOncol Rep
14569062Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway. (2004 Jan)Ye YNJ Pharmacol Exp Ther
22317764Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. (2012 Apr 1)Zhang YClin Cancer Res
25644676Impact of kidney function and urinary protein excretion on intima-media thickness in Japanese patients with type 2 diabetes. (2015 Oct)Nakade YClin Exp Nephrol
26253541Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement. (2015 Aug 8)Fu SChin J Cancer
24390215Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma. (2014 Aug)Mackinnon AC JrMod Pathol
20215545Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. (2010 Mar 15)Ross HJClin Cancer Res
21155880Aberrant expression of epidermal growth factor receptor and its interaction with protein kinase C delta in inflammation associated neoplastic transformation of human esophageal epithelium in high risk populations. (2011 Feb)Parthasarathy SJ Gastroenterol Hepatol
26739511Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening. (2016 Jan 7)Yang YSci Rep
26620131The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. (2015 Dec 1)Fraser SDBMC Nephrol
26359571FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. (2015 Dec)Lee SMClin Nucl Med
27185988Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival. (2016 May-Jun)Maturu VNLung India
29110846EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. (2017 Nov)Han BLung Cancer
25641062CKD and the risk of acute, community-acquired infections among older people with diabetes mellitus: a retrospective cohort study using electronic health records. (2015 Jul)McDonald HIAm J Kidney Dis
24875193Skin autofluorescence and all-cause mortality in stage 3 CKD. (2014 Aug 7)Fraser SDClin J Am Soc Nephrol
19173195[Long-term remission after erlotinib therapy in an elderly patient with advanced non-small-cell lung cancer. Case report and conclusions for clinical practice]. (2008)Duchnowska RPneumonol Alergol Pol
19280309Histoculture drug response assay for gefitinib in non-small-cell lung cancer. (2009 Mar)Yoshimasu TGen Thorac Cardiovasc Surg
29332331EGFR mutations and tumor metastases in patients with nonsmall cell lung cancer in the South of Russia. (2017 Nov-Dec)Kit OIJ BUON
25468311Association of advanced glycation end products and chronic kidney disease with macroangiopathy in type 2 diabetes. (2015 Mar)Rigalleau VJ Diabetes Complications
24743704Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. (2014 May 27)Li SBr J Cancer
28038980Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs. (2017 Jul)Lynch JAClin Lung Cancer
22887466Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. (2013 Jan)Shaw ATAnn Oncol
26988828[Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment]. (2016 Mar 23)Liu JJZhonghua Zhong Liu Za Zhi
29312770Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung. (2017 Dec)Kalchiem-Dekel OJ Thorac Dis
26554801The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer. (2015 Nov)Zhang YMedicine (Baltimore)
19270482EGFR and KRAS mutations in patients with adenocarcinoma of the lung. (2009 Mar)Jang TWKorean J Intern Med
17520577Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. (2007 Jan-Mar)Cappuzzo FInt J Biol Markers
21933557Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment. (2011 Aug)Song ZBChin Med J (Engl)
27173985Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis. (2016 Aug)Matsumura YInteract Cardiovasc Thorac Surg
17114658Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. (2006 Nov 20)Hanna NJ Clin Oncol
22897510Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib. (2012 Sep)Liam CKAsia Pac J Clin Oncol
25657019BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. (2015 May)Couraud SEur Respir J
29650325Improving the genetic signature of prostate cancer, the somatic mutations. (2018 Jun)Martinez-Gonzalez LJUrol Oncol
18271929Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. (2008 Feb)Toyooka SCancer Sci
15816608Analysis of the response and toxicity to gefitinib of non-small cell lung cancer. (2005 Jan-Feb)Konishi JAnticancer Res
24163741Molecular biology of lung cancer. (2013 Oct)Cooper WAJ Thorac Dis
29286114Cigarette smoke-induced EGFR activation promotes epithelial mesenchymal migration of human retinal pigment epithelial cells through regulation of the FAK-mediated Syk/Src pathway. (2018 Mar)Park GBMol Med Rep
28066597The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. (2016 Nov)Cha YKJ Thorac Dis
26316933Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases. (2012)Yano YLung Cancer Int
23803047Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups. (2013)Zhang YAsian Pac J Cancer Prev
27164304Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae. (2016 Sep)Iwama EJ Thorac Oncol
24720835Expression of beclin 1 in non-small cell lung cancer: an immunohistochemical study. (2015 Jul)Lv ZQClin Respir J
19826035Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. (2009 Nov 1)Sholl LMCancer Res
22247002Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. (2012 Dec)Spector MEHead Neck
22321543[Relationship between mutations of epidermal growth factor receptor gene and clinicopathologic features of non-small cell lung cancers]. (2011 Oct)Wang FZhonghua Bing Li Xue Za Zhi
25098376Relevance of target-organ lesions as predictors of mortality in patients with diabetes mellitus. (2014 Oct)Bianco HTArq Bras Cardiol
27169468Prevalence of osteo-renal impairment in the Romanian HIV cohort. (2016 Mar 8)Streinu-Cercel ABMC Infect Dis
27042123Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes. (2016)Wang TOnco Targets Ther
28373815Systemic treatment of non-small cell lung cancer brain metastases. (2016)Cedrych IContemp Oncol (Pozn)
25174465[Influence of blood uric acid on all-cause deaths]. (2014 Jun)Li YZhonghua Liu Xing Bing Xue Za Zhi
17224267EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. (2007 Feb)Na IIEur J Cancer
16890322L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. (2006 Oct)Sasaki HLung Cancer
14977086Epidermal growth factor receptor and p53 expression in T1-T2 glottic cancer involving the anterior or posterior commissure. (2004 Jan)Rucci LActa Otolaryngol
23613374[Diabetes and kidneys]. (2013 May)Gackler DDtsch Med Wochenschr
29780256The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients. (2018)Cao LOnco Targets Ther
27575421Clinicopathological, Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern. (2016 Dec)Masai KJ Thorac Oncol
23988776EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. (2014 Mar)Warth AEur Respir J
21513367Erlotinib: as maintenance monotherapy in non-small-cell lung cancer. (2011 Jun 1)Muir VJBioDrugs
21387273Clinicopathological features of lung adenocarcinoma with KRAS mutations. (2011 Sep 15)Kakegawa SCancer
24612948Aldosterone and glomerular filtration--observations in the general population. (2014 Mar 10)Hannemann ABMC Nephrol
19661247Matrix metalloproteinase-14 mediates a phenotypic shift in the airways to increase mucin production. (2009 Nov 1)Deshmukh HSAm J Respir Crit Care Med
27987580Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. (2016 Dec)Chapman AMLung Cancer
29447182The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. (2018)Chang WYPLoS One
23932486Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. (2013 Oct)Yamaguchi NLung Cancer
27851714Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. (2016 Dec 15)Marcus JLJ Acquir Immune Defic Syndr
28644837Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. (2017)Abernethy APPLoS One
29016597The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study. (2017 Oct)Shardlow APLoS Med
29127119RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition. (2018 Mar 15)Hayashi TClin Cancer Res
25361983Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. (2015 Jan)Kobayashi YAnn Oncol
20659620Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. (2010 Sep)Murakami SLung Cancer
21992731Lung cancer in never smokers. (2011 Oct)Torok SFuture Oncol
26665197[The prognostic role of expression of p16 tumor suppressor gene in Hungarian patients with oral squamous cell carcinoma]. (2015 Dec)Vankos JBMagy Onkol
21531529Impact of renal insufficiency on clinical outcomes in patients with critical limb ischemia undergoing endovascular revascularization. (2011 Jun)Willenberg TJ Vasc Surg
18983495African-American ethnicity is associated with higher plasma levels of D-dimer in adults with hypertension. (2009 Jan)Khaleghi MJ Thromb Haemost
26727745[Was it necessary to modify the classification of chronic kidney disease stages designed by NKF KDOQI? - "Nefrotest" study results]. (2015)Januszko-Giergielewicz BPrzegl Lek
27250568Effects of smoking and its cessation on creatinine- and cystatin C-based estimated glomerular filtration rates and albuminuria in male patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry. (2016 Oct)Ohkuma THypertens Res
22425916EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. (2012 Apr)Milella MJ Thorac Oncol
27100677Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression. (2016)Sato KPLoS One
26767032Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma. (2014 Sep)Zhu JThorac Cancer
26904214Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors. (2016 Jan)Cui SJ Thorac Dis
26904215Clinicopathologic correlates of postoperative N1 or N2 nodal upstaging in non-small cell lung cancer. (2016 Jan)Moon YJ Thorac Dis
23677552[Gender-specific difference in lung cancer]. (2013 May)Serke MPneumologie
24962661Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence. (2014 Nov)Rausch SUrol Oncol
28528401Cardiovascular disease biomarkers are associated with declining renal function in type 2 diabetes. (2017 Aug)Jenks SJDiabetologia
29383112Unique circulating microRNAs in relation to EGFR mutation status in Japanese smoker male with lung adenocarcinoma. (2017 Dec 29)Ito SOncotarget
28043144Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer. (2017)Zhao XDNeoplasma
25432788Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. (2014 Nov 29)Burtness BTrials
27033384[Mutation status of epidermal growth factor receptor and KRAS gene in non-small cell lung cancers at Xuanwei regions of Yunnan Province]. (2016 Apr 8)Yang CSZhonghua Bing Li Xue Za Zhi
22701684Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. (2012)Cockayne DAPLoS One
27033383[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer]. (2016 Apr 8)Chen LFZhonghua Bing Li Xue Za Zhi
18394748Adenocarcinoma of lung in never smoked children. (2008 Aug)Park JALung Cancer
20672704[Application of epidermal growth factor receptor tyrosine kinase inhibitor as the first-line therapy in patients with advanced non-small cell lung cancer]. (2010 Jan)Xu YZhongguo Fei Ai Za Zhi
23336484[Epithelial growth factor receptor mutation status to the effective of survival in non-small cell lung cancer after surgery]. (2012 Dec)Liu YZhonghua Wai Ke Za Zhi
29155119High serum bilirubin is associated with lower prevalence of peripheral arterial disease among cardiac patients. (2018 Jan)Ozeki MClin Chim Acta
25007143Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. (2014 Dec)Boland JMAm J Surg Pathol
21412268Association of standardized estimated glomerular filtration rate with the prevalence of hypertension among adults in the United States. (2011 Aug)Liu XJ Hum Hypertens
16322287Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. (2005 Dec 1)Haura EBClin Cancer Res
23154553Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. (2012 Dec)D'Angelo SPJ Thorac Oncol
26622815Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients. (2015 Oct)Papadopoulou EOncol Lett
16204011Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. (2005 Nov 1)Bell DWJ Clin Oncol
27568346Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. (2016 Nov)Huynh TGJ Thorac Oncol
26273395Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements. (2015 Jul)Wu SThorac Cancer
16912157Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. (2006 Aug 15)Inukai MCancer Res
27793199Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China. (2016 Oct 28)Li XBMC Cancer
21527061East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. (2011 May)Zhou WChin J Cancer
22525557Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. (2012 Jun)Tsai THJ Thorac Oncol
19369630Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. (2009 May)De Oliveira Duarte Achcar RAm J Clin Pathol
24419411A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). (2014 Feb)Shi YJ Thorac Oncol
24736066Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. (2014 Apr)Gazdar AJ Thorac Oncol
27180747[Correlation between serum free fatty acid level and estimated glomerular filtration rate in type 2 diabetic patients]. (2016 May 10)Xuan LZhonghua Yi Xue Za Zhi
16003726EGFR and erbB2 mutation status in Japanese lung cancer patients. (2006 Jan 1)Sasaki HInt J Cancer
21592614EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. (2011 Dec)Jia XLLung Cancer
27027665Gene aberrations for precision medicine against lung adenocarcinoma. (2016 Jun)Saito MCancer Sci
29078775Visceral adiposity and renal function: an observational study from SPECT-China. (2017 Oct 27)Zhang KLipids Health Dis
19424162Mid-regional pro-adrenomedullin is associated with pulse pressure, left ventricular mass, and albuminuria in African Americans with hypertension. (2009 Aug)Al-Omari MAAm J Hypertens
29764592[Analysis of the First Diagnosis Symptom and Its Influencing Factors in 500 Patients with Lung Cancer]. (2018 May 20)Zhang XZhongguo Fei Ai Za Zhi
21567014Serum levels of growth-factor receptors, egfr and Neu in asbestosis patients - a follow-up-study. (1994 May)Partanen RInt J Oncol
22208386Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. (2011 Dec 1)Jiang RMol Diagn Ther
22912784Proteasome inhibition augments cigarette smoke-induced GM-CSF expression in trophoblast cells via the epidermal growth factor receptor. (2012)Fu YYPLoS One
26505339Relationship of EGFR DNA methylation with the severity of non-small cell lung cancer. (2015 Oct 5)Li JGenet Mol Res
26599269Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. (2015)Gautschi OOncol Res Treat
18340507Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. (2008 Mar)Fukui TGen Thorac Cardiovasc Surg
23435014Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. (2013 May)Andujar PMutagenesis
23913929Chronic kidney disease defined by cystatin C predicts mobility disability and changes in gait speed: the Framingham Offspring Study. (2014 Mar)Liu CKJ Gerontol A Biol Sci Med Sci
29169877Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. (2018 Jan)Herbst RSLancet Oncol
28777825Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients. (2017)Tudor RAPLoS One
24309368Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment. (2014 Feb)Kim HRLung Cancer
24888607Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. (2014 Sep)Kim TJJ Surg Oncol
29731061Impact of Cigarette Smoking on Living Kidney Donors. (2018 May)Yoon YETransplant Proc
29487786Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma. (2018)Satoh SRespir Med Case Rep
28697799Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. (2017 Jul 11)Zobel EHCardiovasc Diabetol
21126404[Phophorylated Akt protein expression in non-small cell lung cancer]. (2007 Oct 20)Zhou ZZhongguo Fei Ai Za Zhi
28614418IL-33 and ST2 levels in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events, and survival. (2017)Gungor OPLoS One
18827604An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. (2008 Oct)Kawada IJ Thorac Oncol
28366517Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. (2017 Sep)Grams MEAm J Kidney Dis
29587953[Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features]. (2018 Mar 20)Xiao YZhongguo Fei Ai Za Zhi
29147576Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668). (2017)Yang HESMO Open
28386880Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study. (2018 Feb)Girardat-Rotar LJ Nephrol
14710013Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. (2004 Jan)Leong JLLaryngoscope
24850843FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. (2014 Aug 1)Wang RClin Cancer Res
27888377Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China. (2017 Jan)Li HClin Exp Metastasis
21479375Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation. (2008 Jan-Feb)Baldini EMol Med Rep
26331821Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer. (2015 Sep 1)Ni JCancer
16043829TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. (2005 Sep 1)Herbst RSJ Clin Oncol
25605811Are pre-existing markers of chronic kidney disease associated with short-term mortality following acute community-acquired pneumonia and sepsis? A cohort study among older people with diabetes using electronic health records. (2015 Jun)McDonald HINephrol Dial Transplant
28249105Advanced glycation end-products (AGEs) and associations with cardio-metabolic, lifestyle, and dietary factors in a general population: the NQplus study. (2017 Jul)Botros NDiabetes Metab Res Rev
18393776Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). (2006 Jan)Metro GRev Recent Clin Trials
17060486EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. (2007 Jan)van Zandwijk NAnn Oncol
16334162Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. (2005 Nov-Dec)Kawai HAnticancer Res
25582278EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. (2015 Mar)Yang YLung Cancer
21052000Mapping EGFR1 mutations in patients with lung adenocarcinoma. (2010 Dec)Vlastos FDiagn Mol Pathol
23172928Risk stratification by 24-hour ambulatory blood pressure and estimated glomerular filtration rate in 5322 subjects from 11 populations. (2013 Jan)Boggia JHypertension
25407901Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. (2014 Nov 18)Guo YBMC Cancer
14582710Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer. (2003 Sep)Gelibter AJ Exp Clin Cancer Res
19543508Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. (2009 Jun)Park SHJ Korean Med Sci
20237940Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. (2010 Dec)Lee YJJ Cancer Res Clin Oncol
19841986Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. (2010 Mar)Suzuki MAnn Surg Oncol
28559820Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer. (2017 Jan-Apr)Yamasaki MCase Rep Oncol
26579581Genetic and environmental predictors of chronic kidney disease in patients with type 2 diabetes and diabetic foot ulcer: a pilot study. (2015 Oct)Mrozikiewicz-Rakowska BJ Physiol Pharmacol
22768234Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. (2012)An SJPLoS One
21368495[A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib]. (2011 Feb)Morio AGan To Kagaku Ryoho
17239298Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology. (2006 Nov)Achille MClin Lung Cancer
24205279Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status. (2013)Planck MPLoS One
25059228Comparison of predictive value for first cardiovascular event between Japanese GFR equation and coefficient-modified CKD-EPI equation. (2015 Jun)Terawaki HClin Exp Nephrol
24528049Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic malaysian patient population. (2014)Liam CKAsian Pac J Cancer Prev
18701186Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. (2009 Apr)Traynor AMLung Cancer
25122436Clinical characteristics, tumor, node, metastasis status, and mutation rate in domain of epidermal growth factor receptor gene in serbian patients with lung adenocarcinoma. (2014 Sep)Zaric BJ Thorac Oncol
21783417Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. (2011 Aug)Zhou CLancet Oncol
20210241DNA/RNA markers for colorectal cancer risk in preserved stool specimens: a pilot study. (2009 Nov-Dec)Kato ITumori
22573488EGFR exon 19 in-frame deletion and polymorphisms of DNA repair genes in never-smoking female lung adenocarcinoma patients. (2013 Jan 15)Yang SYInt J Cancer
26567910Effect of renal impairment on atherosclerosis: only partially mediated by homocysteine. (2016 Jun)Spence JDNephrol Dial Transplant
28449488Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation. (2017 Mar)Ning HJ Thorac Dis
26271527Circulating concentrations of vitamin E isomers: Association with bone turnover and arterial stiffness in post-menopausal women. (2015 Dec)Hampson GBone
25824430Association between circulating thrombopoietin levels and cardiovascular risk prediction scores in renal transplant recipients. (2015)Mansell HAm J Nephrol
25054777APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. (2015 Jan)Freedman BIKidney Int
23111824Age and association of kidney measures with mortality and end-stage renal disease. (2012 Dec 12)Hallan SIJAMA
24446743Human papilloma virus detection and typing in 334 lung cancer patients. (2014 Jul)Sagerup CMActa Oncol
25468806Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes. (2015 Jun)Theilade SAm J Hypertens
25276347Factors influencing survival after kidney transplant failure. (2014)McCaughan JATransplant Res
23415169Vitamin D and prognosis in acute myocardial infarction. (2013 Oct 3)Ng LLInt J Cardiol
24976335Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas. (2014 Aug)Luo SYLung Cancer
27519166DASH (Dietary Approaches to Stop Hypertension) Diet and Risk of Subsequent Kidney Disease. (2016 Dec)Rebholz CMAm J Kidney Dis
24201754Tetraspanins CD9 and CD151, epidermal growth factor receptor and cyclooxygenase-2 expression predict malignant progression in oral epithelial dysplasia. (2013 Nov 26)Nankivell PBr J Cancer
25800570[Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis]. (2015 Mar)Cao FZhongguo Fei Ai Za Zhi
27257133Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. (2016 Oct)Suda KJ Thorac Oncol
26788139EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer. (2015 Dec)Ren WOncol Lett
20598769Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. (2011 Jan)Sun JMLung Cancer
25855240Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. (2016 Jun)Chung CJ Oncol Pharm Pract
22359227Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. (2012 Aug 15)Kim WYCancer
26026961Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR-mutated lung cancer via nickel-induced microRNA-21 expression. (2015 Aug 19)Chiou YHToxicol Lett
26793845EGFR MUTATIONS IN NON-SMALL CELL LUNG CANCER: LOCAL EPIDEMIOLOGY AND CLINICAL IMPORTANCE. (2015 Oct-Dec)Rusu-Cordunean FRev Med Chir Soc Med Nat Iasi
21272253Evidence for severe atherosclerotic changes in chronic hemodialysis patients: comparative autopsy study against cardiovascular disease patients without chronic kidney disease. (2011 Feb)Suzuki CTher Apher Dial
25399973[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma]. (2014 Aug 13)Lou NZhonghua Yi Xue Za Zhi
24581168[Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations]. (2014 Feb)Zhu XZhongguo Fei Ai Za Zhi
24568474Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? (2014)Usuda KAsian Pac J Cancer Prev
8747384Chemoprevention trials in the cervix: design, feasibility, and recruitment. (1995)Mitchell MFJ Cell Biochem Suppl
26183547Organization of primary care pathway in head and neck oncology (short version): Organization of chemotherapy in head and neck oncology. (2015 Sep)Pavillet JEur Ann Otorhinolaryngol Head Neck Dis
25608155Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation. (2015 Mar)Lee EYClin Nucl Med
27346415Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. (2016 Nov)Takada KJ Thorac Oncol
19046792Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. (2009 Jul)Lopez-Malpartida AVLung Cancer
17473657The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. (2007 May)Buckingham LEJ Thorac Oncol
20091490Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. (2010 Jan-Feb)Chitalia NJ Nephrol
28741082Dietary total antioxidant capacity and incidence of chronic kidney disease in subjects with dysglycemia: Tehran Lipid and Glucose Study. (2017 Jul 24)Asghari GEur J Nutr
22882865Downregulating activated epidermal growth factor receptor has no effect on RBM5 expression. (2012 Jul)Masilamani TJChin Med J (Engl)
25710804Development and validation of a model to predict 5-year risk of death without ESRD among older adults with CKD. (2015 Mar 6)Bansal NClin J Am Soc Nephrol
17317723Tobacco smoke cooperates with interleukin-1beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. (2007 Jun)Barbieri SSFASEB J
27282326[Breast metastases from lung cancers with the EGFR mutation]. (2017 Jan)Assouline PRev Mal Respir
24033955Association of CYBA rs7195830 polymorphism with estimated glomerular filtration rate in an adult Han sample from Jiangsu province, China. (2013)Fan KLChin Med J (Engl)
27978869[Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis]. (2016 Dec 20)Hong CZhongguo Fei Ai Za Zhi
23937608EGFR mutations in US Hispanic versus non-Hispanic white patients with lung adenocarcinoma. (2014 Apr)Zhang WArch Pathol Lab Med
29199694Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients. (2017 Jan-Mar)Wang TIndian J Cancer
27992557An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China. (2016)Wei WEPLoS One
18474878EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. (2008 Jul 1)Kumar BJ Clin Oncol
17681096ErbB4 expression and mutation in Japanese patients with lung cancer. (2007 Jul)Sasaki HClin Lung Cancer
26265108Relationship between mild-to-moderate chronic kidney disease and decreased bone mineral density in Chinese adult population. (2015 Sep)Kong XInt Urol Nephrol
20510047[Association of risk factors for cardiovascular disease and the rate of glomerular filtration: a cross-sectional study in the population from certain areas of Beijing]. (2010 Mar)Wang FZhonghua Liu Xing Bing Xue Za Zhi
16343367Second- and third-line treatments in non-small cell lung cancer. (2006 Jan)Kumar ACurr Treat Options Oncol
25715252High incidence of EGFR mutations in pneumonic-type non-small cell lung cancer. (2015 Feb)Liu JMedicine (Baltimore)
29631966MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. (2018 Mar 17)Reis HClin Lung Cancer
28764641Prediction of new onset of end stage renal disease in Chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study. (2017 Aug 1)Wan EYFBMC Nephrol
25798276Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis. (2015 Mar)Nakao MMol Clin Oncol
26490356Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. (2016 Jan)Sheng MEur J Clin Pharmacol
27852066Cigarette smoking reduced renal function deterioration in hypertensive patients may be mediated by elevated homocysteine. (2016 Dec 27)Huang FOncotarget
20087691Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. (2011 Mar)Kuo LCMed Oncol
25706305Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis. (2015)Zhao FPLoS One
21126411[Predictive factors of gefitinib response and survival in Chinese patients with local advanced or metastatic non-small cell lung cancer]. (2007 Oct 20)Lin LZhongguo Fei Ai Za Zhi
24852187Value of (1)(8)F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. (2014 Oct)Ko KHEur J Nucl Med Mol Imaging
19473722Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. (2010 Mar)Tiseo MLung Cancer
28357502Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. (2017 Jun)Penno GDiabetologia
20637128Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. (2010 Jul 19)Liang ZBMC Cancer
28124437Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. (2017 Aug)Wang TFAsia Pac J Clin Oncol
21606196ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. (2011 Jul)Pillai SMol Cell Biol
25970685Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation. (2015 Jul)Sato SAm J Surg Pathol
24692734Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer. (2014 Apr)Horiike AAnticancer Res
25902172Relevance of EGFR gene mutation with pathological features and prognosis in patients with non-small-cell lung carcinoma. (2015 Mar)Wang CDAsian Pac J Trop Med
18506667Targeted therapy in advanced non-small-cell lung cancer. (2008 Jun)Gettinger SSemin Respir Crit Care Med
16015534Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. (2005 Apr)Ready NSemin Oncol
25189950Single nucleotide polymorphisms in the D-loop region of mitochondrial DNA and age-at-onset of patients with chronic kidney disease. (2014)Bai YChin Med J (Engl)
20107422High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. (2010 Mar)Go HJ Thorac Oncol
20107420First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status. (2010 Mar)Lee YJJ Thorac Oncol
28299459The impact of evacuation on the incidence of chronic kidney disease after the Great East Japan Earthquake: The Fukushima Health Management Survey. (2017 Dec)Hayashi YClin Exp Nephrol
21247966EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. (2011 Apr)Koh YJpn J Clin Oncol
24744849Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients. (2012 Apr)Prasad GVClin Kidney J
29123415Impact of hypertrophic pulmonary osteoarthropathy on patients with lung cancer. (2017)Fang YHOnco Targets Ther
29123416Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer. (2017)Tufman AOnco Targets Ther
19464045Happyhour, a Ste20 family kinase, implicates EGFR signaling in ethanol-induced behaviors. (2009 May 29)Corl ABCell
19884854Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors. (2010 Jan)Chen KYJ Thorac Oncol
20840812[Detection of epidermal growth factor receptor mutations in non-small cell lung cancer tumor specimens from various ways by denaturing high-performance liquid chromatography]. (2010 Sep)Chen SZhongguo Fei Ai Za Zhi
19260752Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. (2009 Mar)Zakowski MFArch Pathol Lab Med
24321840Male sex and vascular risk factors affect cystatin C-derived renal function in older people without diabetes or overt vascular disease. (2014 May)Werner KBAge Ageing
19855375Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. (2010 Feb)Dacic SMod Pathol
23489557EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. (2013 Jun)Faehling MLung Cancer
27262212Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. (2016 Aug)Noonan SAJ Thorac Oncol
28423587The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC. (2017 Apr 4)Yang HOncotarget
22093627[EGFR gene copy number, ERCC1 and BRCA1 protein expression and their relationship in non-small cell lung cancer]. (2011 Jul)Deng QHZhonghua Zhong Liu Za Zhi
23908693Epidermal growth factor receptor exon 20 mutation increased in post-chemotherapy patients with non-small cell lung cancer detected with patients' blood samples. (2013 Aug)Wang YTransl Oncol
27797893Diet Soda Consumption and Risk of Incident End Stage Renal Disease. (2017 Jan 6)Rebholz CMClin J Am Soc Nephrol
29500455Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy. (2018 Mar 2)Tang DSci Rep
25129367Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE). (2014 Oct)Sarosi VLung Cancer
9655037Increased expression of epidermal growth factor receptor in normal epithelium adjacent to head and neck carcinomas independent of tobacco and alcohol abuse. (1998 Mar)van Oijen MGOral Dis
23557216SOX7 is down-regulated in lung cancer. (2013 Apr 4)Hayano TJ Exp Clin Cancer Res
22449680Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation. (2012)Tanaka KIntern Med
17962911Molecular targets in squamous cell carcinoma of the head and neck. (2007 Jun)Shirai KCurr Treat Options Oncol
17551677Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. (2007 Mar)Bencardino KIntern Emerg Med
21521776Genomic profiles specific to patient ethnicity in lung adenocarcinoma. (2011 Jun 1)Broet PClin Cancer Res
23688269Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer. (2013 May 20)Mo MLJ Exp Clin Cancer Res
19577767CHRNA5 gene D398N polymorphism in Japanese lung adenocarcinoma. (2010 Jul)Sasaki HJ Surg Res
27926500The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations. (2017 Jan 10)Lin JHOncotarget
28280984Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. (2018 Jan)Saito MSurg Today
18332634Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction. (2008)Chung AWJ Vasc Res
17431338[Prediction of effectiveness of EGFR tyrosine kinase inhibitors for the patients with by EGFR mutations]. (2007 Apr)Uramoto HGan To Kagaku Ryoho
25701171Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. (2015 Mar)Paz-Ares LLancet Oncol
26775573[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)]. (2016 Jan)Hamard CAnn Pathol
29530732Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. (2018 Feb 21)Petrelli FClin Lung Cancer
26102733LB03.07: ANTIHYPERTENSIVE THERAPY AND RISK OF ADMISSIONS FOR MOOD DISORDERS. (2015 Jun)Boal AJ Hypertens
27442811Combined CD44, c-MET, and EGFR expression in p16-positive and p16-negative head and neck squamous cell carcinomas. (2017 Mar)Baschnagel AMJ Oral Pathol Med
27655296Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia. (2016 Sep 21)Brcic LDiagn Pathol
19307230Alcohol consumption and 5-year onset of chronic kidney disease: the AusDiab study. (2009 Aug)White SLNephrol Dial Transplant
20085868Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. (2010 Jan)Kuo CHClin Lung Cancer
25708168Serum uric acid and other short-term predictors of electrocardiographic alterations in the Brisighella Heart Study cohort. (2015 May)Cicero AFEur J Intern Med
21626329The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma. (2011 Jun)Kawano DSurg Today
26621340Cardiotrophin-1 is inversely associated with obesity in non-diabetic individuals. (2015 Dec 1)Hung HCSci Rep
28860859Head and neck cancer: improving outcomes with a multidisciplinary approach. (2017)Lo Nigro CCancer Manag Res
28207110Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. (2007 S4 - Jan-Mar)Cappuzzo FInt J Biol Markers
28625654LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer. (2017 Jun)Imperatori ALung Cancer
17052296Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. (2006 Nov)Kato TRespirology
21714678A new tool to detect kidney disease in Chinese type 2 diabetes patients: comparison of EZSCAN with standard screening methods. (2011 Sep)Ozaki RDiabetes Technol Ther
27711203Health-Related Quality of Life in Korean Adults with Hearing Impairment: The Korea National Health and Nutrition Examination Survey 2010 to 2012. (2016)Baek MKPLoS One
28689332Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis. (2017 Nov)Kim HRJ Cancer Res Clin Oncol
17290066Lung cancer in never smokers: a review. (2007 Feb 10)Subramanian JJ Clin Oncol
20184812The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model. (2010 Feb)Hemingway HHealth Technol Assess
25695028Elevated Blood Pressure and Serum gamma -Glutamyltransferase as Significant Characteristics of Smokers With Chronic Kidney Disease. (2014 Jul)Noborisaka YNephrourol Mon
23573306FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer. (2013)Kawakami MInt J Clin Exp Pathol
8205534Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. (1994 Jun 15)Shin DMCancer Res
28415730A polymorphism at IGF1 locus is associated with anemia. (2017 May 16)Marini MAOncotarget
26025465Low 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 levels are independently associated with macroalbuminuria, but not with retinopathy and macrovascular disease in type 1 diabetes: the EURODIAB prospective complications study. (2015 May 30)Engelen LCardiovasc Diabetol
24236082Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis. (2013)OuYang PYPLoS One
26377178Association of hearing impairment with chronic kidney disease: a cross-sectional study of the Korean general population. (2015 Sep 16)Seo YJBMC Nephrol
16393673Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. (2006 Feb)de Boer WIAm J Clin Pathol
23913494A community study of the prevalence, risk factors and pattern of chronic kidney disease in Osun State, South West Nigeria. (2013 Apr-Jun)Oluyombo RWest Afr J Med
24520400Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. (2014)Sesti GPLoS One
19493678Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. (2009 Aug)Cho WCEur J Cancer
23802852Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. (2014 Mar)McQuitty EArch Pathol Lab Med
23801726Derivation and validation of a renal risk score for people with type 2 diabetes. (2013 Oct)Elley CRDiabetes Care
28952227Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma. (2017 Jul-Aug)Wang QJ BUON
26846215Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study. (2016 Aug)Obradovic JTumour Biol
26888425Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients. (2016 May)Tian GFuture Oncol
20878128Estrogen receptor beta and epidermal growth factor receptor as early-stage prognostic biomarkers of non-small cell lung cancer. (2010 Nov)Mauro LVOncol Rep
21929449Screening of a population at risk of chronic kidney disease: analysis of factors associated with low eGFR and microalbuminuria. (2011)Lezaic VRen Fail
24521684c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation. (2014 Mar 1)Baschnagel AMInt J Radiat Oncol Biol Phys
24282590Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers. (2013)Zhang HPLoS One
25179480Independent predictors of early mortality after coronary artery bypass grafting in a single centre experience--does gender matter? (2015)Miskowiec DLKardiol Pol
19262485The differential effect of cigarette smoking on glomerular filtration rate and proteinuria in an apparently healthy population. (2009 Mar)Yoon HJHypertens Res
29742701Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy. (2018 May)Wei MMedicine (Baltimore)
23244191Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia. (2012 Dec 17)Abedi-Ardekani BBMC Cancer
15015626Long-term effect of gefitinib (ZD1839) on squamous cell carcinoma of the lung. (2004 Jan-Feb)Kozuki TAnticancer Res
24818747Detection of mutation-specific epidermal growth factor receptor (E746-A750del) and lack of detection of human papillomavirus in oral squamous cell carcinoma. (2014 Oct)Grimm MInt J Oral Maxillofac Surg
26601720Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis. (2016 Feb)Bjaanaes MMMol Oncol
19609951Frequency of and variables associated with the EGFR mutation and its subtypes. (2010 Feb 1)Tanaka TInt J Cancer
22340046[Correlation between EGFR gene mutation and high copy number and their association with the clinicopathological features in Chinese patients with non-small cell lung cancer]. (2011 Sep)Li ZZhonghua Zhong Liu Za Zhi
24376700Attenuation of cigarette smoke-induced airway mucus production by hydrogen-rich saline in rats. (2013)Ning YPLoS One
27470969PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? (2016 Sep 15)Gettinger SClin Cancer Res
25873611Importance of ethnicity and smoking status in EGFR gene testing in lung cancers. (2015 May 1)Chung CAm J Health Syst Pharm
25873612Importance of ethnicity and smoking status in EGFR gene testing in lung cancers. (2015 May 1)Engle JAAm J Health Syst Pharm
20703235C-reactive protein is associated with cigarette smoking-induced hyperfiltration and proteinuria in an apparently healthy population. (2010 Nov)Sauriasari RHypertens Res
27469295High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. (2016 Nov - Dec)Zobel EHJ Diabetes Complications
23919423Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. (2013 Oct)Xia NExp Lung Res
27042119Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor. (2016)Yang CJOnco Targets Ther
22980975Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. (2012 Sep 14)Imielinski MCell
28299524Lung function and impaired kidney function in relation to metabolic syndrome. (2017 Jul)Lee KInt Urol Nephrol
21521057Outcomes of reintervention for recurrent disease after percutaneous iliac angioplasty and stenting. (2011 Apr)Davies MGJ Endovasc Ther
29544718Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. (2018 Feb 19)Takashima YClin Lung Cancer
23148507The association between chronic kidney disease and cardiovascular disease risk factors in atomic bomb survivors. (2013 Jan)Sera NRadiat Res
25180059Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples. (2014 Jun)Zhao CTransl Oncol
28537660Relation between blood pressure variability and early renal damage in hypertensive patients. (2017 May)Yin LHEur Rev Med Pharmacol Sci
29446042The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations. (2018 Jun)Taniguchi YInt J Clin Oncol
23783567Prevalence and predictors of abdominal aortic calcification in healthy living kidney donors. (2014 Jan)Leckstroem DCInt Urol Nephrol
29413057Tumor biomarker testing in non-small-cell lung cancer: A decade of change. (2018 Feb)VanderLaan PALung Cancer
20008630Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. (2010 Jan 20)Lee YJJ Clin Oncol
25355724Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. (2015 Jan)Sun JMAnn Oncol
28494184Current status of research and treatment for non-small cell lung cancer in never-smoking females. (2017 Jun 3)Saito SCancer Biol Ther
27896857Former smoking and early and long-term graft outcome in renal transplant recipients: a retrospective cohort study. (2017 Feb)Van Laecke STranspl Int
23591159Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. (2013 Jul)Tanaka KJ Thorac Oncol
24144839A common polymorphism in pre-microRNA-146a is associated with lung cancer risk in a Korean population. (2014 Jan 15)Jeon HSGene
29285859Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population. (2018 Mar)Dekkers IAJ Thromb Haemost
15815931Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. (2005 May)Soung YHVirchows Arch
25806093RARbeta2 hypermethylation is associated with poor recurrence-free survival in never-smokers with adenocarcinoma of the lung. (2015)Kim YClin Epigenetics
26711930Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. (2016 Jan)Tissot CLung Cancer
25565774Clinicopathological significance and potential drug target of T-cadherin in NSCLC. (2015)Wang ZDrug Des Devel Ther
27008586Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer. (2017 Jan)Bu SAnn Surg Oncol
26582178The performance of NLST screening criteria in Asian lung cancer patients. (2015 Nov 18)Kumar VBMC Cancer
28881820Brain metastases in patients with non-small cell lung cancer: the role of mutated-EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination. (2017 Aug 8)Hsiao SHOncotarget
25775907[The relationship between EGFR mutation and clinico-pathological features of lung adenocarcinoma in residents of southern Russia]. (2014)Vodolazhskii DIKlin Med (Mosk)
20634796Plasma C-terminal pro-endothelin-1 is associated with target-organ damage in African Americans with hypertension. (2010 Nov)Habib AAm J Hypertens
28329858Cystatin C and the Risk of Frailty and Mortality in Older Men. (2017 Jul 1)Hart AJ Gerontol A Biol Sci Med Sci
28575038Plasma brain-derived neurotrophic factor concentration is a predictor of chronic kidney disease in patients with cardiovascular risk factors - Hyogo Sleep Cardio-Autonomic Atherosclerosis study. (2017)Kurajoh MPLoS One
19861857Can serial eGFR, body mass index and smoking predict renal allograft survival in south Asian patients. (2009 Nov)Mohamed Ali AASaudi J Kidney Dis Transpl
24284182[Relationship between estimated glomerular filtration rate level and clinical characteristics and outcome in patients with angiographic coronary artery disease and normal serum creatinine]. (2013 Jul)Li QZhonghua Xin Xue Guan Bing Za Zhi
19704257Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features. (2009 Sep)El-Zammar OADiagn Mol Pathol
21418917[Epidemiological characteristics of subclinical target organ damage in urban adult residents with hypertension in Tianjin and its relationships with renin-angiotensin-aldosterone system]. (2011 Feb 15)Li YLZhonghua Yi Xue Za Zhi
29713618Relationship between Nutrition Intake and Estimated Glomerular Filtration Rate in Korean Adults (30-65 years) from the Korea National Health and Nutrition Examination Survey 2013-2014. (2018 Apr)Ryu JClin Nutr Res
28840008Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study. (2017 Jul)Zhang JJ Thorac Dis
24828667Small-cell lung cancers in patients who never smoked cigarettes. (2014 Jun)Varghese AMJ Thorac Oncol
25338663Estrogen adversely affects the prognosis of patients with lung adenocarcinoma. (2015 Jan)Hsu LHCancer Sci
29246019Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study. (2017 Nov 21)Liu ROncotarget
29618796Prognostic value of cancer antigen -125 for lung adenocarcinoma patients with brain metastasis: A random survival forest prognostic model. (2018 Apr 4)Wang HSci Rep
18662213Cystatin-C, renal function, and incidence of hip fracture in postmenopausal women. (2008 Aug)LaCroix AZJ Am Geriatr Soc
21889392Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. (2011 Oct)Argiris AOral Oncol
27347674Increased Levels of Copeptin, a Surrogate Marker of Arginine Vasopressin, Are Associated with an Increased Risk of Chronic Kidney Disease in a General Population. (2016)Tasevska IAm J Nephrol
26851496Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population. (2016 May)Leduc NJ Thorac Oncol
22560843Clinical risk implications of the CKD Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) Study equation for estimated GFR. (2012 Aug)Matsushita KAm J Kidney Dis
25742943Impact of cystatin-C level on the prevalence and angiographic characteristics of vasospastic angina in Korean patients. (2015)Lee SNInt Heart J
26290437Effects of health intervention program on cardiometabolic risk profiles from health evaluation center in Asian population: a longitudinal study and propensity analysis. (2015 Aug 20)Liu CCHealth Qual Life Outcomes
17922974CCND1 messenger RNA expression is correlated with EGFR mutation status in lung cancer. (2007 Sep)Sasaki HClin Lung Cancer
18726117EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. (2009 Feb)Sasaki HJ Cancer Res Clin Oncol
24442099Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. (2014 Mar)Wang JJ Cancer Res Clin Oncol
25635035Metabolically healthy obesity and risk of incident CKD. (2015 Apr 7)Hashimoto YClin J Am Soc Nephrol
25255396Blood pressure and renal function decline: a 7-year prospective cohort study in middle-aged rural Chinese men and women. (2015 Jan)Wang QJ Hypertens
22088449Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. (2011 Jul 5)Wang HPChin Med J (Engl)
29511884Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma. (2018 May)Nakasone SJ Cancer Res Clin Oncol
21242665The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients. (2011)Wojas-Krawczyk KRespiration
26769766Bicarbonate Concentration, Acid-Base Status, and Mortality in the Health, Aging, and Body Composition Study. (2016 Feb 5)Raphael KLClin J Am Soc Nephrol
25421919The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. (2015 Feb)Skov BGAPMIS
25249428A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). (2014 Nov)Matsumoto YLung Cancer
26898612Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT. (2016 Mar)Li DLung Cancer
22825454A smoking-associated 7-gene signature for lung cancer diagnosis and prognosis. (2012 Oct)Wan YWInt J Oncol
27298405Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer. (2016 Aug 20)Rusthoven CGJ Clin Oncol
26767007Efficacy of Icotinib treatment in patients with stage IIIb/IV non-small cell lung cancer. (2014 May)Qin NThorac Cancer
22000696A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer. (2012 Mar)Pallis AGClin Lung Cancer
29352819Dietary fibre intake in relation to the risk of incident chronic kidney disease. (2018 Mar)Mirmiran PBr J Nutr
29228652Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma in situ and minimally invasive adenocarcinoma of lung. (2017 Nov 17)Yu ROncotarget
24736073Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. (2014 Apr)Lim SHJ Thorac Oncol
16800964Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. (2006 May)Clark GMClin Lung Cancer
21110926[Expression and their clinical significance of SSTR2A, SSTR5 and EGFR in non-small cell lung cancer]. (2007 Feb 20)Liu XZhongguo Fei Ai Za Zhi
26070907Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer. (2016 Apr)Takenaka TSurg Today
27008846CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment. (2016 Jul)Warner JLJ Am Med Inform Assoc
20886633Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. (2011 Feb 15)Togashi YCancer
19803472Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. (2009 Oct)Li XChem Res Toxicol
21853345Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy. (2012 Sep)Hirashima TMed Oncol
16863509EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. (2006 Aug)Yokoyama TCancer Sci
24629638Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. (2014 May)Kim MHLung Cancer
18549475Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. (2008 Jun 12)Blons HBMC Med Genomics
22398717Not all inflammatory markers are linked to kidney function: results from a population-based study. (2012)Pruijm MAm J Nephrol
29263509[Analysis of epidermal growth factor receptor mutations and its clinico-pathologic characteristics of the primary lung adenocarcinoma in Xinjiang Uighur Autonomous Region]. (2016 Aug 18)Ma XMBeijing Da Xue Xue Bao Yi Xue Ban
27470518Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. (2017 Mar)Wind SClin Pharmacokinet
18843258Vitamin D levels and patient outcome in chronic kidney disease. (2009 Jan)Ravani PKidney Int
20525802Lung injury and cancer: Mechanistic insights into ceramide and EGFR signaling under cigarette smoke. (2010 Sep)Goldkorn TAm J Respir Cell Mol Biol
18981628Risk factors for progression in patients with early-stage chronic kidney disease in the Japanese population. (2008)Yoshida TIntern Med
25736926Cannabis smoke can be a major risk factor for early-age laryngeal cancer--a molecular signaling-based approach. (2015 Aug)Bhattacharyya STumour Biol
27699239Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. (2016 Sep 8)Lizotte PHJCI Insight
24248816Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. (2014 Jan)Liu WSMed Oncol
27987577Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs. (2016 Dec)Jiang JLung Cancer
18956645[Detection of epidermal growth factor receptor gene mutations in non-small cell lung cancers by real-time polymerase chain reaction using scorpion amplification refractory mutation system]. (2008 May)Zhang JZhonghua Bing Li Xue Za Zhi
25047354Fluctuation between fasting and 2-H postload glucose state is associated with chronic kidney disease in previously diagnosed type 2 diabetes patients with HbA1c >/= 7%. (2014)Wang CPLoS One
19853477Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging. (2010 Mar)Semba RDJ Ren Nutr
24854557[Efficacy of gefitinib for young patients with unknown EGFR gene mutation in advanced lung adenocarcinoma]. (2014 May)Liu YZhongguo Fei Ai Za Zhi
29722148EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China. (2018 May 2)Pi CThorac Cancer
29745081Distribution of EGFR SNPs -191C/A and 181946G/A in patients with lung cancer depending on smoking status in the Republic of Srpska, Bosnia and Herzegovina. (2018 Mar-Apr)Elez-Burnjakovic NJ BUON
29413048Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells? (2018 Feb)Zhou FLung Cancer
29413045PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. (2018 Feb)Takada KLung Cancer
23932319The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. (2013 Sep)Izar BAnn Thorac Surg
24803578Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations. (2014 Jul 1)Kohno MClin Cancer Res
25434695A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. (2014 Dec 1)Hong SSci Rep
28118631Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations. (2017)Igawa SOncol Res Treat
24760387Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection. (2015 Mar)Jeon JHEur J Cardiothorac Surg
21300759EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients. (2011 Apr 15)Yang SYClin Cancer Res
27226640Activation of Epidermal Growth Factor Receptor/p38/Hypoxia-inducible Factor-1alpha Is Pivotal for Angiogenesis and Tumorigenesis of Malignantly Transformed Cells Induced by Hexavalent Chromium. (2016 Jul 29)Kim DJ Biol Chem
28507206Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. (2017 Sep)Yao ZHOncologist
26045824High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients. (2015)Zhao CInt J Clin Exp Pathol
25634451Non-hemodynamic predictors of arterial stiffness after 17 years of follow-up: the Malmo Diet and Cancer study. (2015 May)Gottsater MJ Hypertens
23110940EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. (2012 Oct 30)Lee HLRadiat Oncol
29713040Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma. (2018 Apr 30)Chan AWHMod Pathol
29300770Oxytocin is lower in African American men with diabetes and associates with psycho-social and metabolic health factors. (2018)Eisenberg YPLoS One
16930767PIK3CA mutation status in Japanese lung cancer patients. (2006 Nov)Kawano OLung Cancer
28881815Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. (2017 Aug 8)Dugay FOncotarget
27468938ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. (2016 Oct)Reck MJ Thorac Oncol
23265235Epidermal growth factor receptor mutation study for 5 years, in a population of patients with non-small cell lung cancer. (2013 Jan-Feb)Castro ASRev Port Pneumol
18932251Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. (2008 Dec 1)Wu CCCancer
22223435EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: a meta-analysis. (2012 Jan)Ren JHEnviron Mol Mutagen
21440690Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. (2011 Jun 10)Marko-Varga GJ Proteomics
23555641Association among polymorphisms in EGFR gene exons, lifestyle and risk of gastric cancer with gender differences in Chinese Han subjects. (2013)Zhang JPLoS One
22386825Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function. (2012 Jul)Singh DKDiabetes Res Clin Pract
29217530The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). (2018 Mar 1)Aisner DLClin Cancer Res
25404271[Clinical characteristics and outcomes of lung cancer patients with EGFR mutations in exons 19 and 21]. (2014 Nov)Liu RZhongguo Fei Ai Za Zhi
25926253Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status. (2015 May-Jun)Sousa VRev Port Pneumol (2006)
25074318DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. (2014 Jul 30)Nakamura KCardiovasc Diabetol
16144918Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. (2005 Sep 1)Shibata TClin Cancer Res
18423781High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. (2008 Oct)Perng RPLung Cancer
26807249Patterns of epidermal growth factor receptor mutation in non-small-cell lung cancers in the Gulf region. (2015 Nov)Jazieh ARMol Clin Oncol
23515407Characteristics of lung cancers harboring NRAS mutations. (2013 May 1)Ohashi KClin Cancer Res
24709377[Preliminary analysis of the relationship between peripheral arterial disease and other atherosclerosis markers and diabetic nephropathy]. (2014 Sep-Oct)Rioja JClin Investig Arterioscler
27051298Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment. (2016)Yang CJOnco Targets Ther
18039118Lung cancer preneoplasia. (2006)Wistuba IIAnnu Rev Pathol
25783515Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma. (2015 Jun)Ho TYClin Nucl Med
25360521Fluctuation between fasting and 2-H postload glucose state is associated with glomerular hyperfiltration in newly diagnosed diabetes patients with HbA1c < 7%. (2014)Hou XPLoS One
26483334[Detection and Analysis of EGFR and KRAS Mutations in the Patients with Lung Squamous Cell Carcinomas]. (2015 Oct 20)Zhang HZhongguo Fei Ai Za Zhi
28197929Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease. (2017 Mar)Mahmood MQMed Oncol
21964526Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma. (2011 Nov)Nishio MJ Thorac Oncol
23599765Abnormal methylation of seven genes and their associations with clinical characteristics in early stage non-small cell lung cancer. (2013 Apr)Zhao YOncol Lett
26001141The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. (2015 Jun)Lee JYJ Thorac Oncol
26175310Phylogenetic analysis of multiple FISH markers in oral tongue squamous cell carcinoma suggests that a diverse distribution of copy number changes is associated with poor prognosis. (2016 Jan 1)Wangsa DInt J Cancer
21282368Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes. (2011 Mar)Li HYDiabetes
27339447Genetic and environmental influences on the associations between change in kidney function and changes in cardiometabolic factors in Koreans. (2017 Jun)Song YMClin Exp Nephrol
23251849Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts. (2012 Dec)Suda KAging Dis
25567908Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. (2015 Aug 15)Drilon AClin Cancer Res
18028892Investigation of the prevalence of CKD in 13,383 Chinese hospitalised adult patients. (2008 Jan)Liu BCClin Chim Acta
28367239Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations. (2017)Zheng ZJ Cancer
17409999Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. (2006 Nov)Kris MGJ Thorac Oncol
18414067Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. (2008 Apr)Phisitkul KAm J Med Sci
25267753How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis. (2014 Nov 10)Zwicker JIJ Clin Oncol
16452191Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. (2006 Feb 1)Toyooka SCancer Res
17908966The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. (2007 Oct 1)Toyooka SClin Cancer Res
16288303HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. (2005 Dec 12)Cappuzzo FBr J Cancer
21645455[Expressions of c-Cbl, Cbl-b and EGFR and its role of prognosis in NSCLC]. (2011 Jun)Jiao XZhongguo Fei Ai Za Zhi
21645458[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy]. (2011 Jun)Shi CZhongguo Fei Ai Za Zhi
26380227Direct association of visit-to-visit HbA1c variation with annual decline in estimated glomerular filtration rate in patients with type 2 diabetes. (2015)Takenouchi AJ Diabetes Metab Disord
17105366Should every lung cancer patient be tested for EGFR mutation? (2006 Dec)Cappuzzo FExpert Opin Ther Targets
25288236Molecular alterations in non-small cell lung carcinomas of the young. (2014 Dec)VandenBussche CJHum Pathol
28624921Lung Adenocarcinoma Survival in EGFR-Mutated African-Caribbean Patients: A Multicenter Study in the French West Indies. (2017 Oct)Leduc NTarget Oncol
21615826Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. (2011 Jul)Liu QWDis Esophagus
24095952Increased expression of heat shock protein 70 in chronic obstructive pulmonary disease. (2013 Nov)Dong JInt Immunopharmacol
27039821Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China. (2016)Zhou JAsian Pac J Cancer Prev
27033561Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria. (2016 Jul)von Scholten BJDiabetologia
25013472Relative influence of c-Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non-small cell lung cancer. (2014 Aug)Xiao HOncol Lett
21458841The association between total urinary arsenic concentration and renal dysfunction in a community-based population from central Taiwan. (2011 Jun)Chen JWChemosphere
21807767Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer. (2011)Pirl WFOncologist
29277178[Clinical Significance and Mechanism of PI3K p110beta Overexpression in Non-small Cell Lung Cancer]. (2017 Dec 20)Xiong YZhongguo Fei Ai Za Zhi
25862146PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. (2015 Jun)Chang YLLung Cancer
23074402Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. (2010)-Ont Health Technol Assess Ser
23709419The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. (2013 Jul)Kim HRYonsei Med J
23489305EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients? (2007 Oct)Finocchiaro GExpert Opin Med Diagn
19134404[The detection by denaturing high performance liquid chromatography of epidermal growth factor receptor mutation in tissue and peripheral blood from patients with advanced non-small cell lung cancer]. (2008 Dec)Bai HZhonghua Jie He He Hu Xi Za Zhi
23226486Association of maximum weight with hyperuricemia risk: a retrospective study of 21,414 Chinese people. (2012)Gao BPLoS One
17956637Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study. (2007 Oct 24)Choi JEBMC Cancer
26553372Hyperhomocysteinemia predicts renal function decline: a prospective study in hypertensive adults. (2015 Nov 10)Xie DSci Rep
26019016Factors Responsible for Plasma beta-Amyloid Accumulation in Chronic Kidney Disease. (2016 Jul)Gronewold JMol Neurobiol
19675059Prevalence of chronic kidney disease in patients with suspected sleep apnoea. (2010 Jan)Fleischmann GNephrol Dial Transplant
24643899Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy. (2014 Aug)Lin MWAnn Surg Oncol
27227356Former smokers with non-small-cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis. (2016 Aug)Zheng SCancer Med
27161973Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study. (2016 Jul 1)Kawaguchi TJ Clin Oncol
28445978Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database. (2017 Apr 11)Weng SSOncotarget
23428780Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice. (2013)Zugazagoitia JOncology
22103903Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China. (2012)Lu HYNeoplasma
18694616Serum folate is associated with coronary heart disease independently of homocysteine in Turkish men. (2008 Oct)Onat AClin Nutr
18243402Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? (2008 Jul)Dongiovanni DLung Cancer
26208325Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. (2015)Chatziandreou IPLoS One
28322191MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations. (2017 Mar)Song ZClin Lung Cancer
23242440How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? (2013 Jan)Hata AJ Thorac Oncol
23242442Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. (2013 Jan)Varghese AMJ Thorac Oncol
24724747Routine implementation of EGFR mutation testing in clinical practice in Flanders: 'HERMES' project. (2014 Apr)Janssens AActa Clin Belg
28322512Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation. (2017 May)Kaseda KThorac Cancer
23782814Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. (2013 Jul)Wu YLLancet Oncol
15498267[Expression of epidermal growth factor receptor and MUC5AC on human airway with chronic obstructive pulmonary disease]. (2004 Sep)Mao LZhonghua Jie He He Hu Xi Za Zhi
28025329Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. (2017 Jan 15)Seow WJHum Mol Genet
21176469[Primary result of the efficacy and tolerance of gefitinib in advanced non-small cell lung cancer patients with brain metastasis]. (2006 Oct 20)Wang YZhongguo Fei Ai Za Zhi
25397519Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy. (2014)Cozzi-Lepri AJ Int AIDS Soc
27259329Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. (2016 Aug)Imyanitov ENMol Diagn Ther
29321093A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib and Afatinib in Japanese Patients with Non-small Cell Lung Cancer. (2018 Jan 10)Fujiwara AOncol Res
17649787Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M. (2007 Jul-Aug)Jancarikova DAnticancer Res
27363219[Reference Intervals of Standard Test Items in Ningen Dock Examination]. (2016 Mar)Yamakado MRinsho Byori
28369481Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. (2017 Nov 14)van den Berg MJEur Heart J
21119248Geftinib. (2010 Jul-Sep)Gupta AJ Cancer Res Ther
23559152Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. (2013 Aug)Lee JKAnn Oncol
24595526Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa). (2014 May)Fu MVirchows Arch
18261354[Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer]. (2007 Nov 20)Wang YZhonghua Yi Xue Za Zhi
25611230Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors. (2015 Feb)Toffalorio FJ Thorac Oncol
24649342Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small-cell lung cancer. (2014 Mar)Hsiao SHMol Clin Oncol
23555654Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. (2013)Chen XPLoS One
28376144Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. (2017 Jun 1)Lee CKJ Natl Cancer Inst
29167001[Association between the ALK Gene Status and the Efficacy of First-line Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma]. (2017 Nov 20)Chen MZhongguo Fei Ai Za Zhi
20339098Circulating resistin is increased with decreasing renal function in a general Japanese population: the Hisayama Study. (2010 Oct)Kawamura RNephrol Dial Transplant
25189529Whole-genome sequencing of asian lung cancers: second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers. (2014 Nov 1)Krishnan VGCancer Res
26131116Mutation of the epidermal growth factor receptor gene and its impact on the efficacy of gefitinib in advanced non-small cell lung cance. (2015)Li XNInt J Clin Exp Med
26622712A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report. (2015 Sep)Wang YOncol Lett
25500090Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on chinese population. (2014 Dec)Han XTransl Oncol
26597211Statins are independently associated with increased HbA1c in type 1 diabetes--The Thousand & 1 Study. (2016 Jan)Jensen MTDiabetes Res Clin Pract
29719560Cytomorphological features as predictors of epidermal growth factor receptor mutation status in lung adenocarcinoma. (2018)Sharma SCytojournal
17054433Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. (2007 Jan)Matsuo KCancer Sci
21544845Regulation of cigarette smoke-mediated mucin expression by hypoxia-inducible factor-1alpha via epidermal growth factor receptor-mediated signaling pathways. (2012 Apr)Yu HJ Appl Toxicol
23689218Clinical characteristics of 274 non-small cell lung cancer patients in China. (2013)Chen YOnkologie
26459407Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey. (2015 Nov)Lee SHJ Pathol Transl Med
26823551Impaired Glucose and Insulin Homeostasis in Moderate-Severe CKD. (2016 Sep)de Boer IHJ Am Soc Nephrol
27709733EGF-Amphiregulin Interplay in Airway Stem/Progenitor Cells Links the Pathogenesis of Smoking-Induced Lesions in the Human Airway Epithelium. (2017 Mar)Zuo WLStem Cells
25641064Fetal Smoke Exposure and Kidney Outcomes in School-Aged Children. (2015 Sep)Kooijman MNAm J Kidney Dis
26156625A Trial of Pitavastatin Versus Rosuvastatin for Dyslipidemia in Chronic Kidney Disease. (2015)Abe MJ Atheroscler Thromb
27424979Real-time PCR assay with high resolution melting for EGFR and BIM mutation of lung cancer. (2016 Jul)Xia JJEur Rev Med Pharmacol Sci
26993607The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. (2016 Jun 14)Bronte GOncotarget
23961259Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study. (2013)Doval DCJ Carcinog
19005564Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events. (2008)Chen ZPLoS One
25152623Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. (2014)Hu HOnco Targets Ther
21406191Arginine/asymmetric dimethylarginine ratio and cardiovascular risk factors in patients with predialytic chronic kidney disease. (2011 Jun)Hov GGClin Biochem
28433570Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry. (2017 Sep)Soo RAClin Lung Cancer
25769456Quantification of concentration and assessment of EGFR mutation in circulating DNA. (2015)Mazurek ACancer Biomark
18940290Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). (2008 Nov 1)Parikh NIAm J Cardiol
24412619Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient. (2014 Mar)Pircher ALung Cancer
28940943Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients. (2017 Nov)Wang TThorac Cancer
22237264High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. (2012 Feb)Sun PLJ Thorac Oncol
25721745Risk factors for renal function decline in adults with normal kidney function: a 7-year cohort study. (2015 Aug)Qin XJ Epidemiol Community Health
26358312Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox". (2015 Nov)Arrieta OLung Cancer
26392415Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study. (2015 Nov 10)Xu YOncotarget
18666211Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation. (2008 Sep 15)Tian LCancer
23953602Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. (2013 Aug 16)Piotrowski KCardiovasc Diabetol
26472514Low serum magnesium is associated with coronary artery calcification in a Korean population at low risk for cardiovascular disease. (2015 Nov)Lee SYNutr Metab Cardiovasc Dis
24920890Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis. (2014)Primiani AInt J Chron Obstruct Pulmon Dis
24377888[Factors related to the poor coronary collateral circulation in patients with coronary artery disease]. (2013 Oct)He MPZhonghua Xin Xue Guan Bing Za Zhi
26069097[Estrogen Receptors and their Impact for Prognosis and Therapy of Lung Cancer - New Insights to an Underestimated Mechanism]. (2015 Jun)Bruckl WMPneumologie
29496250Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. (2018 Mar)Okamoto ILung Cancer
19349493Current treatments for advanced stage non-small cell lung cancer. (2009 Apr 15)Stinchcombe TEProc Am Thorac Soc
29228697EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. (2017 Nov 17)Tseng CHOncotarget
18356552Homocysteine or renal impairment: which is the real cardiovascular risk factor? (2008 Jun)Potter KArterioscler Thromb Vasc Biol
26220538Prevalence and determinants of chronic kidney disease in rural and urban Cameroonians: a cross-sectional study. (2015 Jul 30)Kaze FFBMC Nephrol
24825341Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults. (2014 Jul)Kizer JRAtherosclerosis
25354134Dipstick proteinuria is an independent predictor of high on treatment platelet reactivity in patients on clopidogrel, but not aspirin, admitted for major adverse cardiovascular events. (2015)Davila CDPlatelets
25494516A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer. (2016 Jan)Kureshi NIEEE J Biomed Health Inform
17595754Associations between ten biological tumor markers in squamous cell cervical cancer and serum estradiol, serum progesterone and smoking. (2007 May-Jun)Lindstrom AKAnticancer Res
26335629Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations. (2015)Igawa SOncology
26273671GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. (2015)Adela RJ Diabetes Res
29190621NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy. (2018)Kauffmann-Guerrero DRespiration
29798216[Research progress of amphiregulin and its role in airway inflammatory disease]. (2018 Jan 5)Gao LLin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
25503445Fasting blood glucose, but not 2-h postload blood glucose or HbA1c, is associated with mild decline in estimated glomerular filtration rate in healthy Chinese. (2015 Jan)Sun YInt Urol Nephrol
20681447[K-RAS gene mutations in patients with non-small cell lung cancer]. (2010 Jun)Zhang YZhongguo Fei Ai Za Zhi
16503085Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. (2006 Apr)Haneda HLung Cancer
28838990Marijuana Use and Estimated Glomerular Filtration Rate in Young Adults. (2017 Oct 6)Ishida JHClin J Am Soc Nephrol
22776036Prevalence, determinants and co-morbidities of chronic kidney disease among First Nations adults with diabetes: results from the CIRCLE study. (2012 Jul 9)Dyck RFBMC Nephrol
22278599Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis. (2012 Jun)Shin MJClin Exp Nephrol
19690148Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. (2009 Sep 1)Ohashi KCancer Res
25605150Epidermal growth factor receptor mutations in Japanese men with lung adenocarcinomas. (2014)Tomita MAsian Pac J Cancer Prev
23098378Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. (2013 Jan)Li HLung Cancer
21933749Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. (2011 Oct)Shaw ATLancet Oncol
23783797Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene. (2013 Sep)Krawczyk POncol Rep
25239726A prospective clinical trial of specialist renal nursing in the primary care setting to prevent progression of chronic kidney: a quality improvement report. (2014 Sep 20)Walker RCBMC Fam Pract
20441712Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. (2010 Apr)Black CHealth Technol Assess
18594528Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. (2008 Jul 22)Koivunen JPBr J Cancer
27747151A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation. (2016)Imamura FRespir Med Case Rep
26759157Determinants and burden of chronic kidney disease in a high-risk population in Korea: results from a cross-sectional study. (2016 Sep)Kang YUKorean J Intern Med
23922552The Association between Parathyroid Hormone Levels and Hemoglobin in Diabetic and Nondiabetic Participants in the National Kidney Foundation's Kidney Early Evaluation Program. (2013 Jul)Memon ICardiorenal Med
26629421Treatment of advanced squamous cell carcinoma of the lung: a review. (2015 Oct)Derman BATransl Lung Cancer Res
21030453Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. (2011 Jan)Cadranel JEur Respir J
28210105Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer. (2010)Wilson CLung Cancer (Auckl)
27885542A consensus statement on the gender perspective in lung cancer. (2017 May)Isla DClin Transl Oncol
25635036Vascular calcification and bone mineral density in recurrent kidney stone formers. (2015 Feb 6)Shavit LClin J Am Soc Nephrol
29491268Parathyroid Hormone Levels Are Independently Associated with eGFR and Albuminuria: The Dong-gu Study. (2018)Choi SWJ Nutr Sci Vitaminol (Tokyo)
25360721Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis. (2014)Wang YPLoS One
24466154Ion channel gene expression in lung adenocarcinoma: potential role in prognosis and diagnosis. (2014)Ko JHPLoS One
25393991Determinants of IL-6 levels during HIV infection. (2014)Borges AHJ Int AIDS Soc
17296816Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature. (2007 Feb)Araujo AOncologist
17296817Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. (2007 Feb)Toschi LOncologist
28219201[Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation]. (2017 Feb 23)Wang ZHZhonghua Zhong Liu Za Zhi
21480819Cystatin C and baseline renal function among HIV-infected persons in the SUN Study. (2012 Feb)Overton ETAIDS Res Hum Retroviruses
26340131Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. (2015 Dec 15)Chan DCInt J Cardiol
21623266EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. (2011 May)Helland AJ Thorac Oncol
27123149EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature. (2016 May)Yang YOncol Lett
19157632Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. (2009 Sep)Kim JELung Cancer
21420271[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]. (2011 Apr)Hadoux JPresse Med
25243942Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma. (2015 Jan)Jeong CJClin Nucl Med
28201810The association between Dietary Approaches to Stop Hypertension and incidence of chronic kidney disease in adults: the Tehran Lipid and Glucose Study. (2017 Apr 1)Asghari GNephrol Dial Transplant
19692129Effects of cigarette smoking on mucin production in human middle ear epithelial cells. (2009 Oct)Cho JGInt J Pediatr Otorhinolaryngol
23786968What is the phenotype of patients with gastrointestinal intolerance to metformin? (2013 Sep)Hermans MPDiabetes Metab
23410901Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease. (2013 Apr)Nakamichi SJpn J Clin Oncol
15788673Predictors of the response to gefitinib in refractory non-small cell lung cancer. (2005 Mar 15)Kim KSClin Cancer Res
16198442Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. (2006 Jan)Uramoto HLung Cancer
28685219Clinicopathological Significance of Micropapillary Pattern in Lung Adenocarcinoma. (2018 Jul)Pyo JSPathol Oncol Res
21775064Problems involved in the clinical trials for non-small cell lung carcinoma. (2012 May)Saijo NCancer Treat Rev
20591816Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients. (2011 Jan)Tanaka KNephrol Dial Transplant
28144970Pulmonary adenocarcinoma with epidermal growth factor receptor-mutations in asbestos exposed non-smokers: A case series. (2017 Mar)Kradin RLAm J Ind Med
24948201Does the KDIGO CKD risk stratification based on GFR and proteinuria predict kidney graft failure? (2014 Sep)Bucsa CInt Urol Nephrol
29247171Computer-Aided Nodule Assessment and Risk Yield (CANARY) may facilitate non-invasive prediction of EGFR mutation status in lung adenocarcinomas. (2017 Dec 15)Clay RSci Rep
26350052Molecular Testing in Multiple Synchronous Lung Adenocarcinomas: Case Report and Literature Review. (2016 Feb)Rafael OCInt J Surg Pathol
29232915Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma. (2017 Dec 11)Levy MMed Sci (Basel)
23016573Inflammation, oxidative stress, glomerular filtration rate, and albuminuria in elderly men: a cross-sectional study. (2012 Sep 27)Nerpin EBMC Res Notes
29556515Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor. (2018 Jan)Solanki HSOncoscience
23818594EGF shifts human airway basal cell fate toward a smoking-associated airway epithelial phenotype. (2013 Jul 16)Shaykhiev RProc Natl Acad Sci U S A
28790845Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations. (2017)Song XOnco Targets Ther
24683472Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4. (2014 Apr)Kiu Weber CIClin Kidney J
29463039The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting. (2018 Feb 18)Saito RInt J Mol Sci
27449344Survival of Patients with Advanced Non-Small Cell Lung Cancer Enrolled in Clinical Trials. (2016)Arrieta OOncology
17409975Establishment and expression profiling of new lung cancer cell lines from Chinese smokers and lifetime never-smokers. (2006 Nov)Lam DCJ Thorac Oncol
21562939Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features. (2011 Aug)Yano TInt J Clin Oncol
15949588NNK-induced hamster lung adenocarcinomas over-express beta2-adrenergic and EGFR signaling pathways. (2005 Jul)Schuller HMLung Cancer
29227909Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review. (2018 Jan)Oronsky BNeoplasia
27268911Smoking, hormonal factors and molecular markers in female lung cancer. (2016)Schveigert DNeoplasma
11133506Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. (2001 Jan)Takeyama KAm J Physiol Lung Cell Mol Physiol
22321547[Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer]. (2011 Oct)Fan MJZhonghua Bing Li Xue Za Zhi
18543225[Mutations in exon 19 of EGFR gene in non-small cell lung cancer from Chinese patients]. (2008 Jun)Wang HYZhonghua Yi Xue Yi Chuan Xue Za Zhi
28855035[Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma]. (2017 Aug 20)Qian KZhongguo Fei Ai Za Zhi
18367287EGFR FISH versus mutation: different tests, different end-points. (2008 May)Cappuzzo FLung Cancer
28087951A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma. (2016 Aug 30)Zhao COncotarget
24155926HIV gp120 induces mucus formation in human bronchial epithelial cells through CXCR4/alpha7-nicotinic acetylcholine receptors. (2013)Gundavarapu SPLoS One
24923577Urinary kidney injury molecule-1 and the risk of cardiovascular mortality in elderly men. (2014 Aug 7)Carlsson ACClin J Am Soc Nephrol
21216486Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. (2011 Mar)Gridelli CLung Cancer
22464348Lung cancer in never smokers--a review. (2012 Jun)Couraud SEur J Cancer
14739904Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. (2004 Apr)Deeb GMod Pathol
28103968[Gene Expression and Clinical Characteristics of Molecular Targeted Therapy in Non-small Cell Lung Cancer Patients in Shandong]. (2017 Jan 20)Qiao XZhongguo Fei Ai Za Zhi
28677807Torilis japonica extract fraction compound, EGFR-targeted inhibition of cancer abnormal metastasis in A549 lung cancer cells. (2017 Aug)Kim GTOncol Rep
23127161Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study. (2013 Feb)Gardener HMetab Syndr Relat Disord
22199344Clinical significance of hypermethylation status in NSCLC: evaluation of a 30-gene panel in patients with advanced disease. (2011 Dec)Pesek MAnticancer Res
27861565The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas. (2016)Cho JPLoS One
21595912High rates of albuminuria but not of low eGFR in urban indigenous Australians: the DRUID study. (2011 May 19)Maple-Brown LJBMC Public Health
22267755Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. (2012 Jul)Scoccianti CEur Respir J
28294470Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer. (2017 Jun)Tode NCancer Sci
29373900Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinomas: A Single Center Study from Iran (2018 Jan 27)Basi AAsian Pac J Cancer Prev
15738541Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. (2005 Apr 10)Mitsudomi TJ Clin Oncol
25838227Defining normality in a European multinational cohort: Critical factors influencing the 99th percentile upper reference limit for high sensitivity cardiac troponin I. (2015)Krintus MInt J Cardiol
18706747Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan. (2008 Dec)Cheng TYAm J Kidney Dis
24279718Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. (2013 Nov 26)Rossing HHBMC Res Notes
19026460Association of an EGFR intron 1 SNP with never-smoking female lung adenocarcinoma patients. (2009 Jun)Jou YSLung Cancer
25738220Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. (2015 May)Sholl LMJ Thorac Oncol
25558292Individualized Survival and Treatment Response Predictions in Breast Cancer Patients: Involvements of Phospho-EGFR and Phospho-Her2/neu Proteins. (2008 May 27)Guo LOpen Clin Cancer J
15121636Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-alpha-converting enzyme in human airway epithelial (NCI-H292) cells. (2004 Aug)Shao MXAm J Physiol Lung Cell Mol Physiol
29079040Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. (2018 Jan)Aguiar FArch Bronconeumol
19204017Association of kidney function and uncarboxylated matrix Gla protein: data from the Heart and Soul Study. (2009 Jul)Parker BDNephrol Dial Transplant
28914263Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. (2018 Feb)Tang ZMod Pathol
16002951Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. (2005 Jul)Zheng ZChest
16002952Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. (2005 Jul)Hsieh RKChest
23551194Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. (2013 Jun)Lindeman NIArch Pathol Lab Med
20493771Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. (2010 Jun)Cappuzzo FLancet Oncol
23425898[Clinic characteristics and prognosis in 102 non-small cell lung cancer patients less than 40 years old]. (2013 Feb)Qu LZhongguo Fei Ai Za Zhi
24436478Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4. (2014 Apr)Xu HClin J Am Soc Nephrol
26104035Evidence supporting the need for considering the effects of smoking on drug disposition and effectiveness in medication practices: a systematic narrative review. (2015 Aug)Sohn HSInt J Clin Pharmacol Ther
17452061Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas. (2007 Aug)Inamura KLung Cancer
26873401Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. (2016 May)Sawada GGastroenterology
23018352Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor kappaB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis. (2012 Oct)Giaginis CMed Sci Monit
25126481Establishment and characterization of a singaporean chinese lung adenocarcinoma cell line with four copies of the epidermal growth factor receptor gene. (2014 Aug 1)Choong MLBiores Open Access
25964053Chronic hyperglycemia is associated with acute kidney injury in patients undergoing CABG surgery--a cohort study. (2015 May 12)Oezkur MBMC Cardiovasc Disord
23661716Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? (2013 Oct)Ou SHJ Clin Pathol
25789627Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. (2015)Hsu KHPLoS One
26200269Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. (2015 Aug)Shim HSJ Thorac Oncol
25228365High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer. (2014 Dec)Stone EIntern Med J
28434967Cysteinylated transthyretin as a discriminator of cardiovascular risk in patients with diabetes mellitus. (2017 Jul)Wakabayashi IClin Chim Acta
22605530Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. (2012 Dec 1)Paik PKCancer
20817668Risk factors for the development of albuminuria and renal impairment in type 2 diabetes--the Swedish National Diabetes Register (NDR). (2011 Apr)Afghahi HNephrol Dial Transplant
21575523[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer]. (2011 Mar)Zhao LDZhonghua Zhong Liu Za Zhi
12559770Acquired somatic mutations in the molecular pathogenesis of COPD. (2003 Feb)Anderson GPTrends Pharmacol Sci
22492281Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma. (2012 Dec)Togashi YMed Oncol
26766969Correlation study and significance of the EGFR expression in serum, lymph nodes and tumor tissue of NSCLC. (2014 Jan)Zhuo YThorac Cancer
18541260EGFR polymorphism of the kinase domain in Japanese lung cancer. (2008 Aug)Sasaki HJ Surg Res
23625155Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by alpha1 nicotinic acetylcholine receptor-mediated activation in PC9 cells. (2013 Jun)Wang SJ Thorac Oncol
24147598Molecular profiling of EGFR family in chronic obstructive pulmonary disease: correlation with airway obstruction. (2013 Dec)Anagnostis AEur J Clin Invest
23629442High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases. (2013 Jun)Morita SAm J Surg Pathol
27500967ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India. (2016 Oct)Bal AAPMIS
23931872Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease. (2013 Aug)Ekart RTher Apher Dial
26689248Polymorphism of rs9387478 correlates with overall survival in female nonsmoking patients with lung cancer. (2016 May 28)Han JFInt J Biol Markers
23425628Invited commentary: the etiology of lung cancer in men compared with women. (2013 Apr 1)Alberg AJAm J Epidemiol
27191886Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. (2016 Jul 19)Hsu CHOncotarget
19756735Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells. (2010 Mar)Komiya KJ Cancer Res Clin Oncol
21738052Uromodulin gene variant is associated with type 2 diabetic nephropathy. (2011 Sep)Ahluwalia TSJ Hypertens
16052218Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. (2005 Aug 8)Sonobe MBr J Cancer
28238555Prediction of five-year all-cause mortality in Chinese patients with type 2 diabetes mellitus - A population-based retrospective cohort study. (2017 Jun)Wan EYFJ Diabetes Complications
28676214DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. (2017 Aug)Takamochi KLung Cancer
22120634p120-catenin modulates airway epithelial cell migration induced by cigarette smoke. (2012 Jan 6)Zhang LBiochem Biophys Res Commun
18166835EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. (2008 Jan)Inamura KJ Thorac Oncol
25634006Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). (2015 May)Arrieta OJ Thorac Oncol
29398676Association of the Serum Endostatin Level, Renal Function, and Carotid Atherosclerosis of Healthy Residents of Japan: Results from the Kyushu and Okinawa Population Study (KOPS). (2018 Feb 2)Kato YJ Atheroscler Thromb
23786997Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. (2013 Sep)Tomonaga NClin Lung Cancer
28212407Epidemiology of low-proteinuric chronic kidney disease in renal clinics. (2017)De Nicola LPLoS One
24134530Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification. (2013 Oct 17)van Eupen MGCardiovasc Diabetol
24989169Moderate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease. (2014 Aug)Lee YCScand J Gastroenterol
27118687Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). (2016 Sep)Staplin NAm J Kidney Dis
27766545From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? (2016 Dec)D'Argento ECurr Treat Options Oncol
24994038Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer. (2014 Dec)Deng LLJ Cancer Res Clin Oncol
18984626Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). (2009 Apr)Yokoyama HNephrol Dial Transplant
29456848Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations. (2018 Mar)Hung MSMol Clin Oncol
26621152Assessment of the clinical relevance of 17q25.3 copy number and three-dimensional telomere organization in non-small lung cancer patients. (2016 Apr)Sunpaweravong PJ Cancer Res Clin Oncol
9178701Differential inhibition of epidermal growth factor signaling pathways in rat hepatocytes by long-term ethanol treatment. (1997 Jun)Saso KGastroenterology
27633965Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer. (2017)Fu PRev Recent Clin Trials
27217997Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey. (2016)Sag SOSpringerplus
26149460TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung Cancer. (2015 Nov 15)Wei RClin Cancer Res
29719437A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR-mutated lung adenocarcinoma. (2018 Apr)Cao YCurr Oncol
29685824Monitoring of patients with type 2 diabetes and nephropathy in a specialized diabetic nephropathy clinic seems to be beneficial. (2018 Apr 13)Vallianou NDiabetes Metab Syndr
21422434Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). (2011 May 1)Ramalingam SSJ Clin Oncol
26632403Smoking-Related Renal Histologic Injury in IgA Nephropathy Patients. (2016 Jan)Cha YJYonsei Med J
27976463High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases. (2017 Jan)Mori SPathol Int
25426275Association between Apolipoprotein E Polymorphism and Chronic Kidney Disease in the Korean General Population: Dong-gu Study. (2014 Nov)Choi SWKorean J Fam Med
27142166ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy. (2016 May 3)Incharoen PWorld J Surg Oncol
29222872Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function. (2018 Feb)Zhou JThorac Cancer
27437773Consensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma. (2016 Aug 16)Ringner MOncotarget
27394925Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival. (2016 Sep)Kanbay MEur J Intern Med
23866929Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature. (2013 Jul 18)Sakai YMultidiscip Respir Med
21082022Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. (2010 Oct 28)Padmanabhan SPLoS Genet
27542180A Graphical Model of Smoking-Induced Global Instability in Lung Cancer. (2018 Jan-Feb)Wang YIEEE/ACM Trans Comput Biol Bioinform
28930715Cigarette Smoking Attenuates Kidney Protection by Angiotensin-Converting Enzyme Inhibition in Nondiabetic Chronic Kidney Disease. (2017)Roehm BAm J Nephrol
18250552Association between chronic kidney disease and carotid intima-media thickening in individuals with hypertension and impaired glucose metabolism. (2007 Nov)Ishizaka NHypertens Res
18250555Association between obesity and chronic kidney disease in Japanese: differences in gender and hypertensive status? (2007 Nov)Ishizaka NHypertens Res
22810899Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. (2013 Jan 15)Johnson MLCancer
27027313Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristics. (2016 Nov)Sabri AEur Radiol
26284326[Clinically relevant, gender-specific differences in colorectal carcinoma (CRC)]. (2015 Aug)Hoffken NZ Gastroenterol
25747806Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. (2015 May)Wu KLLung Cancer
7884573The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. (1994 Dec)Partanen RJ Occup Med
24192511A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease. (2014 Jan)Mariano CLung Cancer
29302581Novel Genetic Associations Between Lung Cancer and Indoor Radon Exposure. (2017 Dec)Choi JRJ Cancer Prev
24459065Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. (2014 May)Zhang YTumour Biol
23314596Serum surfactant protein D is associated with the prognosis in patients with chronic kidney disease. (2013 Jun)Xie FJ Cardiovasc Med (Hagerstown)
22510379Pre-hypertension as a significant predictor of chronic kidney disease in a general population: the Ohasama Study. (2012 Aug)Kanno ANephrol Dial Transplant
22498112Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. (2012 Aug)Pirker RLung Cancer
19227598[Molecular diagnostics of epidermal growth factor receptor in non-small cell lung cancer]. (2007 Oct)Timar JLege Artis Med
23014527Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. (2012 Nov 15)Dogan SClin Cancer Res
27542277The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. (2016 Nov 8)Yang YOncotarget
16243431High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. (2006 Aug 8)Sriuranpong VCancer Lett
17457280[New biological treatments for lung cancer]. (2007 Feb)Zalcman GRev Pneumol Clin
20720405Heritability of renal function and inflammatory markers in adult male twins. (2010)Raggi PAm J Nephrol
29290777Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells. (2018)Cui SJ Cancer
23403410Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients. (2013 Feb)Baykara OExp Ther Med
27039166Impact of renal function on mean platelet volume and its relationship with coronary artery disease: A single-centre cohort study. (2016 May)Verdoia MThromb Res
26692946Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition. (2015)Liu MAm J Transl Res
29683890Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients. (2018 Apr 20)Tseng JSJ Immunother
25955322Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. (2015)Jain APLoS One
18090579Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. (2007 Dec)Boldrini LJ Thorac Oncol
25830914Transcriptome analysis in patients with chronic kidney disease on hemodialysis disclosing a key role for CD16+CX3CR1+ monocytes. (2015)Schepers EPLoS One
15870715Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. (2005 May 23)Nishio MBr J Cancer
29137260Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma. (2017 Oct 10)Dong YOncotarget
29191596PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. (2017 Oct)Brody RLung Cancer
24643262Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? (2014 Apr)Ou SHPostgrad Med J
21411993Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors. (2011)Kim STChemotherapy
28884500Under-diagnosed chronic kidney disease in Jordanian adults: prevalence and correlates. (2018 Mar)Khalil AAJ Ren Care
24137465Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system. (2013 Oct)Krawczyk POncol Lett
18418018EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients. (2008 Apr)Wang ZOnkologie
26268750[Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma]. (2015 Mar)Wang KZhonghua Bing Li Xue Za Zhi
19269703Relationship of plasma erythropoietin to long-term outcome in acute coronary syndrome. (2010 Aug 20)Szummer KInt J Cardiol
25158139Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations. (2014 Aug 25)Yilmaz AInt J Environ Res Public Health
29022685Inverse Relationship between Adherence to the Mediterranean Diet and Serum Cystatin C Levels. (2017 Sep)Vallianou NGCent Eur J Public Health
22507644Human papillomavirus and gene mutations in head and neck squamous carcinomas. (2012 May)Friedland PANZ J Surg
27939360Cellular and molecular mechanisms underlying alcohol-induced aggressiveness of breast cancer. (2017 Jan)Wang YPharmacol Res
19650855Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment. (2009 Oct)Jida MCancer Sci
21965761Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study. (2011 Oct)Choi DRAnticancer Res
25664625Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. (2015 May)Lohinai ZJ Thorac Oncol
24965407Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan. (2014 Apr-Jun)Lai SWJ BUON
25975578The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. (2015)Lin CCancer Biol Ther
23744164The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy. (2013)Nicos MPneumonol Alergol Pol
24505486Bone mineral metabolism parameters and urinary albumin excretion in a representative US population sample. (2014)Ellam TPLoS One
22948239Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. (2012)Kanbay MAm J Nephrol
26462160FGF-23/Vitamin D Axis in Type 1 Diabetes: The Potential Role of Mineral Metabolism in Arterial Stiffness. (2015)Llaurado GPLoS One
24794276Comparison of the impact of open and endovascular abdominal aortic aneurysm repair on renal function. (2014 Sep)Saratzis AJ Vasc Surg
19231023Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. (2009 Nov)Cedres SLung Cancer
28693248Exon 7 splicing variant of estrogen receptor alpha is associated with pathological invasiveness in smoking-independent lung adenocarcinoma. (2017 Jul)Suzuki AOncol Lett
29660007Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. (2018 Apr 11)Pilemann-Lyberg SNephrol Dial Transplant
29142753Long-term survival in a patient with metastatic squamous cell lung carcinoma: A case report. (2017 Nov)Barletta EMol Clin Oncol
25381341Association of serum bicarbonate with incident functional limitation in older adults. (2014 Dec 5)Yenchek RClin J Am Soc Nephrol
22036089Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors. (2012 Jan)Leary AFEur J Cancer
25082736Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines. (2015 Mar 1)Olthof NCInt J Cancer
17198584[Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status]. (2006 Oct 10)Xu CRZhonghua Yi Xue Za Zhi
24388371Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer. (2014 Jan)Kobayashi MRespir Investig
23991042Factors other than the glomerular filtration rate that determine the serum beta-2-microglobulin level. (2013)Stanga ZPLoS One
22975805The transcriptional landscape and mutational profile of lung adenocarcinoma. (2012 Nov)Seo JSGenome Res
21550561Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. (2011 Mar)Farina GClin Lung Cancer
25853240Associations between renal hyperfiltration and serum alkaline phosphatase. (2015)Oh SWPLoS One
25222473Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations. (2014 Sep 12)Yilmaz AInt J Environ Res Public Health
21187500Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. (2010 Dec)Bonanno LAnticancer Res
22780936[Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma]. (2012 Feb)Zhang RXZhonghua Zhong Liu Za Zhi
17904685Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. (2008 Jan)Kim YTLung Cancer
29335443Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. (2018 Jan 15)Nahar RNat Commun
15895392Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. (2005 Dec)Di Maio MJ Cell Physiol
25366782Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer. (2014 Oct 31)Han YGenet Mol Res
23741221Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested? (2013 May)Schwitter MCase Rep Oncol
21316260Targeting phosphoinositide 3-kinase signalling in lung cancer. (2011 Nov)Wojtalla ACrit Rev Oncol Hematol
25886900Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and type between Uighur and Han ethnic groups in Xinjiang Autonomous Region. (2015 Feb 28)Li XBMC Genet
28090009Prognostic Impact of Atrial Fibrillation and New Risk Score of Its Onset in Patients at High Risk of Heart Failure- A Report From the CHART-2 Study. (2017 Jan 25)Yamauchi TCirc J
25456362Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. (2014 Dec)Janne PALancet Oncol
27612966Acrolein and thiol-reactive electrophiles suppress allergen-induced innate airway epithelial responses by inhibition of DUOX1 and EGFR. (2016 Nov 1)Danyal KAm J Physiol Lung Cell Mol Physiol
22325357Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. (2012 Apr)De Greve JLung Cancer
22593442EGFR and P-GP expression in oropharyngeal mucosa in relation to smoking. (2012 May)Baumeister PAnticancer Res
23419507Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma. (2013 May)Fujimoto DLung Cancer
23552377Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. (2013 Jul)Lindeman NIJ Thorac Oncol
23524710Detection of epidermal growth factor receptor intensity in asymptomatic fully impacted lower third molar follicles of smoking and nonsmoking patients. (2013 Mar)Ozarslan SKJ Craniofac Surg
25424620Kidney biomarkers associated with blood lead, mercury, and cadmium in premenopausal women: a prospective cohort study. (2015)Pollack AZJ Toxicol Environ Health A
24789720The application of real-time PCR technique to detect rare cell clones with primary T790M Substitution of EGFR gene in metastases of non-small cell lung cancer to central nervous system in chemotherapy naive patients. (2014 Oct)Powrozek TPathol Oncol Res
2747273918F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer. (2016 Jul)Guan JMedicine (Baltimore)
16219624Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. (2005 Dec)Dutu TAnn Oncol
20830227Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. (2010 Sep)Hong JKorean J Intern Med
27538148[Analysis of epidermal growth factor receptor mutations and its clinico-pathologic characteristics of the primary lung adenocarcinoma in Xinjiang Uighur Autonomous Region]. (2016 Feb 18)Ma XMBeijing Da Xue Xue Bao Yi Xue Ban
22087435Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. (2011 Nov 10)de Mello RAWorld J Clin Oncol
17493170Epidermal growth factor receptor mutations in lung cancers. (2007 May)Yatabe YPathol Int
17618705Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer. (2007 Nov)Usuda JLung Cancer
26068378Limitations in the Use of Serum Epidermal Growth Factor Receptor Mutations as Prognostic Markers for Non-Small-Cell Lung Cancer. (2015)Zhang YMed Princ Pract
23299280Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung. (2014 Feb)Rahman SInt J Clin Oncol
25933346Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. (2015)Bandera APLoS One
16552419Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. (2006 Mar 27)Sugio KBr J Cancer
19690778Malignant fibrous histiocytoma of larynx with giant cell: case report and histological-clinical considerations. (2009)Anghelina FRom J Morphol Embryol
27504739Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus. (2016 Dec)Jensen TMDiabet Med
19185949Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. (2009 Oct)Hosokawa SLung Cancer
22200795Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. (2012 Mar)Sasaki HMol Med Rep
24909166Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages. (2015 Apr 16)Kumar SOncogene
25113306US lung cancer trends by histologic type. (2014 Sep 15)Lewis DRCancer
21223687[Clinicopathological features and prognostic implications of EGFR/c-Met gene copy number and protein expression in non-small cell lung cancer]. (2010 Nov)Ai TZhonghua Zhong Liu Za Zhi
17409827Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. (2006 Jan)Argiris AJ Thorac Oncol
23877438CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. (2013 Oct)Matsuura SOncol Rep
25770175Vascular calcification in patients with nondialysis CKD over 3 years. (2015 Apr 7)Gorriz JLClin J Am Soc Nephrol
22191026The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases. (2011)Usui KPulm Med
29191580Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis. (2017 Oct)Wang ZLung Cancer
27368006Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion. (2016 Jun)Verma AMedicine (Baltimore)
25349974PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. (2015 Jan 6)D'Incecco ABr J Cancer
23788756The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. (2013 Sep)Kim HRAnn Oncol
28275237The association of alcohol and smoking with CKD in a Japanese nationwide cross-sectional survey. (2017 Aug)Matsumoto AHypertens Res
24565983Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. (2014 May)Vainshtein JMOral Oncol
26923333Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods. (2016 Feb 29)Shi XSci Rep
26893860Genetic alterations in lung adenocarcinoma with a micropapillary component. (2016 Feb)Furukawa MMol Clin Oncol
19160880How to prevent progression to end stage renal disease. (2007 Jul-Sep)Riegersperger MJ Ren Care
19674811The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. (2010 Jun)Sun JMLung Cancer
28145643Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers. (2017 Mar)Lee HYJ Korean Med Sci
28959653p-Benzoquinone initiates non-invasive urothelial cancer through aberrant tyrosine phosphorylation of EGFR, MAP kinase activation and cell cycle deregulation: Prevention by vitamin C. (2017)Ganguly SToxicol Rep
28957410The association between the apolipoprotein B/A-I ratio and coronary calcification may differ depending on kidney function in a healthy population. (2017)Kim SHPLoS One
21655907Lung cancers unrelated to smoking: characterized by single oncogene addiction? (2011 Aug)Suda KInt J Clin Oncol
27071409Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers. (2016 Jul)Ho GYFJ Natl Cancer Inst
15604253Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. (2004 Dec 15)Kosaka TCancer Res
27046167Micropapillary: A component more likely to harbour heterogeneous EGFR mutations in lung adenocarcinomas. (2016 Apr 5)Cai YRSci Rep
25275610Triglyceride levels are closely associated with mild declines in estimated glomerular filtration rates in middle-aged and elderly Chinese with normal serum lipid levels. (2014)Hou XPLoS One
27001591Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient. (2016 May 1)Presley CJJ Clin Oncol
29270615Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. (2018 Feb 1)Lee CKJAMA Oncol
27393502Air bronchogram: A potential indicator of epidermal growth factor receptor mutation in pulmonary subsolid nodules. (2016 Aug)Dai JLung Cancer
22966299Hypermethylation of the large tumor suppressor genes in Japanese lung cancer. (2010 Mar)Sasaki HOncol Lett
22707299Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. (2012 Nov)Ren SCell Biochem Biophys
22966295Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients. (2010 Mar)Sasaki HOncol Lett
23151275Relationships between serum MCP-1 and subclinical kidney disease: African American-Diabetes Heart Study. (2012 Nov 14)Murea MBMC Nephrol
22175900Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis. (2011 Dec)Zhang JHistopathology
25234657Tongue carcinoma infrequently harbor common actionable genetic alterations. (2014 Sep 19)Tan DSBMC Cancer
28210132EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers? (2013)Wang QLung Cancer (Auckl)
22028277Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. (2012 Jan)Zoppini GDiabetes Care
26667343KRAS-Mutant Lung Cancers in the Era of Targeted Therapy. (2016)Naidoo JAdv Exp Med Biol
25127713Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders. (2015 Jan 1)Kappelmayer JClin Chim Acta
23669275Residential proximity to major roadways and renal function. (2013 Aug)Lue SHJ Epidemiol Community Health
18508816Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. (2008 Oct)Wu SGEur Respir J
29168339Prognostic value of PD-L1 expression in combination with CD8(+) TILs density in patients with surgically resected non-small cell lung cancer. (2018 Jan)Yang HCancer Med
29328373Integrative gene ontology and network analysis of coronary artery disease associated genes suggests potential role of ErbB pathway gene EGFR. (2018 Mar)Ghatge MMol Med Rep
16270096EGFR inhibitors: what have we learned from the treatment of lung cancer? (2005 Nov)Giaccone GNat Clin Pract Oncol
24755888A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer. (2014 Jul)Yu HCancer Biol Ther
9816131Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. (1996 Oct)Kurie JMClin Cancer Res
20631634Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. (2010 Sep)Lin CCJ Thorac Oncol
27223332First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. (2016 May 25)Greenhalgh JCochrane Database Syst Rev
26927890Clinical Relevance of Different Papillary Growth Patterns of Pulmonary Adenocarcinoma. (2016 Jun)Warth AAm J Surg Pathol
28513466Non-small cell lung cancer - mutations, targeted and combination therapy. (2017 May 17)Kutkowska JPostepy Hig Med Dosw (Online)
17932690Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. (2008 May)Sasaki HJ Cancer Res Clin Oncol
18814932Chromosomal instability is a risk factor for poor prognosis of adenocarcinoma of the lung: Fluorescence in situ hybridization analysis of paraffin-embedded tissue from Korean patients. (2009 Apr)Choi CMLung Cancer
23883544Renal insufficiency without albuminuria is associated with peripheral artery atherosclerosis and lipid metabolism disorders in patients with type 2 diabetes. (2013)Yamashita TJ Atheroscler Thromb
26621000[Relationship between primary lung cancer and tobacco consumption. Results of the KBP-2010-CPHG study by the French College of General Hospital Respiratory Physicians]. (2016 Sep)Coetmeur DRev Mal Respir
23481268Mouse models for lung cancer. (2013 Apr)Kwon MCMol Oncol
24193009EGFR autophosphorylation but not protein score correlates with histologic and molecular subtypes in lung adenocarcinoma. (2013 Dec)Moldvay JDiagn Mol Pathol
25806302Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. (2014 Aug)Mitsudomi TTransl Lung Cancer Res
24944210The association between underweight and the development of albuminuria is different between sexes in relatively healthy Korean subjects. (2014 Nov)Jang CMNephrol Dial Transplant
19932544Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. (2010 Jan)Bash LDAm J Kidney Dis
16865253Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. (2006 Sep)Endo KOncol Rep
27188576Non-small-cell lung cancer. (2015 May 21)Gridelli CNat Rev Dis Primers
25886585Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients. (2015 Mar 1)Zhang QBMC Cancer
24477503Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. (2014 Jun)Lee YGThromb Haemost
27020204Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations. (2016 Jan)Clay TDPathology
21178715Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. (2011 Jan)Laack EJ Thorac Oncol
25232377EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis. (2014)Wang SInt J Clin Exp Med
22387125Prognostic features, human papillomavirus status, and epidermal growth factor receptor expression in oral squamous cell carcinoma in young adults. (2012 Nov-Dec)Thomas LAm J Otolaryngol
25745045No impact of passive smoke on the somatic profile of lung cancers in never-smokers. (2015 May)Couraud SEur Respir J
28549835Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study. (2017 Nov)Jiang TClin Lung Cancer
29557814Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity. (2018 Jun)Park YHAnticancer Drugs
26683928Genomic Copy Number Variations Characterize the Prognosis of Both P16-Positive and P16-Negative Oropharyngeal Squamous Cell Carcinoma After Curative Resection. (2015 Dec)Rhie AMedicine (Baltimore)
23302304[Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system]. (2012 Oct)Gao JZhonghua Bing Li Xue Za Zhi
27799390Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases. (2016 Nov)Ruano-Ravina AEur Respir J
28709937Detection of Lung Cancer and EGFR Mutation by Electronic Nose System. (2017 Oct)Shlomi DJ Thorac Oncol
27789961Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience. (2016)Lin LOnco Targets Ther
23723294Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). (2013 Sep)Dearden SAnn Oncol
16273222Expression of p63, COX-2, EGFR and beta-catenin in smokers and patients with squamous cell carcinoma of the head and neck reveal variations in non-neoplastic tissue and no obvious changes in smokers. (2005 Dec)Boldrup LInt J Oncol
26474957Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. (2015 Dec)Tseng JSLung Cancer
25456736Recurrent TERT promoter mutations in non-small cell lung cancers. (2014 Dec)Ma XLung Cancer
25145782Ocular and systemic factors associated with glaucoma in chronic kidney disease patients. (2014 Nov)Djordjevic-Jocic JInt Urol Nephrol
20956191The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. (2010 Sep)Armour AAEur Respir Rev
25667646Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer. (2015 Mar)Xu CWExp Ther Med
26362141EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience. (2015 Dec)Naderi SCancer Epidemiol
29404927Fast GFR decline and progression to CKD among primary care patients with preserved GFR. (2018 Mar)Koraishy FMInt Urol Nephrol
27388008Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed. (2016 Jul 7)Park SBMC Cancer
23518631Combined large cell neuroendocrine carcinoma and adenocarcinoma with epidermal growth factor receptor mutation in a female patient who never smoked. (2014)Yoshida YAnn Thorac Cardiovasc Surg
22537942Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. (2012 Apr 26)Liang HJ Exp Clin Cancer Res
20855974Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer. (2010 Nov 1)Takeshita MCancer Biol Ther
22957255Circulating adiponectin is associated with renal function independent of age and serum lipids in west africans. (2012)Doumatey APInt J Nephrol
28433448Anemia complicating type 2 diabetes: Prevalence, risk factors and prognosis. (2017 Jul)Gauci RJ Diabetes Complications
25251543Contribution of impaired renal function to cardiovascular risk prediction models in renal transplant recipients. (2014 Dec)Benguzzi MClin Transplant
20113268Screening for decreased renal function in taxi drivers in Tehran, Iran. (2010 Jan)Mahdavi-Mazdeh MRen Fail
26508917The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib. (2015 Oct)Park DITuberc Respir Dis (Seoul)
23137952Sex differences in hypertension-related renal and cardiovascular diseases in Italy: the I-DEMAND study. (2012 Dec)Muiesan MLJ Hypertens
24222150Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status. (2013 Nov)Okuma YAnticancer Res
28094058Association between dietary patterns, cadmium intake and chronic kidney disease among adults. (2018 Feb)Shi ZClin Nutr
27368123Adiponectin is associated with early diabetic kidney disease in adults with type 1 diabetes: A Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. (2017 Feb)Bjornstad PJ Diabetes Complications
24137397Keap1 mutations in lung cancer patients. (2013 Sep)Sasaki HOncol Lett
25773866Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. (2015 May)Tsai THLung Cancer
23562183Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. (2013 Jul)Lindeman NIJ Mol Diagn
17429853Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. (2007 Aug)Gu DHum Mutat
27105879The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients. (2016 Oct)Sarosi VPathol Oncol Res
19064969Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. (2009 Jan 20)Nose NJ Clin Oncol
28484878The association between creatinine versus cystatin C-based eGFR and cardiovascular risk in children with chronic kidney disease using a modified PDAY risk score. (2017 Aug)Sharma SPediatr Nephrol
26975535Serum uric acid: A strong and independent predictor of metabolic syndrome after adjusting for body composition. (2016 Apr)Yu TYMetabolism
27919997Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. (2016 Dec)Isla DAnticancer Res
27921038The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China. (2016 Oct)Xue CKidney Dis (Basel)
25462681Cadmium, type 2 diabetes, and kidney damage in a cohort of middle-aged women. (2014 Nov)Barregard LEnviron Res
23255934Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. (2013 Jan)Kim HJOncol Lett
21482987Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. (2011 May 20)D'Angelo SPJ Clin Oncol
24758907[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status]. (2014 Apr)Hong WZhongguo Fei Ai Za Zhi
27049360Creatinine measurement on dry blood spot sample for chronic kidney disease screening. (2016 Mar)Silva ACJ Bras Nefrol
23159001[Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer]. (2012 Aug)Li XZhonghua Zhong Liu Za Zhi
22339900Association of physician care with mortality in Kidney Early Evaluation Program (KEEP) participants. (2012 Mar)Saab GAm J Kidney Dis
21046302Serum level of soluble Hsp70 is associated with vascular calcification. (2011 May)Krepuska MCell Stress Chaperones
24729716Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. (2014)Li HOnco Targets Ther
23036155Impact of age on epidermal growth factor receptor mutation in lung cancer. (2012 Dec)Ueno TLung Cancer
15998906Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. (2005 Oct 1)Hirsch FRJ Clin Oncol
18789554Non-small cell lung cancer-smokers or non-smokers, does it matter? (2009 Mar)Barlesi FLung Cancer
26371700Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. (2015 Nov)Lee SJLung Cancer
28949965CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation. (2017)Zhao JPLoS One
29467863Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma. (2018 Mar)Yang YOncol Lett
20404520Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. (2010 Apr 15)Xu YCancer Biol Ther
19671850Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. (2009 Aug 15)Rodig SJClin Cancer Res
27103824Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer. (2016)Wen MOnco Targets Ther
22866092EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy. (2011 Mar)Kim YHOncol Lett
28839996Clinical profiles and trend analysis of newly diagnosed lung cancer in a tertiary care hospital of East China during 2011-2015. (2017 Jul)Wang PJ Thorac Dis
26940775A genetic view of laryngeal cancer heterogeneity. (2016 May 2)de Miguel-Luken MJCell Cycle
23242503Serum gamma-glutamyltransferase levels are inversely related to endothelial function in chronic kidney disease. (2013 Aug)Yilmaz MIInt Urol Nephrol
17477876Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. (2007 May 3)Liu YBMC Cancer
25274394Pulse wave reflection is associated with diabetes duration, albuminuria and cardiovascular disease in type 1 diabetes. (2014 Dec)Theilade SActa Diabetol
25239875Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation. (2014 Oct)Zou JJ Int Med Res
20564408Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. (2010 Jun 15)Kim STCancer
25173459Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation. (2014 Nov)Igawa SCancer Chemother Pharmacol
26311121Heterogeneity of (18)F-FDG PET combined with expression of EGFR may improve the prognostic stratification of advanced oropharyngeal carcinoma. (2016 Feb 1)Wang HMInt J Cancer
29733545Overexpression of S100A14 contributes to malignant progression and predicts poor prognosis of lung adenocarcinoma. (2018 May 7)Ding FThorac Cancer
21778168Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. (2012 Feb)Girard NEur Respir J
27340283Creatinine-Based and Cystatin C-Based GFR Estimating Equations and Their Non-GFR Determinants in Kidney Transplant Recipients. (2016 Sep 7)Keddis MTClin J Am Soc Nephrol
24055406Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. (2013 Nov)Hosgood HD 3rdRespir Med
26102513Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma. (2015)Shan LPLoS One
21336183Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. (2011 Apr)Camidge DRJ Thorac Oncol
21778164Cigarette smoke impairs airway epithelial barrier function and cell-cell contact recovery. (2012 Feb)Heijink IHEur Respir J
29394888Diabetic kidney disease in the elderly: prevalence and clinical correlates. (2018 Feb 2)Russo GTBMC Geriatr
24667263[Clinicopathological and prognostic significance of a panel of tumor biomarkers in lung adenocarcinoma: a tissue microarray study]. (2014 Mar)Yang XZhongguo Fei Ai Za Zhi
29113190Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland. (2017 Nov)Ramlau ROncol Lett
20945327Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. (2011 Feb 1)Richards KLCancer
20473935CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. (2011 Mar 1)Koga TInt J Cancer
26622749Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. (2015 Sep)Soh JOncol Lett
27602151Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients. (2016 Sep)Polanska HOncol Lett
29735453[Correlation between fasting C-peptide and serum uric acid in patients with type 2 diabetes mellitus]. (2018 Apr 20)Liang QNan Fang Yi Ke Da Xue Xue Bao
22430133Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. (2011-2012)Xu JCancer Biomark
25588859Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. (2015 May 26)Campos-Gomez SInt J Biol Markers
19098404[Efficacy of gefitinib according to smoking status in non-small cell lung cancer patients]. (2008 Dec)Shukuya TGan To Kagaku Ryoho
18403609EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. (2008 May)Li ARJ Mol Diagn
28332473Correlation analysis of renal ultrasound elastography and clinical and pathological changes in patients with chronic kidney disease. (2017 Jun)Peng LClin Nephrol
28289532Association between high cystatin C levels and carotid atherosclerosis. (2017 Feb 26)Kobayashi TWorld J Cardiol
22263017Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. (2010 Mar)Bethune GJ Thorac Dis
18262213Recurrent exposure to nicotine differentiates human bronchial epithelial cells via epidermal growth factor receptor activation. (2008 May 1)Martinez-Garcia EToxicol Appl Pharmacol
22459775The relationship between pulmonary emphysema and kidney function in smokers. (2012 Sep)Chandra DChest
25410789Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer. (2015 Jun)Sim SHJ Cancer Res Clin Oncol
19787214The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. (2009 Nov)Li MOncol Rep
19531623Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. (2009 Jul 1)Brannan JMClin Cancer Res
23988622Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology. (2013 Nov)Zhang HJ Mol Diagn
22335251Prevalence and risk factors for chronic kidney disease in patients with coronary artery disease. (2012 Mar)Bao YSCurr Med Res Opin
24626096Factors associated with D-dimer levels in HIV-infected individuals. (2014)Borges AHPLoS One
29489642Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma. (2018 Mar)Zhang PMedicine (Baltimore)
22595958Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama Study. (2012 Aug)Terata SJ Hypertens
22523180EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- and never-smoking U.S. women. (2012 Jun)Taga MCancer Epidemiol Biomarkers Prev
29656747Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. (2018 May)Fujimoto DLung Cancer
29698957Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations. (2018 Apr 26)Nishinarita NOncology
25216867Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer. (2014 Oct)Ying HMed Oncol
20974743Associations of low-level urine cadmium with kidney function in lead workers. (2011 Apr)Weaver VMOccup Environ Med
27358590k-RAS mutations in non-small cell lung cancer patients treated with TKIs among smokers and non-smokers: a meta-analysis. (2016)Jiang AGContemp Oncol (Pozn)
10448316Increased serum concentrations of growth factor receptors and Neu in workers previously exposed to asbestos. (1999 Feb)Lahat NOccup Environ Med
25097333Prevalence of chronic kidney disease among adults in a rural community in South India: Results from the kidney disease screening (KIDS) project. (2014 Jul)Anupama YJIndian J Nephrol
25982666Plasma heat shock protein 27 is increased in renal dysfunction and habitual smoking in a Japanese general population. (2016 Jan)Nakayoshi TJ Cardiol
26998075Association between histopathological subtype, (18)F-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in lung adenocarcinoma. (2016 Mar)Qiang GOncol Lett
23050865Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis. (2012 Oct 10)Xu CJ Hematol Oncol
25743114Serum cystatin C levels are associated with asymptomatic peripheral arterial disease in type 2 diabetes mellitus patients without overt nephropathy. (2015 May)Huh JHDiabetes Res Clin Pract
28386744Impact of chronic kidney disease among Korean adults with chronic obstructive pulmonary disease. (2017 Jul)Kim MYInt Urol Nephrol
22154074Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review. (2012 Jul)Mitchell PClin Lung Cancer
18492490Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. (2009 Feb)Shoji TAtherosclerosis
27066930Risk Factors for Rapid Kidney Function Decline Among African Americans: The Jackson Heart Study (JHS). (2016 Aug)Young BAAm J Kidney Dis
24575772EGFR gene mutations in patients with adenosquamous lung carcinoma. (2014 Dec)Powrozek TAsia Pac J Clin Oncol
24440279A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). (2014 Mar)Zhou QLung Cancer
27301980Glycemic Control, Renal Complications, and Current Smoking in Relation to Excess Risk of Mortality in Persons With Type 1 Diabetes. (2016 Sep)Ahlen EJ Diabetes Sci Technol
27438512Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer. (2018 Apr)Jia XAppl Immunohistochem Mol Morphol
24748981APOBEC3B gene overexpression in non-small-cell lung cancer. (2014 May)Sasaki HBiomed Rep
24831979Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. (2014 Jun)Gregorc VLancet Oncol
28472989Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. (2017 May 4)Yang MJ Hematol Oncol
20480735Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. (2010 Apr 30)Oxnard GROncology (Williston Park)
26601054Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. (2015)Rangachari DCancer Treat Commun
29730379Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients. (2018 May 3)Garassino MCJ Thorac Oncol
25264883Associations between epidermal growth factor receptor gene mutation and serum tumor markers in advanced lung adenocarcinomas: a retrospective study. (2014 Sep)Pan YQChin Med Sci J
27467545Adipophilin expression in lung adenocarcinoma is associated with apocrine-like features and poor clinical prognosis: an immunohistochemical study of 328 cases. (2017 Jan)Fujimoto MHistopathology
28306749Cigarette smoking and cardio-renal events in patients with atherosclerotic renal artery stenosis. (2017)Drummond CAPLoS One
17409930Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. (2006 Sep)Zhang WJ Thorac Oncol
21389698Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. (2011)Kanbay MAm J Nephrol
26739349Budesonide and fluticasone propionate differentially affect the airway epithelial barrier. (2016 Jan 6)Heijink IHRespir Res
21389694Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. (2011)Kanbay MAm J Nephrol
25291939Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients. (2014)Pan JBClin Lab
28273997Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy. (2017 Jan)Abubaker MJ Clin Diagn Res
16533793Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. (2006 Mar 1)Tam IYClin Cancer Res
25245172Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis. (2015 Jan)Hsu CLJ Geriatr Oncol
25453393The association of leptin and homocysteine with renal function impairment in a population of Taiwanese adults. (2015 Oct)Chen JYClin Nutr
23728725Distribution of and factors contributing to chronic kidney disease in a middle-aged working population. (2013 Nov)Noborisaka YEnviron Health Prev Med
23879483Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. (2013 Jul 23)Ono ABMC Cancer
20926401EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. (2010 Oct 15)Sakairi YClin Cancer Res
29107665Eps8 expression is significantly lower in p16(+) head and neck squamous cell carcinomas (HNSCCs) compared with p16(-) HNSCCs. (2018 Feb)Nasri EHum Pathol
22613338[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase]. (2012 May)Li JZhongguo Fei Ai Za Zhi
22701635Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. (2012)Menzaghi CPLoS One
18478265A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. (2008 Dec)Sasaki HJ Cancer Res Clin Oncol
23806795Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? (2013 Sep)Bauml JLung Cancer
28875927Ascending aortic diameter is associated with hypertension in Korean men. (2017 Aug 29)Suh EClin Invest Med
28321111Relationships Between Clinical, Self-Reported, and Donation Specific Outcomes: A Prospective Follow-up Study 10 Years After Kidney Donation. (2017 Mar 21)Meyer KBAnn Transplant
24906365MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI. (2015 Jun)Lindberg SEur J Prev Cardiol
19096302Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. (2009 Jan)Kosaka TJ Thorac Oncol
17452971A second-generation profiling system for quantitative methylation analysis of multiple gene promoters: application to lung cancer. (2007 Oct 4)Sano AOncogene
29255137Optimal Vitamin D Status in a Middle-Aged and Elderly Population Residing in Shanghai, China. (2017 Dec 19)Aleteng QMed Sci Monit
25439691Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. (2014 Nov)Ramalingam SSLancet Oncol
17285735Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. (2007 Jan)Sequist LVOncologist
21558399Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. (2011 May 15)Rizvi NAClin Cancer Res
25099525Metabolic abnormalities, but not obesity, contribute to the mildly reduced eGFR in middle-aged and elderly Chinese. (2014 Sep)Wang CInt Urol Nephrol
25657199The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. (2015 Mar)Hasegawa YOncologist
23852459The incidence of EGFR-activating mutations in bone metastases of lung adenocarcinoma. (2014 Jan)Krawczyk PPathol Oncol Res
28193529Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. (2017 Jun)Suda KJ Thorac Oncol
26147288Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. (2015)Xu JLPLoS One
28911955Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients. (2017 Dec)Gimbrone NTJ Thorac Oncol
17368733Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? (2007 Jun)Fischer BCancer Treat Rev
23873621Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations. (2013 Sep 27)Zeng ZInt J Biol Markers
23887170Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. (2013 Sep)Ellis PMJ Thorac Oncol
27064578Epidemiology of Lung Cancer in Korea: Recent Trends. (2016 Apr)Park JYTuberc Respir Dis (Seoul)
18242762EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. (2008 Aug)Shinmura KLung Cancer
28702772A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. (2017 Sep)Fountzilas CCancer Chemother Pharmacol
23150706RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. (2012 Dec 10)Wang RJ Clin Oncol
27910740Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy. (2016)Gharat SACrit Rev Ther Drug Carrier Syst
25722384Structural and functional assessment of the brain in European Americans with mild-to-moderate kidney disease: Diabetes Heart Study-MIND. (2015 Aug)Murea MNephrol Dial Transplant
22320997Never smokers with lung cancer: analysis of genetic variants. (2011)Xiao HAsian Pac J Cancer Prev
28024695Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. (2017 Jan)Inamura KLung Cancer
21155184Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. (2010 Dec)Choi YHJ Thorac Oncol
26196951Vitamin D Associations With Renal, Bone, and Cardiovascular Phenotypes: African American-Diabetes Heart Study. (2015 Oct)Freedman BIJ Clin Endocrinol Metab
22236865Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. (2012 Jun)Ishikawa MLung Cancer
26762747Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. (2016 Jan)Michels SJ Thorac Oncol
24337681Impact of kidney function and urinary protein excretion on pulmonary function in Japanese patients with chronic kidney disease. (2014 Oct)Nakade YClin Exp Nephrol
20061937Morphometric profiling of lung cancers-its association with clinicopathologic, biologic, and molecular genetic features. (2010 Feb)Okudela KAm J Surg Pathol
24330409Risk factors for incident hyperuricemia during mid-adulthood in African American and white men and women enrolled in the ARIC cohort study. (2013 Dec 11)McAdams-DeMarco MABMC Musculoskelet Disord
21772844Molecular mechanisms of cigarette smoke-induced proliferation of lung cells and prevention by vitamin C. (2011)Dey NJ Oncol
19667264Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. (2009 Sep 10)Shaw ATJ Clin Oncol
25662388Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. (2015 Apr)Kim MYLung Cancer
22736493Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. (2012 Oct)Shaozhang ZGenes Chromosomes Cancer
28932196(-)-Epigallocatechin-3-gallate Reduces Cigarette Smoke-Induced Airway Neutrophilic Inflammation and Mucin Hypersecretion in Rats. (2017)Liang YFront Pharmacol
26124325MMP9, Cyclin D1 and beta-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro. (2015 Jul)Umbreit CAnticancer Res
28186469Blood-Based Nucleic Acid Biomarkers as a Potential Tool to Determine Radiation Therapy Response in Non-Small Cell Lung Cancer. (2017 Mar)Deig CRRadiat Res
22969966Braf and erbB2 mutations correlate with smoking status in lung cancer patients. (2012 May)Sasaki HExp Ther Med
28336963Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma. (2017 Mar 23)Shi ZSci Rep
28861280Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. (2016)Nishio MESMO Open
22072111Eosinophil count is positively correlated with coronary artery calcification. (2012 Mar)Tanaka MHypertens Res
27225988Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial. (2016 Jul 7)Tuttle KRClin J Am Soc Nephrol
28860576PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. (2017 Aug 31)Zhang MSci Rep
22548013Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. (2012 Jan)Nguyen KSJ Oncol Pract
20375690High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data. (2010 May)Wall BMAm J Med Sci
24113002[Progressive patterns of gifitinib treating advanced non-small cell lung cancer after obtained resistance]. (2013 Oct 20)Wang BZhongguo Fei Ai Za Zhi
25232221Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC). (2014 Aug)Chen LChin J Cancer Res
29687154Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC). (2018 Apr 23)Faehling MJ Cancer Res Clin Oncol
19706809Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. (2009 Sep 1)Raso MGClin Cancer Res
21123957Is chronic kidney disease associated with a high ankle brachial index in adults at high cardiovascular risk? (2011)Liu HJ Atheroscler Thromb
22686733Association between microalbuminuria and subclinical atherosclerosis evaluated by carotid artery intima-media in elderly patients with normal renal function. (2012 Jun 11)Kong XBMC Nephrol
21062926Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. (2011 Jan 1)Stabile LPClin Cancer Res
28881771Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative (18)F FDG-PET/CT metrics. (2017 Aug 8)Minamimoto ROncotarget
26860843Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer. (2016 Oct)Nicos MClin Transl Oncol
18039368Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. (2007 Nov 26)Lapperre TSRespir Res
23738762Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. (2014 May)Hwang DHArch Pathol Lab Med
25704955Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. (2015 Apr)Togashi YLung Cancer
26302167Association of relative telomere length with cardiovascular disease in a large chronic kidney disease cohort: the GCKD study. (2015 Oct)Raschenberger JAtherosclerosis
23575413Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients. (2013 Jun)Liam CKJ Thorac Oncol
25351745MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. (2015 Apr 15)Arcila MEClin Cancer Res
15709185The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. (2005 Feb 1)Tokumo MClin Cancer Res
22407457Development of a rapid and practical mutation screening assay for human lung adenocarcinoma. (2012 Jun)Choi HInt J Oncol
29049789Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinoma. (2017 Nov 1)Matsumura YInteract Cardiovasc Thorac Surg
26910625Differences in the prevalence of vitamin D deficiency and hip fractures in nursing home residents and independently living elderly. (2016 Feb 23)Shinkov AArch Endocrinol Metab
26164066Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. (2015 Sep)Preusser MEur J Cancer
17052260Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. (2006 Dec)Miura NCancer Sci
16199108Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. (2005 Dec)Endo KLung Cancer
25765471Impact of epidermal growth factor receptor protein and gene alteration on Taiwanese hepatocellular carcinomas. (2015 Sep)Su YHJ Gastroenterol Hepatol
26324372Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. (2015 Dec 1)Kelly KJ Clin Oncol
19596959Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. (2009 Jul)Pesek MAnticancer Res
28334878High expression of IRE1 in lung adenocarcinoma is associated with a lower rate of recurrence. (2017 Jun 1)Sakatani TJpn J Clin Oncol
15292385Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. (2004 Aug 4)Cappuzzo FJ Natl Cancer Inst
24077454CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. (2013 Nov)Tam KWJ Thorac Oncol
17575133Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. (2007 Jun 15)Mounawar MCancer Res
23478732Gefitinib monotherapy in advanced non-small-cell lung cancer: a retrospective analysis. (2012 Apr-Jun)Shrestha SJNMA J Nepal Med Assoc
27086595Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. (2016 May)Lee TJ Pathol Transl Med
20078870The relation of C--reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study. (2010 Jan 15)Fox ERBMC Nephrol
25118293Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer. (2014 Nov)Tran TNJ Clin Pathol
18948947Somatic mutations affect key pathways in lung adenocarcinoma. (2008 Oct 23)Ding LNature
25609130[Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma]. (2014 Dec)Niu YZhonghua Jie He He Hu Xi Za Zhi
24247268Homocysteine and C-reactive protein as useful surrogate markers for evaluating CKD risk in adults. (2013)Chuang CHKidney Blood Press Res
24345487[Relationship between BIM gene polymorphism and therapeutic efficacy in the retreatment of advanced non-small cell lung cancer with tyrosine kinase inhibitor]. (2013 Dec)Zheng LZhongguo Fei Ai Za Zhi
26573867Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. (2015 Dec)Sohn HSJ Clin Pharm Ther
25524550Association of a polymorphism of the interleukin 6 receptor gene with chronic kidney disease in Japanese individuals. (2015 Apr)Horibe HNephrology (Carlton)
20514306The relationship between the presence of chromosomal instability and prognosis of squamous cell carcinoma of the lung: fluorescence in situ hybridization analysis of paraffin-embedded tissue from 47 Korean patients. (2010 Jun)Yoo JWJ Korean Med Sci
27738317The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. (2016 Nov 29)Zhang YLOncotarget
21483012Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. (2011 May 20)Paik PKJ Clin Oncol
19455247Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays. (2007 Jan 12)Tsiambas ECancer Inform
24189004Risk factors associated with the diagnosis of abdominal aortic aneurysm in patients screened at a regional Veterans Affairs health care system. (2014 Jan)Chun KCAnn Vasc Surg
23448401Significance of CD133 expression in esophageal squamous cell carcinoma. (2013 Mar 1)Okamoto HWorld J Surg Oncol
23886169Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey. (2013)Unal OUAsian Pac J Cancer Prev
29739781Multiple risk factor control, mortality and cardiovascular events in type 2 diabetes and chronic kidney disease: a population-based cohort study. (2018 May 8)Hamada SBMJ Open
22455845[Detection of epidermal growth factor receptor gene mutation in non-small cell lung cancer by allele-specific oligonucleotide-PCR and bi-loop probe specific primer quantitative PCR]. (2012 Jan)Deng LZhonghua Bing Li Xue Za Zhi
17237005[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?]. (2007 Jan)Grenier JBull Cancer
17156891Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. (2007 Jan)Sasaki HLung Cancer
28179328Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema. (2017 Feb)Takeda KAnticancer Res
23287850The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. (2013 Feb)Kim YTJ Thorac Oncol
27994470Identification of feature genes for smoking-related lung adenocarcinoma based on gene expression profile data. (2016)Liu YOnco Targets Ther
26323932Predictors and impact of cytotoxic second-line chemotherapy for stage IIIa-IV nonsmall lung cancer patients in China: A retrospective institution analysis of 132 patients. (2015 Aug)Cheng BJ Cancer Res Ther
7793243[Oncogenes and cancer of the larynx. EGFR, p21 ras and HPV-DNA infections]. (1995 Feb)Almadori GActa Otorhinolaryngol Ital
26632382Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers. (2016 Jan)Wei HYonsei Med J
27565922Hot spot mutations in Finnish non-small cell lung cancers. (2016 Sep)Maki-Nevala SLung Cancer
24351122Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients. (2013 Dec 18)Reinmuth NRespir Res
18657657Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. (2008 Aug)McCullough PAAm Heart J
23341890Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. (2013)Li YPLoS One
16364494EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. (2006 Mar)Yoshimura NLung Cancer
22534670Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma. (2012 Aug)Rivas GLung Cancer
27123299Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer. (2016 May)Miyazaki KMol Clin Oncol
23467672Prevalence of underlying lung disease in smokers with epidermal growth factor receptor-mutant lung cancer. (2013 May)Sekine AOncol Rep
18245806Primary glomerulonephritis: an update on renal survival and determinants of progression. (2008 Mar)Moranne OQJM
2474288The expression of epidermal growth factor receptors in the oral mucosa of patients with oral cancer. (1989)Bergler WArch Otorhinolaryngol
28753770Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. (2016 Jun 24)Joshi MEur Urol Focus
22734179[Is lung cancer in women different?]. (2012 May 23)Ben Aissa ARev Med Suisse
29549910Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. (2018 Mar)Akamine TSurg Oncol
19058870Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. (2009 Jun)Sasaki HLung Cancer
18513581EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. (2008 Jun)Yang CHLung Cancer
19234440EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. (2009 Apr)Inamura KMod Pathol
26175938Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers. (2015)Zhao QAm J Cancer Res
24300132Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. (2014 Feb)Sun JMLung Cancer
22778317First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. (2012 Aug 20)Gridelli CJ Clin Oncol
21537427Renal function in diabetic nephropathy. (2010 May 15)Dabla PKWorld J Diabetes
28506221The association between urbanization and reduced renal function: findings from the China Health and Nutrition Survey. (2017 May 15)Inoue YBMC Nephrol
26704833[Detection of ROS1 fusion gene in pulmonary adenocarcinoma and its clinicopathologic features]. (2015 Jun)Liu JZhonghua Bing Li Xue Za Zhi
28660482Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. (2017 Dec)Remon JClin Transl Oncol
27222360Risk of early mortality after placement of a temporary-permanent pacemaker. (2016 Jul-Aug)Dawood FZJ Electrocardiol
17369616Urinary cotinine as an objective measure of cigarette smoking in chronic kidney disease. (2007 Jul)Jones-Burton CNephrol Dial Transplant